var docs;if (!docs) docs =[]; docs["52"]={"5200":"<p><b>Title</b> Tacrolimus (Topical) / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Grapefruit Juice may decrease the metabolism of Tacrolimus (Topical). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for elevated serum tacrolimus concentrations/toxic effects if grapefruit juice is consumed.</p> \n<p><b>Discussion</b> Due to the ability of grapefruit juice to inhibit the metabolism of tacrolimus, the manufacturer recommends avoiding the use of grapefruit juice during therapy with oral or intravenous tacrolimus.<sup>1</sup><br><br>Blood concentrations are generally low (less than 1 ng/mL) when topical tacrolimus ointment is applied as indicated.<sup>2,3,4,5,6,7,8</sup> However, several cases of elevated blood concentrations (with or without systemic toxicity) have been reported with topical tacrolimus.<sup>9,10,11,12,13,14,15,16,17,18,19</sup> Authors have suggested that systemic exposure may increase with larger applied doses, larger treated areas, occlusion, facial or oral application, and application to inflamed or open lesions. The risk for and clinical significance of drug interactions involving topically applied tacrolimus will likely increase in the presence of these factors as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Prograf (tacrolimus). Deerfield, IL: Fujisawa Healthcare, Inc, 1998.</p>\n<p>2. Prescribing information. Protopic (tacrolimus) . Deerfield, IL: Astellas Pharma US, Inc, January 2009.</p>\n<p>3. Krueger GG, Eichenfield L, Goodman JJ, et al, “Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adult and Pediatric Patients with Moderate to Severe Atopic Dermatits,” <i>J Drugs Dermatol</i>, 2007, 6(2):185-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17373177\">[PubMed 17373177]</a></p>\n<p>4. Draelos Z, Nayak A, Pariser D, et al, “Pharmacokinetics of Topical Calcineurin Inhibitors in Adult Atopic Dermatitis: A Randomized, Investigator-Blind Comparison,” <i>J Am Acad Dermatol</i>, 2005, 53(4):602-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16198779\">[PubMed 16198779]</a></p>\n<p>5. Harper J, Smith C, Rubins A, et al, “A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment After First and Repeated Application to Children With Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 124(4):695-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15816825\">[PubMed 15816825]</a></p>\n<p>6. Undre NA, Moloney FJ, Ahmadi S, et al, “Skin and Systemic Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adults With Moderate to Severe Atopic Dermatitis,” <i>Br J Dermatol</i>, 2009, 160(3):665-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19076975\">[PubMed 19076975]</a></p>\n<p>7. Rubins A, Gutmane R, Valdmane N, et al, “Pharmacokinetics of 0.1% Tacrolimus Ointment After First and Repeated Application to Adults With Moderate to Severe Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 125(1):68-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982304\">[PubMed 15982304]</a></p>\n<p>8. Alaiti S, Kang S, Fiedler C, et al, “Tacrolimus (FK506) Ointment for Atopic Dermatitis: A Phase I Study in Adults and Children,” <i>J Am Acad Dermatol</i>, 1998, 38(1)69-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9448208\">[PubMed 9448208]</a></p>\n<p>9. Kameda G, Kramm C Niehues T, et al, “Unexpected High Serum Levels of Tacrolimus After a Single Topical Application in an Infant,” <i>J Pediatr</i>, 2003, 143(4):462. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12970650\">[PubMed 12970650]</a></p>\n<p>10. Ghislain PD, De Decker I, Lachapelle JM, “Efficacy and Systemic Absorption of Topical Tacrolimus Used in Pyoderma Gangrenosum,” <i>Br J Dermatol</i>, 2004, 150(5):1052-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15149540\">[PubMed 15149540]</a></p>\n<p>11. Kawashima M, Nakagawaw H, Ohtsuki M, et al, “Tacrolimus Concentrations in Blood During Topical Treatment of Atopic Dermatitis,” <i>Lancet</i>, 1996, 348(9036):1240-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8898050\">[PubMed 8898050]</a></p>\n<p>12. Allen DM, Esterly NB, “Significant Systemic Absorption of Tacrolimus After Topical Application in a Patient With Lamellar Ichthyosis,” <i>Arch Dermatol</i>, 2002, 138(9):1259-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12225004\">[PubMed 12225004]</a></p>\n<p>13. Allen A, Siegfried E, Silverman R, et al, “Significant Absorption of Topical Tacrolimus in 3 Patients With Netherton Syndrome,” <i>Arch Dermatol</i>, 2001, 137(6)747-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11405764\">[PubMed 11405764]</a></p>\n<p>14. Pitarch G, Torrijos A, Mahiques L, et al, “Systemic Absorption of Topical Tacrolimus in Pyoderma Gangrenosum,” <i>Acta Derm Venereol</i>, 2006, 86(1)64-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16585995\">[PubMed 16585995]</a></p>\n<p>15. Prot-Labarthe S, Therrien R, Champagne MA, et al, “Toxic Serum Levels of Tacrolimus After Topical Administration in an Infant With Severe Cutaneous Graft-Versus-Host Disease,” <i>Bone Marrow Transplant</i>, 2007, 40(3):295-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17549052\">[PubMed 17549052]</a></p>\n<p>16. Russel RK, Richardson N, Wilson DC, “Systemic Absorption With Complications During Topical Tacrolimus Treatment for Orofactial Crohn Disease,” <i>J Pediatr Gastroenterol Nutr</i>, 2001, 32(2):207-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11321395\">[PubMed 11321395]</a></p>\n<p>17. Teshima D, Ikesue H, Itoh Y, et al, “Increased Topical Tacrolimus Absorption in Generalized Leukemic Erythroderma,” <i>Ann Pharmacother</i>, 2003, 37(10):1444-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14519034\">[PubMed 14519034]</a></p>\n<p>18. Beyerler M, Schmid-Grendelmeier P, Hafner J, “Significantly Elevated Systemic Levels After Occlusive Application of Topical Tacrolimus in Atopic Dermatitis,” <i>Dermatology</i>, 2006, 212(3):260-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16549924\">[PubMed 16549924]</a></p>\n<p>19. Conrotto D, Carrozzo M, Ubertalli AV, et al, “Dramatic Increase of Tacrolimus Plasma Concentration During Topical Treatment for Oral Graft-Versus-Host Disease,” <i>Transplantation</i>, 2006, 82(8):1113-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17060865\">[PubMed 17060865]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5201":"<p><b>Title</b> Tacrolimus (Topical) / Sirolimus</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Sirolimus may enhance the adverse/toxic effect of Tacrolimus (Topical). Tacrolimus (Topical) may enhance the adverse/toxic effect of Sirolimus. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid use of tacrolimus ointment in patients receiving immunosuppressants. Seek alternatives to topical tacrolimus in patients receiving sirolimus as the systemic absorption of tacrolimus may increase risk of toxicity. Monitor for toxic effects of both agents if used concomitantly.</p> \n<p><b>Discussion</b> An excess in mortality, hepatic artery thrombosis (HAT), and graft loss have been observed in de novo liver transplant patients receiving systemic tacrolimus and sirolimus.<sup>1</sup> An increased risk for nephrotoxicity, impaired wound healing, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA), hyperlipidemia, and post-transplantation diabetes mellitus has also been observed with the concomitant use of these two agents.<sup>1,2,3,4,5</sup><br><br>In a small study of renal transplant patients (n=39), the authors note an alarming toxicity profile in association with the use of full dose tacrolimus (trough levels 10-15 ng/mL) and reduced dose sirolimus (trough levels 5-10 ng/mL) when compared to reduced dose tacrolimus (trough levels 5-10 ng/mL) with standard sirolimus dosing (trough levels 10-15 ng/mL).<sup>2</sup> In heart transplant patients, administration of full dose tacrolimus with sirolimus (2 mg/day) was associated with an increased risk of renal impairment, wound healing complications, and insulin-dependent post-transplant diabetes mellitus.<sup>6</sup> <br><br>Blood concentrations are generally low (less than 1 ng/mL) when topical tacrolimus ointment is applied as indicated.<sup>7,8,9,10,11,12,13</sup> However, several cases of elevated blood concentrations (with or without systemic toxicity) have been reported with topical tacrolimus.<sup>14,15,16,17,18,19,20,21,22,23,24</sup> Authors have suggested that systemic exposure may increase with larger applied doses, larger treated areas, occlusion, facial or oral application, and application to inflamed or open lesions. The risk for and clinical significance of drug interactions involving topically applied tacrolimus will likely increase in the presence of these factors as well. Prescribing information for tacrolimus ointment warns against use in immunocompromised patients.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Rapamune (sirolimus). Philadelphia, PA: Wyeth Pharmaceuticals, Inc, July 2007.</p>\n<p>2. Lo A, Fegidi MF, Gaber LW, et al, “Observations Regarding The Use of Sirolimus and Tacrolimus in High-Risk Cadaveric Renal Transplantation,” <i>Clin Transplant</i>, 2004, 18:53-61.</p>\n<p>3. Ciancio G, Burke GW, Gaynor JJ, et al, “A Randomized Long-Term Trial of Tacrolimus/Sirolimus versus Tacrolimus/Mycophenolate versus Cyclosporine/Sirolimus in Renal Transplantation: Three-Year Analysis,” <i>Transplant</i>, 2006, 81(6)845-52.</p>\n<p>4. Sampaio EL, Pinheiro-Machado PG, Garcia R, et al, “Mycophenolate Mofetil Vs. Sirolimus in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen,” <i>Clin Transplant</i>, 2008, 22:141-49.</p>\n<p>5. Zucker MJ, Baran DA, Arroyo LH, et al, “De Novo Immunosuppression With Sirolimus and Tacrolimus in Heart Transplant Recipients Compared With Cyclosporine and Mycophenolate Mofetil: A One-Year Follow Up Analysis,” <i>Transplant Proc</i>, 2005, 37:2231-39.</p>\n<p>6. Prescribing information. Prograf (tacrolimus). Deerfield, IL: Astellas Pharma US, Inc., February 2009.</p>\n<p>7. Prescribing information. Protopic (tacrolimus) . Deerfield, IL: Astellas Pharma US, Inc, January 2009.</p>\n<p>8. Krueger GG, Eichenfield L, Goodman JJ, et al, “Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adult and Pediatric Patients with Moderate to Severe Atopic Dermatits,” <i>J Drugs Dermatol</i>, 2007, 6(2):185-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17373177\">[PubMed 17373177]</a> 9. Draelos Z, Nayak A, Pariser D, et al, “Pharmacokinetics of Topical Calcineurin Inhibitors in Adult Atopic Dermatitis: A Randomized, Investigator-Blind Comparison,” <i>J Am Acad Dermatol</i>, 2005, 53(4):602-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16198779\">[PubMed 16198779]</a></p>\n<p>10. Harper J, Smith C, Rubins A, et al, “A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment After First and Repeated Application to Children With Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 124(4):695-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15816825\">[PubMed 15816825]</a></p>\n<p>11. Undre NA, Moloney FJ, Ahmadi S, et al, “Skin and Systemic Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adults With Moderate to Severe Atopic Dermatitis,” <i>Br J Dermatol</i>, 2009, 160(3):665-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19076975\">[PubMed 19076975]</a></p>\n<p>12. Rubins A, Gutmane R, Valdmane N, et al, “Pharmacokinetics of 0.1% Tacrolimus Ointment After First and Repeated Application to Adults With Moderate to Severe Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 125(1):68-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982304\">[PubMed 15982304]</a></p>\n<p>13. Alaiti S, Kang S, Fiedler C, et al, “Tacrolimus (FK506) Ointment for Atopic Dermatitis: A Phase I Study in Adults and Children,” <i>J Am Acad Dermatol</i>, 1998, 38(1)69-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9448208\">[PubMed 9448208]</a></p>\n<p>14. Kameda G, Kramm C Niehues T, et al, “Unexpected High Serum Levels of Tacrolimus After a Single Topical Application in an Infant,” <i>J Pediatr</i>, 2003, 143(4):462. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12970650\">[PubMed 12970650]</a></p>\n<p>15. Ghislain PD, De Decker I, Lachapelle JM, “Efficacy and Systemic Absorption of Topical Tacrolimus Used in Pyoderma Gangrenosum,” <i>Br J Dermatol</i>, 2004, 150(5):1052-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15149540\">[PubMed 15149540]</a></p>\n<p>16. Kawashima M, Nakagawaw H, Ohtsuki M, et al, “Tacrolimus Concentrations in Blood During Topical Treatment of Atopic Dermatitis,” <i>Lancet</i>, 1996, 348(9036):1240-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8898050\">[PubMed 8898050]</a></p>\n<p>17. Allen DM, Esterly NB, “Significant Systemic Absorption of Tacrolimus After Topical Application in a Patient With Lamellar Ichthyosis,” <i>Arch Dermatol</i>, 2002, 138(9):1259-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12225004\">[PubMed 12225004]</a></p>\n<p>18. Allen A, Siegfried E, Silverman R, et al, “Significant Absorption of Topical Tacrolimus in 3 Patients With Netherton Syndrome,” <i>Arch Dermatol</i>, 2001, 137(6)747-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11405764\">[PubMed 11405764]</a></p>\n<p>19. Pitarch G, Torrijos A, Mahiques L, et al, “Systemic Absorption of Topical Tacrolimus in Pyoderma Gangrenosum,” <i>Acta Derm Venereol</i>, 2006, 86(1)64-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16585995\">[PubMed 16585995]</a></p>\n<p>20. Prot-Labarthe S, Therrien R, Champagne MA, et al, “Toxic Serum Levels of Tacrolimus After Topical Administration in an Infant With Severe Cutaneous Graft-Versus-Host Disease,” <i>Bone Marrow Transplant</i>, 2007, 40(3):295-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17549052\">[PubMed 17549052]</a></p>\n<p>21. Russel RK, Richardson N, Wilson DC, “Systemic Absorption With Complications During Topical Tacrolimus Treatment for Orofactial Crohn Disease,” <i>J Pediatr Gastroenterol Nutr</i>, 2001, 32(2):207-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11321395\">[PubMed 11321395]</a></p>\n<p>22. Teshima D, Ikesue H, Itoh Y, et al, “Increased Topical Tacrolimus Absorption in Generalized Leukemic Erythroderma,” <i>Ann Pharmacother</i>, 2003, 37(10):1444-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14519034\">[PubMed 14519034]</a></p>\n<p>23. Beyerler M, Schmid-Grendelmeier P, Hafner J, “Significantly Elevated Systemic Levels After Occlusive Application of Topical Tacrolimus in Atopic Dermatitis,” <i>Dermatology</i>, 2006, 212(3):260-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16549924\">[PubMed 16549924]</a></p>\n<p>24. Conrotto D, Carrozzo M, Ubertalli AV, et al, “Dramatic Increase of Tacrolimus Plasma Concentration During Topical Treatment for Oral Graft-Versus-Host Disease,” <i>Transplantation</i>, 2006, 82(8):1113-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17060865\">[PubMed 17060865]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5202":"<p><b>Title</b> Temsirolimus / Tacrolimus (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tacrolimus (Topical) may enhance the adverse/toxic effect of Temsirolimus. Temsirolimus may enhance the adverse/toxic effect of Tacrolimus (Topical). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid use of tacrolimus ointment in patients receiving immunosuppressants. Seek alternatives to topical tacrolimus in patients receiving temsirolimus as the systemic absorption of tacrolimus may increase risk of toxicity. Monitor for toxic effects of both agents if used concomitantly.</p> \n<p><b>Discussion</b> Since temsirolimus is the ester pro-drug of sirolimus, the potential for an interaction with tacrolimus is based on published data with oral sirolimus.<br><br>An excess in mortality, hepatic artery thrombosis (HAT), and graft loss have been observed in de novo liver transplant patients receiving systemic tacrolimus and sirolimus.<sup>1</sup> An increased risk for nephrotoxicity, impaired wound healing, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA), hyperlipidemia, and post-transplantation diabetes mellitus has also been observed with the concomitant use of these two agents.<sup>1,2,3,4,5</sup><br><br>In a small study of renal transplant patients (n=39), the authors note an alarming toxicity profile in association with the use of full dose tacrolimus (trough levels 10-15 ng/mL) and reduced dose sirolimus (trough levels 5-10 ng/mL) when compared to reduced dose tacrolimus (trough levels 5-10 ng/mL) with standard sirolimus dosing (trough levels 10-15 ng/mL).<sup>2</sup> In heart transplant patients, administration of full dose tacrolimus with sirolimus (2 mg/day) was associated with an increased risk of renal impairment, wound healing complications, and insulin-dependent post-transplant diabetes mellitus.<sup>6</sup> <br><br>Blood concentrations are generally low (less than 1 ng/mL) when topical tacrolimus ointment is applied as indicated.<sup>7,8,9,10,11,12,13</sup> However, several cases of elevated blood concentrations (with or without systemic toxicity) have been reported with topical tacrolimus.<sup>14,15,16,17,18,19,20,21,22,23,24</sup> Authors have suggested that systemic exposure may increase with larger applied doses, larger treated areas, occlusion, facial or oral application, and application to inflamed or open lesions. The risk for and clinical significance of drug interactions involving topically applied tacrolimus will likely increase in the presence of these factors as well. Prescribing information for tacrolimus ointment warns against use in immunocompromised patients.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Rapamune (sirolimus). Philadelphia, PA: Wyeth Pharmaceuticals, Inc, July 2007.</p>\n<p>2. Lo A, Fegidi MF, Gaber LW, et al, “Observations Regarding The Use of Sirolimus and Tacrolimus in High-Risk Cadaveric Renal Transplantation,” <i>Clin Transplant</i>, 2004, 18:53-61.</p>\n<p>3. Ciancio G, Burke GW, Gaynor JJ, et al, “A Randomized Long-Term Trial of Tacrolimus/Sirolimus versus Tacrolimus/Mycophenolate versus Cyclosporine/Sirolimus in Renal Transplantation: Three-Year Analysis,” <i>Transplant</i>, 2006, 81(6)845-52.</p>\n<p>4. Sampaio EL, Pinheiro-Machado PG, Garcia R, et al, “Mycophenolate Mofetil Vs. Sirolimus in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen,” <i>Clin Transplant</i>, 2008, 22:141-49.</p>\n<p>5. Zucker MJ, Baran DA, Arroyo LH, et al, “De Novo Immunosuppression With Sirolimus and Tacrolimus in Heart Transplant Recipients Compared With Cyclosporine and Mycophenolate Mofetil: A One-Year Follow Up Analysis,” <i>Transplant Proc</i>, 2005, 37:2231-39.</p>\n<p>6. Prescribing information. Prograf (tacrolimus). Deerfield, IL: Astellas Pharma US, Inc., February 2009.</p>\n<p>7. Prescribing information. Protopic (tacrolimus) . Deerfield, IL: Astellas Pharma US, Inc, January 2009.</p>\n<p>8. Krueger GG, Eichenfield L, Goodman JJ, et al, “Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adult and Pediatric Patients with Moderate to Severe Atopic Dermatits,” <i>J Drugs Dermatol</i>, 2007, 6(2):185-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17373177\">[PubMed 17373177]</a> 9. Draelos Z, Nayak A, Pariser D, et al, “Pharmacokinetics of Topical Calcineurin Inhibitors in Adult Atopic Dermatitis: A Randomized, Investigator-Blind Comparison,” <i>J Am Acad Dermatol</i>, 2005, 53(4):602-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16198779\">[PubMed 16198779]</a></p>\n<p>10. Harper J, Smith C, Rubins A, et al, “A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment After First and Repeated Application to Children With Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 124(4):695-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15816825\">[PubMed 15816825]</a></p>\n<p>11. Undre NA, Moloney FJ, Ahmadi S, et al, “Skin and Systemic Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adults With Moderate to Severe Atopic Dermatitis,” <i>Br J Dermatol</i>, 2009, 160(3):665-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19076975\">[PubMed 19076975]</a></p>\n<p>12. Rubins A, Gutmane R, Valdmane N, et al, “Pharmacokinetics of 0.1% Tacrolimus Ointment After First and Repeated Application to Adults With Moderate to Severe Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 125(1):68-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982304\">[PubMed 15982304]</a></p>\n<p>13. Alaiti S, Kang S, Fiedler C, et al, “Tacrolimus (FK506) Ointment for Atopic Dermatitis: A Phase I Study in Adults and Children,” <i>J Am Acad Dermatol</i>, 1998, 38(1)69-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9448208\">[PubMed 9448208]</a></p>\n<p>14. Kameda G, Kramm C Niehues T, et al, “Unexpected High Serum Levels of Tacrolimus After a Single Topical Application in an Infant,” <i>J Pediatr</i>, 2003, 143(4):462. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12970650\">[PubMed 12970650]</a></p>\n<p>15. Ghislain PD, De Decker I, Lachapelle JM, “Efficacy and Systemic Absorption of Topical Tacrolimus Used in Pyoderma Gangrenosum,” <i>Br J Dermatol</i>, 2004, 150(5):1052-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15149540\">[PubMed 15149540]</a></p>\n<p>16. Kawashima M, Nakagawaw H, Ohtsuki M, et al, “Tacrolimus Concentrations in Blood During Topical Treatment of Atopic Dermatitis,” <i>Lancet</i>, 1996, 348(9036):1240-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8898050\">[PubMed 8898050]</a></p>\n<p>17. Allen DM, Esterly NB, “Significant Systemic Absorption of Tacrolimus After Topical Application in a Patient With Lamellar Ichthyosis,” <i>Arch Dermatol</i>, 2002, 138(9):1259-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12225004\">[PubMed 12225004]</a></p>\n<p>18. Allen A, Siegfried E, Silverman R, et al, “Significant Absorption of Topical Tacrolimus in 3 Patients With Netherton Syndrome,” <i>Arch Dermatol</i>, 2001, 137(6)747-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11405764\">[PubMed 11405764]</a></p>\n<p>19. Pitarch G, Torrijos A, Mahiques L, et al, “Systemic Absorption of Topical Tacrolimus in Pyoderma Gangrenosum,” <i>Acta Derm Venereol</i>, 2006, 86(1)64-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16585995\">[PubMed 16585995]</a></p>\n<p>20. Prot-Labarthe S, Therrien R, Champagne MA, et al, “Toxic Serum Levels of Tacrolimus After Topical Administration in an Infant With Severe Cutaneous Graft-Versus-Host Disease,” <i>Bone Marrow Transplant</i>, 2007, 40(3):295-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17549052\">[PubMed 17549052]</a></p>\n<p>21. Russel RK, Richardson N, Wilson DC, “Systemic Absorption With Complications During Topical Tacrolimus Treatment for Orofactial Crohn Disease,” <i>J Pediatr Gastroenterol Nutr</i>, 2001, 32(2):207-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11321395\">[PubMed 11321395]</a></p>\n<p>22. Teshima D, Ikesue H, Itoh Y, et al, “Increased Topical Tacrolimus Absorption in Generalized Leukemic Erythroderma,” <i>Ann Pharmacother</i>, 2003, 37(10):1444-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14519034\">[PubMed 14519034]</a></p>\n<p>23. Beyerler M, Schmid-Grendelmeier P, Hafner J, “Significantly Elevated Systemic Levels After Occlusive Application of Topical Tacrolimus in Atopic Dermatitis,” <i>Dermatology</i>, 2006, 212(3):260-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16549924\">[PubMed 16549924]</a></p>\n<p>24. Conrotto D, Carrozzo M, Ubertalli AV, et al, “Dramatic Increase of Tacrolimus Plasma Concentration During Topical Treatment for Oral Graft-Versus-Host Disease,” <i>Transplantation</i>, 2006, 82(8):1113-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17060865\">[PubMed 17060865]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5203":"<p><b>Title</b> Tacrolimus (Topical) / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may enhance the nephrotoxic effect of Tacrolimus (Topical). Tacrolimus (Topical) may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Tacrolimus (Topical) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Tacrolimus (Topical). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid use of tacrolimus ointment in patients receiving immunosuppressants. Seek alternatives to topical tacrolimus in patients receiving cyclosporine as the systemic absorption of tacrolimus may increase risk of nephrotoxicity. Monitor for elevated serum concentrations/toxic effects of both agents if used concomitantly.</p> \n<p><b>Discussion</b> Both tacrolimus and cyclosporine can be nephrotoxic, and a synergistic effect might be anticipated with their concomitant use. Additionally, as both agents are highly bound to plasma proteins and share common metabolic pathways (both are substrates for CYP3A4 and P-glycoprotein),<sup>2,3,4</sup> elevated serum levels of either agent might be expected with concomitant therapy, possibly furthering the nephrotoxic risks. Further, the prescribing information for tacrolimus ointment warns against use in immunocompromised patients.<sup>5</sup> <br><br>Blood concentrations are generally low (less than 1 ng/mL) when topical tacrolimus ointment is applied as indicated.<sup>5,6,7,8,9,10,11</sup> However, several cases of elevated blood concentrations (with or without systemic toxicity) have been reported with topical tacrolimus.<sup>12,13,14,15,16,17,18,19,20,21,22</sup> Authors have suggested that systemic exposure may increase with larger applied doses, larger treated areas, occlusion, facial or oral application, and application to inflamed or open lesions. The risk for and clinical significance of drug interactions involving topically applied tacrolimus will likely increase in the presence of these factors as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Prograf (tacrolimus). Deerfield, IL: Astellas Pharma US, Inc., February 2009.</p>\n<p>2. Prescribing information. Neoral (cyclosporine). East Hanoverton, NJ: Novartis Pharmaceuticals Corp., August 2005.</p>\n<p>3. Kim RB, “Drugs as P-Glycoprotein Substrates, Inhbitors, and Inducers,” <i>Drug Metab Rev</i> 2002, 34(1&amp;2): 47-54.</p>\n<p>4. Christians U, Jacobsen W, Benet LZ, et al, “Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus,” <i>Clin Pharmacokinet</i> 2002, 41(11): 813-51.</p>\n<p>5. Prescribing information. Protopic (tacrolimus) . Deerfield, IL: Astellas Pharma US, Inc, January 2009.</p>\n<p>6. Krueger GG, Eichenfield L, Goodman JJ, et al, “Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adult and Pediatric Patients with Moderate to Severe Atopic Dermatits,” <i>J Drugs Dermatol</i>, 2007, 6(2):185-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17373177\">[PubMed 17373177]</a> 7. Draelos Z, Nayak A, Pariser D, et al, “Pharmacokinetics of Topical Calcineurin Inhibitors in Adult Atopic Dermatitis: A Randomized, Investigator-Blind Comparison,” <i>J Am Acad Dermatol</i>, 2005, 53(4):602-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16198779\">[PubMed 16198779]</a></p>\n<p>8. Harper J, Smith C, Rubins A, et al, “A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment After First and Repeated Application to Children With Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 124(4):695-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15816825\">[PubMed 15816825]</a></p>\n<p>9. Undre NA, Moloney FJ, Ahmadi S, et al, “Skin and Systemic Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adults With Moderate to Severe Atopic Dermatitis,” <i>Br J Dermatol</i>, 2009, 160(3):665-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19076975\">[PubMed 19076975]</a></p>\n<p>10. Rubins A, Gutmane R, Valdmane N, et al, “Pharmacokinetics of 0.1% Tacrolimus Ointment After First and Repeated Application to Adults With Moderate to Severe Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 125(1):68-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982304\">[PubMed 15982304]</a></p>\n<p>11. Alaiti S, Kang S, Fiedler C, et al, “Tacrolimus (FK506) Ointment for Atopic Dermatitis: A Phase I Study in Adults and Children,” <i>J Am Acad Dermatol</i>, 1998, 38(1)69-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9448208\">[PubMed 9448208]</a></p>\n<p>12. Kameda G, Kramm C Niehues T, et al, “Unexpected High Serum Levels of Tacrolimus After a Single Topical Application in an Infant,” <i>J Pediatr</i>, 2003, 143(4):462. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12970650\">[PubMed 12970650]</a></p>\n<p>13. Ghislain PD, De Decker I, Lachapelle JM, “Efficacy and Systemic Absorption of Topical Tacrolimus Used in Pyoderma Gangrenosum,” <i>Br J Dermatol</i>, 2004, 150(5):1052-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15149540\">[PubMed 15149540]</a></p>\n<p>14. Kawashima M, Nakagawaw H, Ohtsuki M, et al, “Tacrolimus Concentrations in Blood During Topical Treatment of Atopic Dermatitis,” <i>Lancet</i>, 1996, 348(9036):1240-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8898050\">[PubMed 8898050]</a></p>\n<p>15. Allen DM, Esterly NB, “Significant Systemic Absorption of Tacrolimus After Topical Application in a Patient With Lamellar Ichthyosis,” <i>Arch Dermatol</i>, 2002, 138(9):1259-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12225004\">[PubMed 12225004]</a></p>\n<p>16. Allen A, Siegfried E, Silverman R, et al, “Significant Absorption of Topical Tacrolimus in 3 Patients With Netherton Syndrome,” <i>Arch Dermatol</i>, 2001, 137(6)747-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11405764\">[PubMed 11405764]</a></p>\n<p>17. Pitarch G, Torrijos A, Mahiques L, et al, “Systemic Absorption of Topical Tacrolimus in Pyoderma Gangrenosum,” <i>Acta Derm Venereol</i>, 2006, 86(1)64-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16585995\">[PubMed 16585995]</a></p>\n<p>18. Prot-Labarthe S, Therrien R, Champagne MA, et al, “Toxic Serum Levels of Tacrolimus After Topical Administration in an Infant With Severe Cutaneous Graft-Versus-Host Disease,” <i>Bone Marrow Transplant</i>, 2007, 40(3):295-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17549052\">[PubMed 17549052]</a></p>\n<p>19. Russel RK, Richardson N, Wilson DC, “Systemic Absorption With Complications During Topical Tacrolimus Treatment for Orofactial Crohn Disease,” <i>J Pediatr Gastroenterol Nutr</i>, 2001, 32(2):207-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11321395\">[PubMed 11321395]</a></p>\n<p>20. Teshima D, Ikesue H, Itoh Y, et al, “Increased Topical Tacrolimus Absorption in Generalized Leukemic Erythroderma,” <i>Ann Pharmacother</i>, 2003, 37(10):1444-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14519034\">[PubMed 14519034]</a></p>\n<p>21. Beyerler M, Schmid-Grendelmeier P, Hafner J, “Significantly Elevated Systemic Levels After Occlusive Application of Topical Tacrolimus in Atopic Dermatitis,” <i>Dermatology</i>, 2006, 212(3):260-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16549924\">[PubMed 16549924]</a></p>\n<p>22. Conrotto D, Carrozzo M, Ubertalli AV, et al, “Dramatic Increase of Tacrolimus Plasma Concentration During Topical Treatment for Oral Graft-Versus-Host Disease,” <i>Transplantation</i>, 2006, 82(8):1113-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17060865\">[PubMed 17060865]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5204":"<p><b>Title</b> Dolasetron / Atenolol</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Atenolol may increase serum concentrations of the active metabolite(s) of Dolasetron. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> According to dolasetron prescribing information, concurrent use of IV dolasetron with atenolol was associated with a 27% decrease in the clearance of hydrodolasetron (active metabolite of dolasetron).<sup>1</sup> The clinical significance of and mechanism for this apparent interaction are uncertain. Atenolol is not known to directly influence any drug metabolizing enzymes or drug transporters. Also, per dolasetron prescribing information, the beta-blocker propranolol did not alter hydrodolasetron clearance.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Anzemet (dolasetron). Bridgewater, NJ: sanofi-aventis U.S. LLC, August 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5205":"<p><b>Title</b> Dolasetron / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> RifAMPin may decrease serum concentrations of the active metabolite(s) of Dolasetron. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Concentrations of the active metabolite hydrodolasetron were decreased by an average of 28% after 7 days of concurrent rifampin, according to dolasetron prescribing information.<sup>1</sup><br><br>The mechanism for this apparent interaction is likely rifampin-mediated induction of the enzymes (CYP3A and possibly others) responsible for hydrodolasetron metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Anzemet (dolasetron). Bridgewater, NJ: sanofi-aventis U.S. LLC, August 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5206":"<p><b>Title</b> Loratadine / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Amiodarone may increase the serum concentration of Loratadine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to reported QT interval prolongation and Torsades de Pointes with this combination, consider using an alternative to loratadine when possible. If these agents must be used together, monitor QT interval and for signs of dysrhythmias (e.g., syncope) closely.</p> \n<p><b>Discussion</b> Syncope and Torsades de Pointes (TdP) were reported in a 73-year old woman who was receiving chronic amiodarone and had taken loratadine.<sup>1</sup> Similarly, a case series of 6 consecutive patients on chronic amiodarone who were admitted to the ICU with syncope and TdP revealed that 2 of these patients had received concurrent loratadine.<sup>2</sup><br><br>Amiodarone prescribing information notes this potential interaction, cautioning that amiodarone may inhibit the metabolism of loratadine (via CYP3A4 inhibition), increasing the risk for QT prolongation and TdP.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Atar S, Freedberg NA, Antonelli D, et al, “Torsades de Pointes and QT Prolongation Due to a Combination of Loratadine and Amiodarone,” <i>Pacing Clin Electrophysiol</i>, 2003, 26(3):785-6. [PMID: 12698686]</p>\n<p>2. Antonelli D, Atar S, Freedberg NA, et al, “Torsade de Pointes in Patients on Chronic Amiodarone Treatment: Contributing Factors and Drug Interactions,” <i>Isr Med Assoc J</i>, 2005, 7(3):163-5. [PMID: 15792261]</p>\n<p>3. Prescribing information. Cordarone (amiodarone). Philadelphia, PA: Wyeth Pharmaceuticals Inc., 08/2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5207":"<p><b>Title</b> Digoxin / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased digoxin levels/effects with initiation/dose increase of non-steroidal anti-inflammatory agents (NSAIDs). Conversely, monitor for decreased digoxin levels/effects with NSAID discontinuation/dose decrease. Monitor renal function closely with concomitant use of these agents. Elderly patients and/or individuals with impaired renal function may be at greater risk for adverse effects. Digoxin dosage adjustments may be necessary.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Following randomization of heart failure patients on chronic digoxin therapy (125-250 mcg/day) to either indomethacin (50 mg TID x10 days) (n=10) or ibuprofen (600 mg TID x10 days) (n=8), mean digoxin levels increased 40% with indomethacin but were not significantly altered with ibuprofen.<sup>1</sup> Conversely, administration of ibuprofen (1600 mg or more per day x 7 days) increased digoxin levels (59%) in patients (n=12) receiving digoxin (125-250 mcg/day),<sup>2</sup> while administration of digoxin (750 mcg IV as single dose) and indomethacin (50 mcg TID x 2 days) to healthy subjects (n=6) had no significant effect on digoxin clearance or AUC.<sup>3</sup> <br><br>Of note, in studies where an interaction was observed,<sup>1,2</sup> digoxin levels remained therapeutic (less than 2 ng/mL) during and after therapy in all but one patient. No patient was noted to have any signs or symptoms of digoxin toxicity. <br><br>The precise mechanism(s) behind the observed interactions is(are) not known. By inhibiting prostaglandin synthesis, NSAIDs may impair renal perfusion/function and decrease digoxin clearance. Though significant changes in renal performance were not observed in some studies,<sup>1,2,3</sup> decreased renal function and toxic digoxin levels have been reported in infants treated with indomethacin.<sup>4,5</sup> Another consideration might include the possibility that indomethacin or other NSAIDs inhibit the P-glycoprotein transporter of which digoxin is a substrate; however, data from in vitro studies evaluating this effect are somewhat conflicting.<sup>6,7,8</sup><br><br>Indomethacin prescribing information recommends careful monitoring of serum digoxin levels with concomitant use.<sup>9</sup> One author recommends a 50% dosage reduction of digoxin with initiation of indomethacin therapy in infants.<sup>4</sup> Interestingly, the risk of drug interaction with digoxin is mentioned in the prescribing information for some (e.g., indomethacin,<sup>9</sup> diclofenac,<sup>10</sup> naproxen<sup>11</sup>), but not all NSAIDs. Considering its narrow therapeutic window, it would seem prudent to closely monitor digoxin levels in patients receiving concomitant NSAID therapy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Jorgensen HS, Christensen HR, Kampmann JP, “Interaction Between Digoxin and Indomethacin or Ibuprofen,” <i>Br J Clin Pharmacol,</i> 1991, 31:108-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2015162\">[PubMed 2015162]</a></p>\n<p>2. Quattrocchi FP, Robinson JD, Curry RW, et al, “The Effect of Ibuprofen on Serum Digoxin Concentrations,” <i>Drug Intell Clin Pharm,</i> 1983, 17:286-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6839961\">[PubMed 6839961]</a></p>\n<p>3. Finch MB, Johnston GD, Mcdevitt DG, “Pharmacokinetics of Digoxin Alone and in the Presence of Indomethacin Therapy,” <i>Br J Clin Pharmacol,</i> 1984, 17:353-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6712868\">[PubMed 6712868]</a></p>\n<p>4. Koren G, Zarfin Y, Perlman M, et al, “Effects of Indomethacin on Digoxin Pharmacokinetics in Preterm Infants,” <i>Pediatr Pharmacol,</i> 1984, 4(1):25-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6739184\">[PubMed 6739184]</a></p>\n<p>5. Schimmel MS, Inwood RJ, Eidelman AI, at al, “Toxic Digitalis Levels Associated with Indomethacin Therapy in a Neonate,” <i>Clin Pediatr,</i> 1980, 19(11):768-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7428256\">[PubMed 7428256]</a></p>\n<p>6. Draper MP, Martell RL, Levy SB, “Indomethacin-Mediated Reversal of Multidrug Resistance and Drug Efflux in Human and Murine Cell Lines Overexpressing MRP, but not P-Glycoprotein,” <i>Br J Cancer,</i> 1997, 75(6):810-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9062400\">[PubMed 9062400]</a></p>\n<p>7. Zrieki A, Farinotti R, Buyse M, “Cyclooxygenase Inhibitors Down Regulate P-Glycoprotein in Human Colorectal Caco-2 Cell Line,” <i>Pharm Res,</i> 2008, 25(9):1991-2001. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18581209\">[PubMed 18581209]</a></p>\n<p>8. Angelini A, Iezzi M, Di Febbo C, et al, “Reversal of P-Glycoprotein-Mediated Multidrug Resistance in Human Sarcoma MES-SA/Dx-5 Cells by Nonsteroidal Anti-Inflammatory Drugs,” <i>Oncol Rep,</i> 2008, 20:731-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18813811\">[PubMed 18813811]</a></p>\n<p>9. Prescribing information. Indocin (indomethacin). Whitehouse Station, NJ: Merck &amp; Co. Inc., March 2007.</p>\n<p>10. Prescribing information. Voltaren (diclofenac). Dorval, Quebec: Novartis Pharmaceuticals Canada Inc., September 2009.</p>\n<p>11. Prescribing information. Anaprox (naproxen sodium). Mississauga, Ontario: Hoffman-LaRoche Limited, September 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5208":"<p><b>Title</b> Bleomycin / Filgrastim</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Filgrastim may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients more closely for signs/symptoms of bleomycin pulmonary toxicity when used with filgrastim (G-CSF). Be aware that the use of such a combination may increase the risk for potentially severe pulmonary toxicity.</p> \n<p><b>Discussion</b> According to one report, evidence of possible bleomycin-associated pulmonary toxicity was observed in 4 of 5 patients receiving G-CSF in combination with the ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy regimen.<sup>1</sup> The authors considered this noteworthy due to the unusually high rate of toxicity, particularly since the patients with evidence of toxicity received more than 5-fold lower doses of bleomycin that that normally associated with risk of pulmonary toxicity. Another case report describes a patient with rapidly-developing and fatal pulmonary toxicity attributed to concurrent use of bleomycin and G-CSF.<sup>2</sup><br><br>A retrospective analysis of 141 bleomycin-treated patients, 25 (18%) of whom experience bleomycin-associated pulmonary toxicity, similarly identified concurrent G-CSF use as a potential risk factor for pulmonary toxicity.<sup>3</sup> Among patients with pulmonary toxicity, 76% received G-CSF vs. only 47% of bleomycin recipients without pulmonary toxicity (p = 0.014). Increased age and use of the ABVD chemotherapy regimen were also identified as potential risk factors in the univariate analysis; due to the relatively small number of cases available, no multivariate analyses were reported. Several animal studies also support the association between G-CSF (or GM-CSF) use and a greater risk for bleomycin pulmonary toxicity.<sup>4,5,6</sup><br><br>In contrast, one comparison of the rates of bleomycin toxicity reported a similar rate of toxicity among both 29 patients treated with bleomycin plus G-CSF and 57 patients treated with bleomycin, etoposide, and cisplatin (but no G-CSF) (34% vs. 33%, respectively).<sup>7</sup><br><br>Additional data from studies designed to specifically address this issue are needed in order to definitively characterize this purported interaction, but the data currently available seem sufficient to justify greater caution when considering the concurrent use of bleomycin with either G-CSF or GM-CSF.<br><br>The exact mechanism(s) of this possible interaction is not certain, but an increase in granulocyte function and/or number due to G-CSF/GM-CSF administration is suspected.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Matthews JH, “Pulmonary Toxicity of ABVD Chemotherapy and G-CSF in Hodgkin’s Disease: Possible Synergy,” <i>Lancet</i>, 1993, 342:988. [PMID: 7692199]</p>\n<p>2. Dirix L, Schrijvers D, Druwe P, et al, “Pulmonary Toxicity and Bleomycin,” <i>Lancet</i>, 1994, 344:56. [PMID: 7516990]</p>\n<p>3. Martin WG, Ristow KM, Habermann TM, et al, “Bleomycin Pulmonary Toxicity Has a Negative Impact on the Outcome of Patients With Hodgkin’s Lymphoma,” <i>J Clin Oncol</i>, 2005, 23:7614-20. [PMID: 16186594]</p>\n<p>4. Adachi K, Suzuki M, Sugimoto T, et al, “Effects of Granulocyte Colony-Stimulating Factor on the Kinetics of Inflammatory Cells in the Peripheral Blood and Pulmonary Lesions During the Development of Bleomycin-Induced Lung Injury in Rats,” <i>Exp Toxicol Pathol</i>, 2003, 55(1):21-32. [PMID: 12940625]</p>\n<p>5. Adach K, Suzuki M, Sugimoto T, et al, “Granulocyte Colony-Stimulating Factor Exacerbates the Acute Lung Injury and Pulmonary Fibrosis Induced by Intratracheal Administration of Bleomycin in Rats,” <i>Exp Toxicol Pathol</i>, 2002, 53(6):501-10. [PMID: 11926293]</p>\n<p>6. Andreutti D, Gabbiani G, Neuville P, “Early Granulocyte-Macrophage Colony-Stimulating Factor Expression by Alveolar Inflammatory Cells During Bleomycin-Induced Rat Lung Fibrosis,” <i>Lab Invest</i>, 1998, 78(12):1493-502. [PMID: 9881949]</p>\n<p>7. Saxman SB, Nichols CR, Einhorn LH, “Pulmonary Toxicity in Patients with Advanced-Stage Germ Cell Tumors Receiving Bleomycin with and without Granulocyte Colony Stimulating Factor,” <i>Chest</i>, 1997, 111(3):657-60. [PMID: 9118704]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5209":"<p><b>Title</b> Bleomycin / Sargramostim</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sargramostim may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients more closely for signs/symptoms of bleomycin pulmonary toxicity when used with sargramostim (GM-CSF). Be aware that the use of such a combination may increase the risk for potentially severe pulmonary toxicity.</p> \n<p><b>Discussion</b> According to one report, evidence of possible bleomycin-associated pulmonary toxicity was observed in 4 of 5 patients receiving G-CSF in combination with the ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy regimen.<sup>1</sup> The authors considered this noteworthy due to the unusually high rate of toxicity, particularly since the patients with evidence of toxicity received more than 5-fold lower doses of bleomycin that that normally associated with risk of pulmonary toxicity. Another case report describes a patient with rapidly-developing and fatal pulmonary toxicity attributed to concurrent use of bleomycin and G-CSF.<sup>2</sup><br><br>A retrospective analysis of 141 bleomycin-treated patients, 25 (18%) of whom experience bleomycin-associated pulmonary toxicity, similarly identified concurrent G-CSF use as a potential risk factor for pulmonary toxicity.<sup>3</sup> Among patients with pulmonary toxicity, 76% received G-CSF vs. only 47% of bleomycin recipients without pulmonary toxicity (p = 0.014). Increased age and use of the ABVD chemotherapy regimen were also identified as potential risk factors in the univariate analysis; due to the relatively small number of cases available, no multivariate analyses were reported. Several animal studies also support the association between G-CSF (or GM-CSF) use and a greater risk for bleomycin pulmonary toxicity.<sup>4,5,6</sup><br><br>In contrast, one comparison of the rates of bleomycin toxicity reported a similar rate of toxicity among both 29 patients treated with bleomycin plus G-CSF and 57 patients treated with bleomycin, etoposide, and cisplatin (but no G-CSF) (34% vs. 33%, respectively).<sup>7</sup><br><br>Additional data from studies designed to specifically address this issue are needed in order to definitively characterize this purported interaction, but the data currently available seem sufficient to justify greater caution when considering the concurrent use of bleomycin with either G-CSF or GM-CSF.<br><br>The exact mechanism(s) of this possible interaction is not certain, but an increase in granulocyte function and/or number due to G-CSF/GM-CSF administration is suspected.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Matthews JH, “Pulmonary Toxicity of ABVD Chemotherapy and G-CSF in Hodgkin’s Disease: Possible Synergy,” <i>Lancet</i>, 1993, 342:988. [PMID: 7692199]</p>\n<p>2. Dirix L, Schrijvers D, Druwe P, et al, “Pulmonary Toxicity and Bleomycin,” <i>Lancet</i>, 1994, 344:56. [PMID: 7516990]</p>\n<p>3. Martin WG, Ristow KM, Habermann TM, et al, “Bleomycin Pulmonary Toxicity Has a Negative Impact on the Outcome of Patients With Hodgkin’s Lymphoma,” <i>J Clin Oncol</i>, 2005, 23:7614-20. [PMID: 16186594]</p>\n<p>4. Adachi K, Suzuki M, Sugimoto T, et al, “Effects of Granulocyte Colony-Stimulating Factor on the Kinetics of Inflammatory Cells in the Peripheral Blood and Pulmonary Lesions During the Development of Bleomycin-Induced Lung Injury in Rats,” <i>Exp Toxicol Pathol</i>, 2003, 55(1):21-32. [PMID: 12940625]</p>\n<p>5. Adach K, Suzuki M, Sugimoto T, et al, “Granulocyte Colony-Stimulating Factor Exacerbates the Acute Lung Injury and Pulmonary Fibrosis Induced by Intratracheal Administration of Bleomycin in Rats,” <i>Exp Toxicol Pathol</i>, 2002, 53(6):501-10. [PMID: 11926293]</p>\n<p>6. Andreutti D, Gabbiani G, Neuville P, “Early Granulocyte-Macrophage Colony-Stimulating Factor Expression by Alveolar Inflammatory Cells During Bleomycin-Induced Rat Lung Fibrosis,” <i>Lab Invest</i>, 1998, 78(12):1493-502. [PMID: 9881949]</p>\n<p>7. Saxman SB, Nichols CR, Einhorn LH, “Pulmonary Toxicity in Patients with Advanced-Stage Germ Cell Tumors Receiving Bleomycin with and without Granulocyte Colony Stimulating Factor,” <i>Chest</i>, 1997, 111(3):657-60. [PMID: 9118704]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5210":"<p><b>Title</b> Telbivudine / Interferon Alfa-2b</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Interferon Alfa-2b may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concurrent use of these agents when possible; telbivudine prescribing information specifically recommends against concurrent use of telbivudine with interferons. If this combination must be used together, monitor patients closely for signs and symptoms of peripheral neuropathy.</p> \n<p><b>Discussion</b> In one clinical trial, peripheral neuropathy was more common and more severe among patients receiving both telbivudine (600 mg daily) and pegylated interferon alfa-2a (180 mcg SQ weekly) than among patients receiving telbivudine alone.<sup>1</sup> Peripheral neuropathy has been reported with telbivudine monotherapy, but at a rate of only less than 1% according to telbivudine prescribing information.<sup>1</sup> A case series describing adverse effects associated with telbivudine therapy in 5 patients (out of 105 total telbivudine recipients) noted that 3 of the patients had received both telbivudine and interferon.<sup>2</sup> All 3 patients reported signs/symptoms consistent with neuropathy. The patients had been receiving telbivudine for 7-9 months and interferon for 3 months. Optimal clinical management of this reported interaction is uncertain.<br><br>The specific mechanism for this interaction is unknown.<br><br>The effect, if any, of this combination on alpha interferon pharmacokinetics is unknown. Pharmacokinetic studies of the combination have been inconclusive due to the large variability in pegylated interferon alfa-2a pharmacokinetics.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tyzeka (telbivudine). East Hanover, NJ: Novartis Pharmaceutical Corporation, April 2009.</p>\n<p>2. Zhang XS, Jin R, Zhang SB, et al, “Clinical Features of Adverse Reactions Associated with Telbivudine,” <i>World J Gastroenterol</i>, 2008, 14(22):3549-53. [PMID: 18567085]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5211":"<p><b>Title</b> Vitamin K Antagonists / Erythromycin (Ophthalmic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Erythromycin (Ophthalmic) may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects (INR, bleeding/bruising) of vitamin K antagonists with initiation/dose increase of ophthalmic erythromycin, and decreased effects with discontinuation/dose decrease. Dosage adjustments may be necessary.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> A single case report describes a 77 year old female receiving maintenance warfarin therapy (14 mg/week x4 months), whose previously therapeutic INR became supratherapeutic (8.5) approximately 3 weeks after initiating erythromycin ophthalmic ointment therapy. Upon erythromycin discontinuation and warfarin dosage adjustments, the patient’s INR returned to a therapeutic level. Following rechallenge with erythromycin ophthalmic ointment, the patient's INR increased to 4.2. The authors conclude that erythromycin inhibited CYP3A4 metabolism of warfarin and also suggest that concomitant simvastatin therapy in this patient may have enhanced erythromycin absorption via ocular P-glycoprotein (P-gp) inhibition.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Parker DL, Hoffmann TK, Tucker MA, et al, “Elevated International Normalized Ratio Associated with Concurrent Use of Ophthalmic Erythromycin and Warfarin,” <i>Am J Health Syst Pharm,</i> 2010, 67(1):38-41.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5212":"<p><b>Title</b> Zoster Vaccine (Live/Attenuated) / Pneumococcal Polysaccharide Vaccine (23-Valent)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pneumococcal Polysaccharide Vaccine (23-Valent) may diminish the therapeutic effect of Zoster Vaccine (Live/Attenuated). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Zoster vaccine U.S. labeling calls for clinicians to consider separating administration of these vaccines by at least 4 weeks, while the Centers for Disease Control and Prevention advocate administration of these vaccines at the same visit to interested patients.</p> \n<p><b>Discussion</b> Prescribing information for varicella zoster vaccine (VZV, Zostavax) describes a randomized, double-blind study of 473 adults age 60 years or older assigned to receive VZV either concurrently with or 4 weeks following pneumococcal polysaccharide vaccine (23-valent, Pneumovax 23).<sup>1,2</sup> VZV antibody concentrations were significantly lower at 4 weeks post-vaccination in patients receiving the vaccines concurrently (GMT ratio = 0.70). Antibody concentrations for pneumococcal polysaccharide vaccine (polyvalent) antigens were similar between groups. In a retrospective medical record review, individuals who received these vaccines on the same day and those who received the pneumococcal vaccine 30 days to 1 year prior to the VZV (N &gt; 7,000 per group) has no significant difference in subsequent herpes zoster diagnosis during a defined time period.<sup>3</sup><br><br>U.S. prescribing information for VZV recommends considering administration of VZV and the 23-valent pneumococcal polysaccharide vaccine by at least 4 weeks.<sup>1</sup> The Centers for Disease Control and Prevention, in contrast, advocate for the administration of both vaccines in the same visit to interested patients.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Zostavax (zoster vaccine live). Whitehouse Station, NJ: Merck &amp; Co, Inc, 4/2013.</p>\n<p>2. MacIntyre CR, Egerton T, McCaughey M, et al, “Concomitant Administration of Zoster and Pneumococcal Vaccines in Adults (greater than or equal to) 60 Years Old,” <i>Hum Vaccin</i>, 2010, 6(11):894-902. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20980796\">[PubMed 20980796]</a></p>\n<p>3. Tseng HF, Smith N, Sy LS, et al, “Evaluation of the Incidence of Herpes Zoster After Concomitant Administration of Zoster Vaccine and Polysaccharide Pneumococcal Vaccine,” <i>Vaccine</i>, 2011, 29(20):3628-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21435407\">[PubMed 21435407]</a></p>\n<p>4. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention Herpes Zoster Vaccination Information for Health Care Professionals. Last reviewed October 2012. Accessed online 6/7/2013 at http://www.cdc.gov/vaccines/vpd-vac/shingles/hcp-vaccination.htm.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5213":"<p><b>Title</b> Immunosuppressants / Pimecrolimus</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Pimecrolimus may enhance the adverse/toxic effect of Immunosuppressants. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid use of pimecrolimus cream in patients receiving immunosuppressants.</p>\n<div>\n <p><b>Immunosuppressants Interacting Members</b> Abatacept, Abemaciclib, Acalabrutinib, Adalimumab, Ado-Trastuzumab Emtansine, Alemtuzumab, Altretamine, Amsacrine, Anakinra, Antithymocyte Globulin (Equine), Antithymocyte Globulin (Rabbit), AzaCITIDine, AzaTHIOprine, Basiliximab, Beclomethasone (Oral Inhalation), Beclomethasone (Systemic), Belatacept, Belimumab, Belotecan, Betamethasone (Systemic), Bleomycin, Blinatumomab, Brentuximab Vedotin, Brodalumab, Budesonide (Systemic), Busulfan, Cabazitaxel, Canakinumab, Capecitabine, CARBOplatin, Carmustine, Certolizumab Pegol, Chlorambucil, CISplatin, Cladribine, Clofarabine, Copanlisib, Corticotropin, Cortisone, Cyclophosphamide, CycloSPORINE (Systemic), Cytarabine (Conventional), Dacarbazine, Daclizumab, DACTINomycin, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Deflazacort, Dexamethasone (Systemic), Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eculizumab, Elotuzumab, EpiRUBicin, Estramustine, Etanercept, Etoposide, Etoposide Phosphate, Everolimus, Fingolimod, Floxuridine, Fludarabine, Fludrocortisone, Fluorouracil (Systemic), Fluticasone (Oral Inhalation), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Glatiramer Acetate, Golimumab, Guselkumab, Hydrocortisone (Systemic), Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Imiquimod, InFLIXimab, Inotuzumab Ozogamicin, Irinotecan (Conventional), Irinotecan (Liposomal), Ixekizumab, Leflunomide, Lenalidomide, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, Methotrexate, MethylPREDNISolone, MitoMYcin (Systemic), MitoXANTRONE, Mizoribine, Mycophenolate, Natalizumab, Nelarabine, Nilotinib, Obinutuzumab, Ocrelizumab, Ofatumumab, Omacetaxine, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pegaspargase, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PRALAtrexate, PrednisoLONE (Systemic), PredniSONE, Procarbazine, Ribociclib, Rilonacept, RiTUXimab, RomiDEPsin, Ruxolitinib, Sarilumab, Secukinumab, Siltuximab, Sirolimus, SORAfenib, Streptozocin, SUNItinib, Tacrolimus (Systemic), Tegafur, Temozolomide, Temsirolimus, Teniposide, Teriflunomide, Thalidomide, Thioguanine, Thiotepa, Tocilizumab, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Tretinoin (Systemic), Triamcinolone (Systemic), Trifluridine and Tipiracil, Ustekinumab, Vedolizumab, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine<br><b>Exception</b> Cytarabine (Liposomal)</p>\n</div> \n<p><b>Discussion</b> Prescribing information for pimecrolimus cream warns against use in immunocompromised patients.<sup>1</sup> Prolonged immunosuppression with systemic calcineurin inhibitors is associated with increased risk of infection, lymphoma, and skin malignancies. These effects are dependent on immunosuppression intensity and duration. <br><br>Studies in children and adults with atopic dermatitis have consistently demonstrated low systemic exposure from topical pimecrolimus.<sup>1,2,3,4,5,6,7,8,9</sup> Blood concentrations are generally undetectable, and when detectable rarely exceed 2 ng/mL. Absorption appears to be greater in pediatric patients than adult patients, but there is no clear relation between amount of cream applied or extent of body surface area treated and blood concentrations. Nonetheless, malignancies related to the use of topical pimecrolimus have been reported. Although the overall incidence of these is unknown.<sup>10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Elidel (pimecrolimus). East Hanover, NJ: Novartis Pharmaceuticals Corporation, May 2009.</p>\n<p>2. ODS Postmarketing Safety Review (PID 040609). Pediatric Advisory Committee meeting of the Food and Drug Administration, Washington, DC, October 2005. Accessed online January 19, 2010 at http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2_01_04_Pimecrolimus%20IMS%20Cleared%20AE%20LT%202%20YO%20Malignancy.pdf.</p>\n<p>3. Eichenfield LF, Ho V, Matsunaga J, Leclerc P, Paul C, Hanifin JM, “Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis,” <i>J Dermatol,</i> 2007, 34(4):231-6.</p>\n<p>4. Lakhanpaul M, Davies T, Allen BR, Schneider D, “Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*,” <i>Exp Dermatol,</i> 2006, 15(2):138-41.</p>\n<p>5. Harper J, Green A, Scott G, et al, “First experience of topical SDZ ASM 981 in children with atopic dermatitis,” <i>Br J Dermatol,</i> 2001, 144(4):781-7.</p>\n<p>6. Ling M, Gottlieb A, Pariser D, et al, “A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis,” <i>J Dermatolog Treat,</i> 2005, 16(3):142-8.</p>\n<p>7. Van Leent EJ, De Vries HJ, Ebelin ME, Burtin P, Scott G, Bos JD, “Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel) for up to 1 year,” <i>iJ Dermatolog Treat,</i> 2007, 18(1):19-22.</p>\n<p>8. Allen BR, Lakhanpaul M, Morris A, et al, “Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients,” <i>Arch Dis Child,</i> 2003, 88(11):969-73.</p>\n<p>9. Draelos Z, Nayak A, Pariser D, et al, “Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison,” <i>J Am Acad Dermatol,</i> 2005, 53:602-9.</p>\n<p>10. Van Leent EJ, Ebelin M-E, Burtin P, et al, “Low systemic exposure after repeated topical application of pimecrolimus (Elidel, SD Z ASM 981) in patients with atopic dermatitis,” <i>Dermatology,</i> 2002, 204(1):63-8.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5214":"<p><b>Title</b> Vitamin K Antagonists / MetroNIDAZOLE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> MetroNIDAZOLE (Systemic) may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to concomitant therapy with metronidazole and vitamin K antagonists. If concomitant therapy cannot be avoided, consider reducing the dose of the vitamin K antagonist and monitor for increased INR/bleeding if metronidazole is initiated/dose increased.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The mean prothrombin time (PT) increased 42% and the half-life of the more potent S-warfarin enantiomer increased 56% in 8 healthy volunteers when warfarin (1.5 mg/kg single oral dose) was administered following a 7-day course of metronidazole (250 mg three times per day).<sup>1</sup> The pharmacokinetics of the less potent R-warfarin isomer were unaltered. Two case reports describe a potential interaction between metronidazole and warfarin.<sup>2,3</sup> In the first case, a 31-year-old female on stable warfarin therapy experienced a lower extremity hematoma requiring hospitalization and an elevated PT of 147 seconds (normal 17 to 19 seconds) after being treated with metronidazole (750 mg per day) for a week.<sup>2</sup> In the second case, a 78-year-old, warfarin-treated female experienced an intracerebral hemorrhage and had an INR of 8.0 (previous INR of 2.5) 5 days after treatment with metronidazole (250 mg three times daily) and levofloxacin (500 mg daily).<sup>3</sup> Retrospective reviews have also reported an interaction (and patient harm) with the concomitant use of warfarin and metronidazole.<sup>4,5,6</sup> In one review, 14 (44%) of 32 patients who received the combination of warfarin and metronidazole experienced an INR greater than 4.<sup>4</sup> In analyses of administrative claims data, the use of warfarin plus metronidazole was associated with a greater risk of hemorrhage (OR 1.6, 95% CI [1.32-1.89]) compared to use of warfarin alone,<sup>5</sup> and a greater proportion of INR values greater than 4 compared to the use of low-risk (or lower interaction potential) antibiotics (10.1% vs 7.2%, p&lt;0.05).<sup>6</sup> <br><br>One retrospective study evaluated the strategy of a preemptive warfarin dose reduction versus usual care (increased monitoring) in warfarin treated patients initiated on metronidazole.<sup>7</sup> A 35% preemptive warfarin dose reduction resulted in no change in INR versus an INR increase of 1.47 for patients receiving usual care after metronidazole initiation (p=0.01).<sup>7</sup><br><br>The mechanism of this interaction has not been fully investigated, but metronidazole is an inhibitor (weak) of CYP2C9, the primary enzyme responsible for S-warfarin metabolism. The impact of metronidazole on the pharmacokinetics of acenocoumarol has not been studied, but acenocoumarol is also a CYP2C9 substrate and thus may also be susceptible to a similar interaction with metronidazole.</p> \n<p><b>Footnotes</b> </p>\n<p>1. O’Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. <i>N Engl J Med</i>. 1976;295(7):354-357. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=934223\">[PubMed 934223]</a></p>\n<p>2. Kazmier FJ. A significant interaction between metronidazole and warfarin. <i>Mayo Clin Proc</i>. 1976;51(12):782-784. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=994556\">[PubMed 994556]</a></p>\n<p>3. Howard-Thompson A, Hurdle AC, Arnold LB, Finch CK, Sands C, Self TH. Intracerebral hemorrhage secondary to a warfarin-metronidazole interaction. <i>Am J Geriatr Pharmacother</i>. 2008;6(1):33-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18396247\">[PubMed 18396247]</a></p>\n<p>4. Laine K, Forsstrom J, Gronroos P, Irjala K, Kailajarvi M, Scheinin M. Frequency and clinical outcome of potentially harmful drug metabolic interactions in patients hospitalized on internal and pulmonary medicine wards: focus on warfarin and cisapride. <i>Ther Drug Monit</i>. 2000;22(5):503-509. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11034253\">[PubMed 11034253]</a></p>\n<p>5. Zhang K, Young C, Berger J. Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions. <i>J Manag Care Pharm</i>. 2006;12(8):640-648. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17269842\">[PubMed 17269842]</a></p>\n<p>6. Lane MA, Zerinque A, McDonald JR. Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans. <i>Am J Med</i>. 2014;127(7):657-663. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24657899\">[PubMed 24657899]</a></p>\n<p>7. Holt RK, Anderson EA, Cantrell MA, Shaw RF, Egge JA. Preemptive dose reduction of warfarin in patients initiating metronidazole. <i>Drug Metabol Drug Interact</i>. 2010;25(1-4):35-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21417792\">[PubMed 21417792]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5215":"<p><b>Title</b> Immunosuppressants / Tacrolimus (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tacrolimus (Topical) may enhance the adverse/toxic effect of Immunosuppressants. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid use of tacrolimus ointment in patients receiving immunosuppressants.</p>\n<div>\n <p><b>Immunosuppressants Interacting Members</b> Abatacept, Abemaciclib, Acalabrutinib, Adalimumab, Ado-Trastuzumab Emtansine, Alemtuzumab, Altretamine, Amsacrine, Anakinra, Antithymocyte Globulin (Equine), Antithymocyte Globulin (Rabbit), AzaCITIDine, AzaTHIOprine, Basiliximab, Beclomethasone (Oral Inhalation), Beclomethasone (Systemic), Belatacept, Belimumab, Belotecan, Betamethasone (Systemic), Bleomycin, Blinatumomab, Brentuximab Vedotin, Brodalumab, Budesonide (Systemic), Busulfan, Cabazitaxel, Canakinumab, Capecitabine, CARBOplatin, Carmustine, Certolizumab Pegol, Chlorambucil, CISplatin, Cladribine, Clofarabine, Copanlisib, Corticotropin, Cortisone, Cyclophosphamide, CycloSPORINE (Systemic), Cytarabine (Conventional), Dacarbazine, Daclizumab, DACTINomycin, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Deflazacort, Dexamethasone (Systemic), Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eculizumab, Elotuzumab, EpiRUBicin, Estramustine, Etanercept, Etoposide, Etoposide Phosphate, Everolimus, Fingolimod, Floxuridine, Fludarabine, Fludrocortisone, Fluorouracil (Systemic), Fluticasone (Oral Inhalation), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Glatiramer Acetate, Golimumab, Guselkumab, Hydrocortisone (Systemic), Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Imiquimod, InFLIXimab, Inotuzumab Ozogamicin, Irinotecan (Conventional), Irinotecan (Liposomal), Ixekizumab, Leflunomide, Lenalidomide, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, Methotrexate, MethylPREDNISolone, MitoMYcin (Systemic), MitoXANTRONE, Mizoribine, Mycophenolate, Natalizumab, Nelarabine, Nilotinib, Obinutuzumab, Ocrelizumab, Ofatumumab, Omacetaxine, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pegaspargase, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PRALAtrexate, PrednisoLONE (Systemic), PredniSONE, Procarbazine, Ribociclib, Rilonacept, RiTUXimab, RomiDEPsin, Ruxolitinib, Sarilumab, Secukinumab, Siltuximab, Sirolimus, SORAfenib, Streptozocin, SUNItinib, Tacrolimus (Systemic), Tegafur, Temozolomide, Temsirolimus, Teniposide, Teriflunomide, Thalidomide, Thioguanine, Thiotepa, Tocilizumab, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Tretinoin (Systemic), Triamcinolone (Systemic), Trifluridine and Tipiracil, Ustekinumab, Vedolizumab, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine<br><b>Exception</b> Cytarabine (Liposomal)</p>\n</div> \n<p><b>Discussion</b> Prescribing information for tacrolimus ointment warns against use in immunocompromised patients.<sup>1</sup> Prolonged immunosuppression with systemic calcineurin inhibitors is associated with increased risk of infection, lymphoma, and skin malignancies. These effects are dependent on immunosuppression intensity and duration. <br><br>Blood concentrations are generally low (less than 1 ng/mL) when topical tacrolimus ointment is applied as indicated.<sup>1,2,3,4,5,6,7</sup> However, several cases of elevated blood concentrations (with or without systemic toxicity) have been reported with topical tacrolimus.<sup>8,9,10,11,12,13,14,15,16,17,18</sup> Authors have suggested that systemic exposure may increase with larger applied doses, larger treated areas, occlusion, facial or oral application, and application to inflamed or open lesions. The risk for and clinical significance of drug interactions involving topically applied tacrolimus will likely increase in the presence of these factors as well. Malignancies related to the use of topical tacrolimus have been reported, although the overall incidence of these is unknown.<sup>19</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Protopic (tacrolimus) . Deerfield, IL: Astellas Pharma US, Inc, January 2009.</p>\n<p>2. Krueger GG, Eichenfield L, Goodman JJ, et al, “Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adult and Pediatric Patients with Moderate to Severe Atopic Dermatits,” <i>J Drugs Dermatol</i>, 2007, 6(2):185-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17373177\">[PubMed 17373177]</a> 3. Draelos Z, Nayak A, Pariser D, et al, “Pharmacokinetics of Topical Calcineurin Inhibitors in Adult Atopic Dermatitis: A Randomized, Investigator-Blind Comparison,” <i>J Am Acad Dermatol</i>, 2005, 53(4):602-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16198779\">[PubMed 16198779]</a></p>\n<p>4. Harper J, Smith C, Rubins A, et al, “A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment After First and Repeated Application to Children With Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 124(4):695-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15816825\">[PubMed 15816825]</a></p>\n<p>5. Undre NA, Moloney FJ, Ahmadi S, et al, “Skin and Systemic Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adults With Moderate to Severe Atopic Dermatitis,” <i>Br J Dermatol</i>, 2009, 160(3):665-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19076975\">[PubMed 19076975]</a></p>\n<p>6. Rubins A, Gutmane R, Valdmane N, et al, “Pharmacokinetics of 0.1% Tacrolimus Ointment After First and Repeated Application to Adults With Moderate to Severe Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 125(1):68-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982304\">[PubMed 15982304]</a></p>\n<p>7. Alaiti S, Kang S, Fiedler C, et al, “Tacrolimus (FK506) Ointment for Atopic Dermatitis: A Phase I Study in Adults and Children,” <i>J Am Acad Dermatol</i>, 1998, 38(1)69-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9448208\">[PubMed 9448208]</a></p>\n<p>8. Kameda G, Kramm C Niehues T, et al, “Unexpected High Serum Levels of Tacrolimus After a Single Topical Application in an Infant,” <i>J Pediatr</i>, 2003, 143(4):462. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12970650\">[PubMed 12970650]</a></p>\n<p>9. Ghislain PD, De Decker I, Lachapelle JM, “Efficacy and Systemic Absorption of Topical Tacrolimus Used in Pyoderma Gangrenosum,” <i>Br J Dermatol</i>, 2004, 150(5):1052-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15149540\">[PubMed 15149540]</a></p>\n<p>10. Kawashima M, Nakagawaw H, Ohtsuki M, et al, “Tacrolimus Concentrations in Blood During Topical Treatment of Atopic Dermatitis,” <i>Lancet</i>, 1996, 348(9036):1240-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8898050\">[PubMed 8898050]</a></p>\n<p>11. Allen DM, Esterly NB, “Significant Systemic Absorption of Tacrolimus After Topical Application in a Patient With Lamellar Ichthyosis,” <i>Arch Dermatol</i>, 2002, 138(9):1259-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12225004\">[PubMed 12225004]</a></p>\n<p>12. Allen A, Siegfried E, Silverman R, et al, “Significant Absorption of Topical Tacrolimus in 3 Patients With Netherton Syndrome,” <i>Arch Dermatol</i>, 2001, 137(6)747-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11405764\">[PubMed 11405764]</a></p>\n<p>13. Pitarch G, Torrijos A, Mahiques L, et al, “Systemic Absorption of Topical Tacrolimus in Pyoderma Gangrenosum,” <i>Acta Derm Venereol</i>, 2006, 86(1)64-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16585995\">[PubMed 16585995]</a></p>\n<p>14. Prot-Labarthe S, Therrien R, Champagne MA, et al, “Toxic Serum Levels of Tacrolimus After Topical Administration in an Infant With Severe Cutaneous Graft-Versus-Host Disease,” <i>Bone Marrow Transplant</i>, 2007, 40(3):295-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17549052\">[PubMed 17549052]</a></p>\n<p>15. Russel RK, Richardson N, Wilson DC, “Systemic Absorption With Complications During Topical Tacrolimus Treatment for Orofactial Crohn Disease,” <i>J Pediatr Gastroenterol Nutr</i>, 2001, 32(2):207-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11321395\">[PubMed 11321395]</a></p>\n<p>16. Teshima D, Ikesue H, Itoh Y, et al, “Increased Topical Tacrolimus Absorption in Generalized Leukemic Erythroderma,” <i>Ann Pharmacother</i>, 2003, 37(10):1444-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14519034\">[PubMed 14519034]</a></p>\n<p>17. Beyerler M, Schmid-Grendelmeier P, Hafner J, “Significantly Elevated Systemic Levels After Occlusive Application of Topical Tacrolimus in Atopic Dermatitis,” <i>Dermatology</i>, 2006, 212(3):260-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16549924\">[PubMed 16549924]</a></p>\n<p>18. Conrotto D, Carrozzo M, Ubertalli AV, et al, “Dramatic Increase of Tacrolimus Plasma Concentration During Topical Treatment for Oral Graft-Versus-Host Disease,” <i>Transplantation</i>, 2006, 82(8):1113-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17060865\">[PubMed 17060865]</a></p>\n<p>19. ODS Postmarketing Safety Review (PID 040608). Pediatric Advisory Committee meeting of the Food and Drug Administration, Washington, DC, February 2005. Accessed online January 19, 2010 at http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2_01_03_Tacrolimus%20Topical%20IMS%20Cleared%20LT%202%20and%20Malignancy%20Update.pdf.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5216":"<p><b>Title</b> Telbivudine / Peginterferon Alfa-2a</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Peginterferon Alfa-2a may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concurrent use of these agents when possible. Both the telbivudine prescribing information and the Canadian product monograph for pegylated interferon alfa-2a/ribavirin specifically recommend against concurrent use. If this combination must be used together, monitor patients closely for signs and symptoms of peripheral neuropathy.</p> \n<p><b>Discussion</b> In one clinical trial, peripheral neuropathy was more common and more severe among patients receiving both telbivudine (600 mg daily) and pegylated inferferon alfa-2a (180 mcg SQ weekly) than among patients receiving telbivudine alone.<sup>1</sup> Peripheral neuropathy has been reported with telbivudine monotherapy, but at a rate of only less than 1% according to telbivudine prescribing information.<sup>1</sup> A case series describing adverse effects associated with telbivudine therapy in 5 patients (out of 105 total telbivudine recipients) noted that 3 of the patients had received both telbivudine and interferon.<sup>2</sup> All 3 patients reported signs/symptoms consistent with neuropathy. The patients had been receiving telbivudine for 7-9 months and interferon for 3 months. Optimal clinical management of this reported interaction is uncertain. Both the telbivudine prescribing information and the Canadian product monograph for pegylated interferon alfa-2a/ribavirin specifically recommend against concurrent use.<sup>1,3</sup><br><br>The specific mechanism for this interaction is unknown.<br><br>The effect, if any, of this combination on alpha interferon pharmacokinetics is unknown. Pharmacokinetic studies of the combination have been inconclusive due to the large variability in pegylated interferon alfa-2a pharmacokinetics.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tyzeka (telbivudine). East Hanover, NJ: Novartis Pharmaceutical Corporation, April 2009.</p>\n<p>2. Zhang XS, Jin R, Zhang SB, et al, “Clinical Features of Adverse Reactions Associated with Telbivudine,” <i>World J Gastroenterol</i>, 2008, 14(22):3549-53. [PMID: 18567085]</p>\n<p>3. Product Monograph. Pegasys RBV (pegylated interferon alfa-2a and ribavirin). Mississauga, Ontario, Canada: Hoffmann-La Roche Limited, August 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5217":"<p><b>Title</b> Telbivudine / Peginterferon Alfa-2b</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Peginterferon Alfa-2b may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concurrent use of these agents when possible; telbivudine prescribing information specifically recommends against concurrent use of telbivudine with interferons. If this combination must be used together, monitor patients closely for signs and symptoms of peripheral neuropathy.</p> \n<p><b>Discussion</b> In one clinical trial, peripheral neuropathy was more common and more severe among patients receiving both telbivudine (600 mg daily) and pegylated inferferon alfa-2a (180 mcg SQ weekly) than among patients receiving telbivudine alone.<sup>1</sup> Peripheral neuropathy has been reported with telbivudine monotherapy, but at a rate of only less than 1% according to telbivudine prescribing information.<sup>1</sup> A case series describing adverse effects associated with telbivudine therapy in 5 patients (out of 105 total telbivudine recipients) noted that 3 of the patients had received both telbivudine and interferon.<sup>2</sup> All 3 patients reported signs/symptoms consistent with neuropathy. The patients had been receiving telbivudine for 7-9 months and interferon for 3 months. Optimal clinical management of this reported interaction is uncertain. Both the telbivudine prescribing information and the Canadian product monograph for pegylated interferon alfa-2a/ribavirin specifically recommend against concurrent use.<sup>1,3</sup> The US prescribing information for both pegylated interferon alfa-2a and pegylated interferon alfa-2b note that safety of concurrent use with telbivudine has not been studied and caution that there may be an increased risk of peripheral neuropathy.<sup>4,5</sup><br><br>The specific mechanism for this interaction is unknown.<br><br>The effect, if any, of this combination on alpha inferferon pharmacokinetics is unknown. Pharmacokinetic studies of the combination have been inconclusive due to the large variability in pegylated inferferon alfa-2a pharmacokinetics.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tyzeka (telbivudine). East Hanover, NJ: Novartis Pharmaceutical Corporation, April 2009.</p>\n<p>2. Zhang XS, Jin R, Zhang SB, et al, “Clinical Features of Adverse Reactions Associated with Telbivudine,” <i>World J Gastroenterol</i>, 2008, 14(22):3549-53. [PMID: 18567085]</p>\n<p>3. Product Monograph. Pegasys RBV (pegylated interferon alfa-2a and ribavirin). Mississauga, Ontario, Canada: Hoffmann-La Roche Limited, August 2008.</p>\n<p>4. Prescribing information. PegIntron (peginterferon alfa-2b). Kenilworth, NJ: Schering-Plough Corporation, 8/09.</p>\n<p>5. Prescribing information. Pegasys (peginterferon alfa-2a). Nutley, NJ: Hoffmann-La Roche Inc., August 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5219":"<p><b>Title</b> Opioid Analgesics / Oprelvekin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Oprelvekin may increase the serum concentration of Opioid Analgesics. <b>Severity</b> Major <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for signs/symptoms of respiratory depression and/or enhanced sedation with concomitant use of oprelvekin and opioids.</p>\n<div>\n <p><b>Opioid Analgesics Interacting Members</b> Alfentanil, Benzhydrocodone, Buprenorphine, Butorphanol, Codeine, Dihydrocodeine, FentaNYL, Heroin, HYDROcodone, HYDROmorphone, Levorphanol, Meperidine, Meptazinol, Methadone, Morphine (Liposomal), Morphine (Systemic), Nalbuphine, Opium, Opium Tincture, OxyCODONE, OxyMORphone, Paregoric, Pentazocine, Remifentanil, SUFentanil, Tapentadol, TraMADol</p>\n</div> \n<p><b>Discussion</b> A single case report describes a 20 year old female with a history of Wilms disease and subsequent pulmonary relapses, who developed peripheral and pulmonary edema, somnolence, and respiratory depression approximately 1 week after beginning oprelvekin therapy (50 mcg/kg SubQ daily).<sup>1</sup> Prior to oprelvekin therapy, the patient had been stable on several medications including morphine (120 mg twice daily) and phenobarbital. Following discontinuation of oprelvekin and morphine, normal consciousness and presumed baseline pulmonary function were restored. <br><br>Serious fluid retention is associated with use of oprelvekin<sup>2</sup> while respiratory depression and sedation may be observed with opioids (e.g., morphine) and phenobarbital. In concluding the patient experienced a likely drug-drug interaction with morphine and not phenobarbital, the authors note the patient experienced enhanced analgesia from her usual morphine dose while receiving concomitant oprelvekin therapy and further suggest that oprelvekin may have impaired the renal elimination of morphine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Moorehead P, Mandel KM, Johnston DL, “Suspected Interaction of Oprelvekin (rhIL-11) With a Long-Acting Opioid,” <i>Pediatr Blood Cancer,</i> 2008, 51(6):837 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18698585\">[PubMed 18698585]</a></p>\n<p>2. Prescribing information. Neumega (oprelvekin). Philadelphia, PA: Wyeth Pharmaceuticals, Inc., February 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5220":"<p><b>Title</b> Ursodiol / Bile Acid Sequestrants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the serum concentration of Ursodiol. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider administration of ursodiol 5 hours or more after bile acid sequestrants to minimize ursodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin*, Colesevelam, Colestipol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a study of healthy volunteers, simultaneous administration of cholestyramine with ursodiol resulted in fasting serum ursodiol concentrations 42% (day 2 of treatment) and 59% (day 14) lower than ursodiol given alone.<sup>1</sup> Administration of ursodiol 5 hours after cholestyramine resulted in nonsignificant 13% (day 2) and 26% (day 14) decreases. Serum concentrations of other bile acids were not affected by cholestyramine. <br><br>A study of healthy volunteers showed that coadministration of ursodiol and colestimide with a food resulted in 4 out of 5 subjects having lower ursodiol exposure in the first 3 hours and lower serum ursodiol concentrations at 30 minutes post-dose.<sup>2</sup> A study of patients with primary biliary cirrhosis showed that dosing of cholestyramine and ursodiol roughly 5 hours apart resulted in a similar profile of 9/10 measured serum bile acids.<sup>3</sup> Interpretability of these two studies is limited: the first by a short sampling period and lack of statistical analysis, and the second by a defined treatment order and lack of a washout period.<br><br>The likely mechanism of this interaction is adsorption of ursodiol by bile acid sequestrants in the gastrointestinal tract.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rust C, Sauter GH, Oswald M, et al, “Effect of Cholestyramine on Bile Acid Pattern and Synthesis During Administration of Ursodeoxycholic Acid in Man,” <i>Eur J Clin Invest</i>, 2000, 30(2):135-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10651838\">[PubMed 10651838]</a></p>\n<p>2. Takikawa H, Ogasawara T, Sato M, et al, “Effect of Colestimide on Intestinal Absorption of Ursodeoxycholic Acid in Men,” <i>Int J Clin Pharmacol Ther</i>, 2001, 39(12):558-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11770838\">[PubMed 11770838]</a></p>\n<p>3. Taha AS, Allison MC, Myara A, et al, “Does Cholestyramine Reduce the Efficacy of Ursodeoxycholic Acid in Primary Biliary Cirrhosis?” <i>Eur J Gastroenterol Hepatol</i> 1994, 6(6):535-8.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5221":"<p><b>Title</b> Nitrendipine / Ursodiol</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ursodiol may decrease the absorption of Nitrendipine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider therapeutic alternatives. If concomitant therapy cannot be avoided, avoid simultaneous administration</p> \n<p><b>Discussion</b> In a study of six healthy subjects, simultaneous administration of ursodeoxycholic acid (ursodiol) with nitrendipine resulted in a 54% decrease in maximum plasma nitrendipine concentration and a 75% decrease in total nitrendipine exposure.<sup>1</sup> <br><br>The mechanism of this interaction is unknown. It is not clear whether the specific formulations of nitrendipine (brand name Baylotensin) or ursodiol (brand name Urso) used in this study may have contributed to an interaction. The effect of separating doses of these agents is unknown. Howerver, likely mechanisms such as binding / chelation or impaired nitrendipine dissolution could theoretically be reduced by separating doses.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sasaki M, Maeda A, Sakamoto K, et al, “Effect of Bile Acids on Absorption of Nitrendipine in Healthy Subjects,” <i>Br J Clin Pharmacol</i>, 2001, 52(6):699-701. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11736882\">[PubMed 11736882]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5222":"<p><b>Title</b> Norgestimate / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Efavirenz may decrease serum concentrations of the active metabolite(s) of Norgestimate. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Use a reliable barrier contraceptive if efavirenz is used in combination with norgestimate. Continue using barrier contraception for 12 weeks after discontinuation of efavirenz.</p> \n<p><b>Discussion</b> In a clinical study mentioned in efavirenz prescribing information, treatment with efavirenz (600 mg daily) decreased norelgestromin and levonorgestrel maximum concentration (46% and 80% lower, respectively) and AUC (64% and 83% lower, respectively) from an ethinyl estradiol/norgestimate (35 mcg/ 1 mg daily) contraceptive.<sup>1</sup> This likely reflects decreased conversion of norgestimate to its major active metabolites, norelgestromin and norgestrel. Due to the long half-life of efavirenz, barrier contraception is recommended for 12 weeks following efavirenz treatment.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Sustiva (efavirenz). Princeton, NJ: Bristol-Myers Squibb Company, September 2009.</p>\n<p>2. Sevinsky H, Eley T, Persson A, et al, “The Effect of Efavirenz on the Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy HIV-negative Women,” <i>Antivir Ther.</i>, 2011, 16(2):149-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21447863\">[PubMed 21447863]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5223":"<p><b>Title</b> Etonogestrel / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Efavirenz may diminish the therapeutic effect of Etonogestrel. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use a reliable barrier contraceptive if efavirenz is used in combination with etonogestrel. Continue using barrier contraception for 12 weeks after discontinuation of efavirenz.</p> \n<p><b>Discussion</b> Prescribing information for efavirenz describes postmarketing reports of contraceptive failure in patients receiving etonogestrel with efavirenz.<sup>1</sup> Due to the long half-life of efavirenz, barrier contraception is recommended for 12 weeks after efavirenz treatment.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Sustiva (efavirenz). Princeton, NJ: Bristol-Myers Squibb Company, September 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5224":"<p><b>Title</b> Opioid Analgesics / Opioids (Mixed Agonist / Antagonist)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Opioids (Mixed Agonist / Antagonist) may diminish the analgesic effect of Opioid Analgesics. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid these combinations when possible. Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.</p>\n<div>\n <p><b>Opioid Analgesics Interacting Members</b> Alfentanil, Benzhydrocodone, Codeine, Dihydrocodeine, FentaNYL, Heroin, HYDROcodone, HYDROmorphone, Levorphanol, Meperidine, Methadone*, Morphine (Liposomal), Morphine (Systemic)*, Opium, Opium Tincture, OxyCODONE*, OxyMORphone, Paregoric, Remifentanil, SUFentanil, Tapentadol, TraMADol<br><b>Exceptions</b> Buprenorphine, Butorphanol, Meptazinol, Nalbuphine, Pentazocine</p>\n <p><b>Opioids (Mixed Agonist / Antagonist) Interacting Members</b> Buprenorphine*, Butorphanol*, Meptazinol, Nalbuphine*, Pentazocine*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A series of studies was carried out to assess the withdrawal-producing potential of mixed agonist / antagonist opioids relative to naloxone in methadone-dependent (30 mg daily) volunteers. Nalbuphine intramuscular injections (0.375 mg to 6 mg) produced withdrawal symptoms consistent with those produced by naloxone, with increasing effects over the dose range.<sup>1</sup> Pentazocine intramuscular (7.5 mg to 120 mg) and butorphanol intramuscular (0.375 mg to 6 mg) injections produced withdrawal symptoms similar to one another but slightly different from naloxone, with less clear dose-response patterns.<sup>2,3</sup> Buprenorphine did not cause symptoms consistent with withdrawal over a single-dose range of 0.5 mg to 8 mg intramuscularly.<sup>4</sup><br><br>Numerous other case reports and studies support the above findings that nalbuphine, pentazocine, and butorphanol may decrease analgesic effects of opioid agonists and precipitate withdrawal symptoms in patients maintained on these agents.<sup>5,6,7,8,9,10,11 </sup> In contrast to the buprenorphine study above, several later studies demonstrated that buprenorphine may antagonize opioid agonist effects and precipitate withdrawal symptoms.<sup>12,13,14,15</sup> These effects appear to increase with higher buprenorphine doses, greater opioid dependence, and shorter time between opioid agonist dose and buprenorphine dose.<br><br>Mixed agonist / antagonist opioids appear to reduce the effects of pure opioid agonists via competition / antagonism at opioid receptor sites. The exact receptor subtypes affected are unknown and patterns of response may vary by agent. Treatment initiation with mixed agonist / antagonist opioids in patients receiving analgesic opioids could precipitate withdrawal symptoms, necessitate unusually high doses, or lead to therapeutic failure. The prescribing information for several pure opioid agonists (e.g., methadone, oxycodone, fentanyl)<sup>16,17,18</sup> specifically recommend avoiding this combination, although the prescribing information for at least one other pure agonist (hydromorphone)<sup>19</sup> recommends caution but does not specifically recommend avoidance.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Preston KL, Bigelow GE, Liebson IA, “Antagonist Effects of Nalbuphine in Opioid-Dependent Human Volunteers,” <i>J Pharmacol Exp Ther,</i> 1989, 248(3):929-37. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2467983\">[PubMed 2467983]</a></p>\n<p>2. Strain EC, Preston KL, Liebson IA, et al, “Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers,” <i>J Pharmacol Exp Ther,</i> 1993, 267(2):624-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7504098\">[PubMed 7504098]</a></p>\n<p>3. Preston KL, Bigelow GE and Liebson IA, “Butorphanol-Precipitated Withdrawal in Opioid-Dependent Human Volunteers,” <i>J Pharmacol Exp Ther,</i> 1988, 246(2):441-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2457074\">[PubMed 2457074]</a></p>\n<p>4. Strain EC, Preston KL, Liebson IA, et al, “Acute Effects of Buprenorphine, Hydromorphone and Naloxone in Methadone-Maintained Volunteers,” <i>J Pharmacol Exp Ther,</i> 1992, 261(3):985-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1376362\">[PubMed 1376362]</a></p>\n<p>5. Jasinski DR and Mansky PA, “Evaluation of Nalbuphine for Abuse Potential,” <i>Clin Pharmacol Ther,</i> 1972, 13(1):78-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4550324\">[PubMed 4550324]</a></p>\n<p>6. Hartree C, “Caution with Nalbuphine in Patients on Long-Term Opioids,” <i>Palliat Med,</i> 2005, 19(2)168. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15810761\">[PubMed 15810761]</a></p>\n<p>7. Smith J and Guly H, “Nalbuphine and Slow Release Morphine,” <i>BMJ,</i> 2004, 328(7453):1426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15191981\">[PubMed 15191981]</a></p>\n<p>8. Houlihan KP,Mitchell RG, Flapan AD, et al, “Excessive Morphine Requirements after Pre-Hospital Nalbuphine Analgesia,” <i>J Accid Emerg Med,</i> 1999, 16(1):29-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9918283\">[PubMed 9918283]</a></p>\n<p>9. Robinson N and Burrows N, “Excessive Morphine Requirements after Pre-Hospital Nalbuphine Analgesia,” <i>J Accid Emerg Med,</i> 1999, 16(5):392. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10505947\">[PubMed 10505947]</a></p>\n<p>10. Lamas X, Farre M and Cami J, “Acute Effects of Pentazocine, Naloxone and Morphine in Opioid-Dependent Volunteers,” <i>J Pharmacol Exp Ther,</i> 1994, 268(3):1485-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8138958\">[PubMed 8138958]</a></p>\n<p>11. Igarashi A, Amagasa S, Yokoo N, et al, “Acute Withdrawal Syndrome in a Butorphanol-Treated Patient: an Adverse Combination of Opioids,” <i>Br J Anaesth,</i> 2008, 101(1):127-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18556700\">[PubMed 18556700]</a></p>\n<p>12. Clark NC, Lintzeris N and Muhleisen PJ, “Severe Opiate Withdrawal in a Heroin User Precipitated by a Massive Buprenorphine Dose,” <i>Med J Aust,</i> 2002, 176:166-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11913917\">[PubMed 11913917]</a></p>\n<p>13. Rosado J, Walsh SL, Bigelow GE, et al, “Sublingual Buprenorphine/Naloxone Precipitated Withdrawal in Subjects Maintained on 100mg of Daily Methadone,” <i>Drug Alcohol Depend,</i> 2007, 90(2-3):261-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17517480\">[PubMed 17517480]</a></p>\n<p>14. Strain EC, Preston KL, Liebson IA, et al, “Buprenorphine Effects in Methadone-Maintained Volunteers: Effects at Two Hours after Methadone,” <i>J Pharmacol Exp Ther,</i> 1995, 272:628-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7853176\">[PubMed 7853176]</a></p>\n<p>15. Walsh SL, June HL, Schuh KJ, et al, “Effects of Buprenorphine and Methadone in Methadone-Maintained Subjects,” <i>Psychopharmacology (Berl),</i> 1995, 119:268-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7675960\">[PubMed 7675960]</a></p>\n<p>16. <i>Dolophine</i> (methadone) [prescribing information]. Columbus, OH: Roxane Laboratories, Inc.; March 2015.</p>\n<p>17. <i>Oxycontin</i> (oxycodone) [prescribing information]. Stamford, CT: Purdue Pharma L.P.; April 2014.</p>\n<p>18. <i>Duragesic</i> (fentanyl) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; April 2014.</p>\n<p>19. <i>Dilaudid</i> (hydromorphone) [prescribing information]. North Chicago, IL: Abbott Laboratories; November 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5225":"<p><b>Title</b> Simvastatin / Protease Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Protease Inhibitors may increase the serum concentration of Simvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of simvastatin and protease inhibitors due to the risk for rhabdomyolysis.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir</p>\n</div> \n<p><b>Discussion</b> Concomitant use with simvastatin is either contraindicated or not recommended in various protease inhibitor prescribing information.<sup>1,2,3,4,5</sup> Several case reports describe the occurrence of rhabdomyolysis in patients receiving both a protease inhibitor and an HMG-CoA reductase inhibitor.<sup>6,7,8</sup> In each of these reports, the patients involved had been receiving either a high-dose HMG-CoA reductase inhibitor and/or multiple drugs capable of interacting with the HMG-CoA reductase inhibitor, making it difficult to make inferences regarding the potential risk with any specific protease inhibitor-HMG-CoA reductase inhibitor pair.<br><br>Pharmacokinetic data further support the potential for a significant interaction between protease inhibitors and at least several of the HMG-CoA reductase inhibitors. Many protease inhibitors are known inhibitors of the CYP3A4 enzyme<sup>9</sup> that accounts for a large portion of the metabolism of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and atorvastatin.<sup>10,11</sup> Additionally, some protease inhibitors have the potential to inhibit or induce drug transporters that are involved in HMG-CoA reductase inhibitor elimination,<sup>6,7</sup> and others are capable of inducing or inhibiting glucuronidation enzymes.<sup>12</sup> Pharmacokinetic studies have reported significant increases in simvastatin,<sup>13,14</sup> atorvastatin,<sup>1,12,13,14,15</sup> and rosuvastatin<sup>1,12,16,17</sup> AUC following concomitant therapy with ritonavir/saquinavir,<sup>14</sup> lopinavir/ritonavir,<sup>15,16,17</sup> tipranavir/ritonavir,<sup>12</sup> nelfinavir,<sup>13</sup>, or indinavir.<sup>1</sup> From these studies the largest effects were generally seen with simvastatin, though the increases observed with atorvastatin and rosuvastatin were smaller, but likely still of clinical importance.<br><br>As discussed, the mechanism of this interaction appears to be protease inhibitor-mediated inhibition of the metabolism/elimination of the HMG-CoA reductase inhibitor (likely via CYP3A4 inhibition, though transporter-related or other mechanisms may also be involved), leading to increased HMG-CoA reductase inhibitor concentrations and toxicities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Crixivan (indinavir). Whitehouse Station, NJ: Merck &amp; Co., Inc., October 2009. </p>\n<p>2. Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristoly Myers Squibb Co., January 2010.</p>\n<p>3. Prescribing information. Norvir (ritonavir). N. Chicago, IL: Abbott Laboratories, November 2009.</p>\n<p>4. Prescribing information. Lexiva (fosamprenavir). Research Triangle Park, NC: GlaxoSmithKline, September 2009.</p>\n<p>5. Prescribing information. Invirase (saquinavir). Nutley, NJ: Roche Laboratories, Inc., Januaryy 2010.</p>\n<p>6. Cheng CH, Miller C, Lowe C, et al., “Rhabdomyolysis Due to Probable Interaction between Simvastatin and Ritonavir,” <i>Am J Health Syst Pharm</i>, 2002, 59:728-30.</p>\n<p>7. Mah Ming JB,Gill MJ, “Drug-Induced Rhabdomyolysis after Concomitant Use of Clarithromycin, Atorvastatin, and Lopinavir/Ritonavir in a Patient with Hiv,” <i>AIDS Patient Care STDS</i>, 2003, 17:207-10.</p>\n<p>8. Schmidt GA, Hoehns JD, Purcell JL, et al., “Severe Rhabdomyolysis and Acute Renal Failure Secondary to Concomitant Use of Simvastatin, Amiodarone, and Atazanavir,” <i>J Am Board Fam Med</i>, 2007, 20:411-6.</p>\n<p>9. Ernest CS, 2nd, Hall SD,Jones DR, “Mechanism-Based Inactivation of Cyp3a by Hiv Protease Inhibitors,” <i>J Pharmacol Exp Ther</i>, 2005, 312:583-91.</p>\n<p>10. Fichtenbaum CJ,Gerber JG, “Interactions between Antiretroviral Drugs and Drugs Used for the Therapy of the Metabolic Complications Encountered During Hiv Infection,” <i>Clin Pharmacokinet</i>, 2002, 41:1195-211.</p>\n<p>11. Neuvonen PJ, Niemi M,Backman JT, “Drug Interactions with Lipid-Lowering Drugs: Mechanisms and Clinical Relevance,” <i>Clin Pharmacol Ther</i>, 2006, 80:565-81.</p>\n<p>12. Prescribing information. Aptivus (tipranavir). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., October 2007.</p>\n<p>13. Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al., “Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Inhibitors Atorvastatin and Simvastatin,” <i>Antimicrob Agents Chemother</i>, 2001, 45:3445-50.</p>\n<p>14. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al., “Pharmacokinetic Interactions between Protease Inhibitors and Statins in Hiv Seronegative Volunteers: Actg Study A5047,” <i>AIDS</i>, 2002, 16:569-77.</p>\n<p>15. Carr RA, Andre AK, Bertz RJ, et al, “Concomitant Administration of ABT-378/ritonavir (ABT-378/r) Results in a Clinically Important Pharmacokinetics (PK) Interaction with Atorvastatin (ATO) but not Pravastatin (PRA),” 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 17-20, 2000: [abstract 1644].</p>\n<p>16. Kiser JJ, Gerber JG, Predhomme JA, et al, “Drug/Drug Interaction between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers,” <i>J Acquir Immune Defic Syndr</i>, 2007, Dec 20 (online, ahead of print).</p>\n<p>17. van der Lee M, Sankatsing R, Schippers E, et al, “Pharmacokinetics and Pharmacodynamics of Combined Use of Lopinavir/Ritonavir and Rosuvastatin in Hiv-Infected Patients,” <i>Antivir Ther</i>, 2007, 12:1127-32.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5226":"<p><b>Title</b> Lovastatin / Protease Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Protease Inhibitors may increase the serum concentration of Lovastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of lovastatin and protease inhibitors due to the risk for rhabdomyolysis.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir</p>\n</div> \n<p><b>Discussion</b> Concomitant use with lovastatin is either contraindicated or not recommended in various protease inhibitor prescribing information.<sup>1,2,3,4,5</sup> Several case reports describe the occurrence of rhabdomyolysis in patients receiving both a protease inhibitor and an HMG-CoA reductase inhibitor.<sup>6,7,8</sup> In each of these reports, the patients involved had been receiving either a high-dose HMG-CoA reductase inhibitor and/or multiple drugs capable of interacting with the HMG-CoA reductase inhibitor, making it difficult to make inferences regarding the potential risk with any specific protease inhibitor-HMG-CoA reductase inhibitor pair.<br><br>Pharmacokinetic data further support the potential for a significant interaction between protease inhibitors and at least several of the HMG-CoA reductase inhibitors. Many protease inhibitors are known inhibitors of the CYP3A4 enzyme<sup>9</sup> that accounts for a large portion of the metabolism of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and atorvastatin.<sup>10,11</sup> Additionally, some protease inhibitors have the potential to inhibit or induce drug transporters that are involved in HMG-CoA reductase inhibitor elimination,<sup>6,7</sup> and others are capable of inducing or inhibiting glucuronidation enzymes.<sup>12</sup> Pharmacokinetic studies have reported significant increases in simvastatin,<sup>13,14</sup> atorvastatin,<sup>1,12,13,14,15</sup> and rosuvastatin<sup>1,12,16,17</sup> AUC following concomitant therapy with ritonavir/saquinavir,<sup>14</sup> lopinavir/ritonavir,<sup>15,16,17</sup> tipranavir/ritonavir,<sup>12</sup> nelfinavir,<sup>13</sup>, or indinavir.<sup>1</sup> From these studies the largest effects were generally seen with simvastatin, though the increases observed with atorvastatin and rosuvastatin were smaller, but likely still of clinical importance.<br><br>As discussed, the mechanism of this interaction appears to be protease inhibitor-mediated inhibition of the metabolism/elimination of the HMG-CoA reductase inhibitor (likely via CYP3A4 inhibition, though transporter-related or other mechanisms may also be involved), leading to increased HMG-CoA reductase inhibitor concentrations and toxicities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Crixivan (indinavir). Whitehouse Station, NJ: Merck &amp; Co., Inc., October 2009. </p>\n<p>2. Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristoly Myers Squibb Co., January 2010.</p>\n<p>3. Prescribing information. Norvir (ritonavir). N. Chicago, IL: Abbott Laboratories, November 2009.</p>\n<p>4. Prescribing information. Lexiva (fosamprenavir). Research Triangle Park, NC: GlaxoSmithKline, September 2009.</p>\n<p>5. Prescribing information. Invirase (saquinavir). Nutley, NJ: Roche Laboratories, Inc., January 2010.</p>\n<p>6. Cheng CH, Miller C, Lowe C, et al., “Rhabdomyolysis Due to Probable Interaction between Simvastatin and Ritonavir,” <i>Am J Health Syst Pharm</i>, 2002, 59:728-30.</p>\n<p>7. Mah Ming JB,Gill MJ, “Drug-Induced Rhabdomyolysis after Concomitant Use of Clarithromycin, Atorvastatin, and Lopinavir/Ritonavir in a Patient with Hiv,” <i>AIDS Patient Care STDS</i>, 2003, 17:207-10.</p>\n<p>8. Schmidt GA, Hoehns JD, Purcell JL, et al., “Severe Rhabdomyolysis and Acute Renal Failure Secondary to Concomitant Use of Simvastatin, Amiodarone, and Atazanavir,” <i>J Am Board Fam Med</i>, 2007, 20:411-6.</p>\n<p>9. Ernest CS, 2nd, Hall SD,Jones DR, “Mechanism-Based Inactivation of Cyp3a by Hiv Protease Inhibitors,” <i>J Pharmacol Exp Ther</i>, 2005, 312:583-91.</p>\n<p>10. Fichtenbaum CJ,Gerber JG, “Interactions between Antiretroviral Drugs and Drugs Used for the Therapy of the Metabolic Complications Encountered During Hiv Infection,” <i>Clin Pharmacokinet</i>, 2002, 41:1195-211.</p>\n<p>11. Neuvonen PJ, Niemi M,Backman JT, “Drug Interactions with Lipid-Lowering Drugs: Mechanisms and Clinical Relevance,” <i>Clin Pharmacol Ther</i>, 2006, 80:565-81.</p>\n<p>12. Prescribing information. Aptivus (tipranavir). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., October 2007.</p>\n<p>13. Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al., “Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Inhibitors Atorvastatin and Simvastatin,” <i>Antimicrob Agents Chemother</i>, 2001, 45:3445-50.</p>\n<p>14. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al., “Pharmacokinetic Interactions between Protease Inhibitors and Statins in Hiv Seronegative Volunteers: Actg Study A5047,” <i>AIDS</i>, 2002, 16:569-77.</p>\n<p>15. Carr RA, Andre AK, Bertz RJ, et al, “Concomitant Administration of ABT-378/ritonavir (ABT-378/r) Results in a Clinically Important Pharmacokinetics (PK) Interaction with Atorvastatin (ATO) but not Pravastatin (PRA),” 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 17-20, 2000: [abstract 1644].</p>\n<p>16. Kiser JJ, Gerber JG, Predhomme JA, et al, “Drug/Drug Interaction between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers,” <i>J Acquir Immune Defic Syndr</i>, 2007, Dec 20 (online, ahead of print).</p>\n<p>17. van der Lee M, Sankatsing R, Schippers E, et al, “Pharmacokinetics and Pharmacodynamics of Combined Use of Lopinavir/Ritonavir and Rosuvastatin in Hiv-Infected Patients,” <i>Antivir Ther</i>, 2007, 12:1127-32.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5227":"<p><b>Title</b> PredniSONE / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of PredniSONE. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical response to prednisone extra closely in patients receiving ritonavir. Prednisone dose reductions may be necessary.</p> \n<p><b>Discussion</b> In a study of 10 healthy subjects, administration of ritonavir (200 mg BID x 14.5 days) decreased prednisolone clearance and significantly increased prednisolone exposure following single 20 mg prednisone doses given on day 4 (37% increase) and day 14 (28% increase) when compared to baseline levels obtained following a single 20 mg dose administered prior to ritonavir.<sup>1</sup> In a study of HIV-positive subjects, prednisolone exposure from a single oral prednisone dose (20 mg) was nonsignficantly higher (31% increase) in patients stabilized on lopinavir/ritonavir therapy compared to subjects not receiving antiretroviral therapy.<sup>2</sup> <br><br>Prednisone prescribing information cautions that use with drugs such as ketoconazole or troleandomycin (strong CYP3A4 inhibitors) may impair corticosteroid metabolism.<sup>3</sup> Ritonavir (also a strong CYP3A4 inhibitor) prescribing information cautions that prednisone dose reductions may be necessary when using these agents concomitantly.<sup>4</sup> While other evidence of a pharmacokinetic interaction between prednisone and another strong CYP3A4 inhibitor has been reported,<sup>5</sup> several in vivo studies have demonstrated little or no effect of such agents on prednisone.<sup>6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Penzak SR, Formentini E, Alfaro RM, et al, “Prednisolone Pharmacokinetics in the Presence and Absence of Ritonavir After Oral Prednisone Administration to Healthy Volunteers,” <i>J Acquir Immune Defic Syndr</i>, 2005, 40(5):573-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16284534\">[PubMed 16284534]</a></p>\n<p>2. Busse KH, Formentini E, Alfaro RM, et al, “Influence of Antiretroviral Drugs on the Pharmacokinetics of Prednisolone in HIV-Infected Individuals,” <i>J Acquir Immune Defic Syndr</i>, 2008, 48(5):561-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18645517\">[PubMed 18645517]</a></p>\n<p>3. Prescribing information. Prednisone. Corona, CA: Watson Pharma Inc., April 2008.</p>\n<p>4. Prescribing information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, November 2009.</p>\n<p>5. Zurcher RM, Frey BM, and Frey FJ, “Impact of Ketoconazole on the Metabolism of Prednisolone,” <i>Clin Pharmacol Ther</i>, 1989, 45(4):366-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2639662\">[PubMed 2639662]</a></p>\n<p>6. Varis T, Kivisto KT, Neuvonen PJ, “The Effect of Itraconazole on the Pharmacokinetics and Pharmacodynamics of Oral Prednisolone,” <i>Eur J Clin Pharmacol</i>, 2000, 56(1):57-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10853878\">[PubMed 10853878]</a></p>\n<p>7. Yamashita SK, Ludwig EA, Middleton E, et al, “Lack of Pharmacokinetic and Pharmacodynamic Interactions Between Ketoconazole and Prednisolone,” <i>Clin Pharmacol Ther</i>, 1991, 49(5):558-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1827622\">[PubMed 1827622]</a></p>\n<p>8. Lebrun-Vignes B, Archer C, Diquet B, et al, “Effect of Itraconazole on the Pharmacokinetics of Prednisolone and Methylprednisolone and Cortisol Secretion in Healthy Subjects,” <i>Br J Clin Pharmacol</i>, 2001, 51(5):443-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11422002\">[PubMed 11422002]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5228":"<p><b>Title</b> Cardiac Glycosides / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consider preemptive dose reductions of cardiac glycosides when itraconazole is initiated/dose increased. Monitor for increased serum concentrations/effects of cardiac glycosides if itraconazole is initiated/dose increased and decreased serum concentrations/effects if itraconazole is discontinued/dose decreased.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several case reports describe substantial increases in digoxin concentrations (often greater than doubling) and / or onset of symptoms of digoxin toxicity with initiation of itraconazole therapy.<sup>1,2,3,4,5,6,7,8</sup> <br><br>Two controlled clinical studies of this interaction in healthy volunteers have been conducted. In the first, subjects receiving 0.25 mg digoxin orally daily for 10 days followed by digoxin 0.25 mg with concurrent itraconazole 200 mg for an additional 10 days had 80% higher serum digoxin concentrations (12 hours post-dose) at the end of the itraconazole phase compared to the digoxin-only phase.<sup>9</sup> In the second study, mean digoxin exposure from a single 0.5 mg dose was approximately 68% higher in the first 72 hours post-dose when subjects were pretreated with itraconazole 200 mg orally daily for 2 days, compared to palcebo.<sup>10</sup> Renal clearance of digoxin was significantly lower with itraconazole than with placebo. <br><br>The primary mechanism of this interaction is most likely inhibition of p-glycoprotein mediated digoxin transport by itraconazole. By this mechanism, itraconazole could both increase digoxin uptake from the gastrointestinal tract and decrease its renal excretion. Inhibition of CYP3A4-mediated digoxin metabolism by itraconazole would be expected to play a small role, if any, given the minor contribution of this pathway to digoxin elimination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rex J, “Itraconazole-Digoxin Interaction,” <i>Ann Intern Med</i>, 1992, 116:525.</p>\n<p>2. Kauffman CA and Bagnasco FA, “Digoxin Toxicity Associated With Itraconazole Therapy,” <i>Clin Infect Dis</i>, 1992, 15:886-7.</p>\n<p>3. Sachs MK, Blanchard LM, and Green PJ, “Interaction of Itraconazole and Digoxin,” <i>Clin Infect Dis</i>, 1993, 16:400-3.</p>\n<p>4. McClean KL and Sheehan GJ, “Interaction Between Itraconazole and Digoxin,” <i>Clin Infect Dis</i>, 1994, 18:259-60.</p>\n<p>5. Cone LA, Himelman RB, Hirschberg JN, et al, “Itraconazole-Related Amaurosis and Vomiting due to Digoxin Toxicity,” <i>West J Med,</i> 1996, 165(5):322.</p>\n<p>6. Mathis AS and Friedman GS, “Coadministration of Digoxin with Itraconazole in Renal Transplant Recipients,” <i>Am J Kidney Dis,</i> 2001, 37(2):E18.</p>\n<p>7. Alderman CP and Jersmann HP, “Digoxin-Itraconazole Interaction,” <i>Med J Aust,</i> 1993, 6/20:838-9.</p>\n<p>8. Alderman CP and Allcroft PD, “Digoxin-Itraconazole Interaction: Possible Mechanisms,” <i>Ann Pharmacother</i>, 1997, 31:438-40.</p>\n<p>9. Jalava KM, Partanen J and Neuvonen PJ, “Itraconazole Descreases Renal Clearance of Digoxin,” <i>Ther Drug Monit,</i> 1997, 609-13.</p>\n<p>10. Partanen J, Jalava KM and Neuvonen PJ, “Itraconazole Increases Serum Digoxin Concentration,” <i>Pharmacol Toxicol,</i> 1996, 79(5):274-6.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5232":"<p><b>Title</b> Lithium / Calcitonin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcitonin may decrease the serum concentration of Lithium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased lithium concentrations when calcitonin is given concomitantly. Dose adjustments may be needed.</p> \n<p><b>Discussion</b> Prescribing information for nasal calcitonin warns that concomitant use with lithium may lead to increased renal lithium clearance and reduced plasma concentrations.<sup>1</sup><br><br>A study of 4 women with bipolar disorder stabilized on lithium treatment showed that daily subcutaneous calcitonin administration for 3 days caused a significant reduction in mean plasma lithium concentrations compared to baseline.<sup>2</sup> Individual decreases in mean lithium plasma concentration ranged from 7% - 30%. Urinary clearance of lithium was studied in two patients and found to increase in both cases.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Miacalcin</i> (calcitonin-salmon) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2009.</p>\n<p>2. Passiu G, Bocchetta A, Martinelli V, et al. Calcitonin decreases lithium plasma levels in man. Preliminary report. <i>Int J Clin Pharmacol Res</i>. 1998;18(4):179-181. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10052028\">[PubMed 10052028]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5234":"<p><b>Title</b> Progestins (Contraceptive) / Tetracyclines</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Tetracyclines may diminish the therapeutic effect of Progestins (Contraceptive). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)</p>\n</div> \n<p><b>Discussion</b> Anecdotal data indicate the possibility that tetracycline antibiotics might inhibit the efficacy of oral contraceptives. These are almost exclusively related to estrogen-containing products.<sup>1,2,3,4,5</sup> A longitudinal, uncontrolled study showed that the incidence of pregnancy in antibiotic/oral contraceptive-receiving patients (n=356) was not statistically different from the control group [no antibiotic] (n=263).<sup>6</sup> Two small studies failed to show any pharmacokinetic effects of tetracycline or doxycycline on ethinyl estradiol or norethindrone.<sup>7,8</sup> A paucity of epidemiologic data suggests that the incidence of pregnancy that occurs with concomitant antibiotic and hormonal contraception is no greater than the incidence during the use of hormonal contraception alone without concomitant antibiotics.<sup>3,6,9</sup> A thorough review of this topic was conducted by Archer et al.<sup>10</sup> They concluded that “available scientific and pharmacokinetic data do not support the hypothesis that antibiotics (with the exception of rifampin) lower the contraceptive efficacy of oral contraceptives.” A year 2000 Practice Bulletin of the American College of Obstetrics and Gynecology recommends the use of nonhormonal contraceptives only with the concomitant use of rifampin or griseofulvin.<sup>11</sup> A proposed (yet otherwise unproven) mechanism for this potential interaction is based on the antibiotic's ability to reduce gut bacteria which are important for hydrolysis of conjugated estrogen, which subsequently permits the reabsorption of the estrogen (ie, enterohepatic circulation is interrupted, resulting in lower serum concentrations of the estrogen). No supporting evidence is available. Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bacon JF and Shenfield GM, “Pregnancy Attributable to Interaction Between Tetracycline and Oral Contraceptives,” <i>Br Med J</i>, 1980, 1:293.</p>\n<p>2. Back DJ, Breckenridge AM, Crawford FE, et al, “Interindividual Variation and Drug Interactions With Hormonal Steroids,” <i>Drugs</i>, 1981, 21:46.</p>\n<p>3. Back DJ, Grimmer FM, Orme ML, et al, “Evaluation of Committee on Safety of Medicines Yellow Card Reports on Oral Contraceptive-Drug Interactions With Anticonvulsants and Antibiotics,” <i>Br J Clin Pharmacol</i>, 1988, 25:527-32.</p>\n<p>4. London BM and Lookingbill DP, “Frequency of Pregnancy in Acne Patients Taking Oral Antibiotics and Oral Contraceptives,” <i>Arch Dermatol</i>, 1994, 130:392-3.</p>\n<p>5. Hughes BR and Cunliffe WJ, “Interactions Between the Oral Contraceptive Pill and Antibiotics,” <i>Br J Dermatol</i>, 1990, 122:717.</p>\n<p>6. Helms SE, Bredle DL, Zajic J, et al, “Oral Contraceptive Failure Rates and Oral Antibiotics,” <i>J Am Acad Dermatol</i>, 1997, 36:705-10.</p>\n<p>7. Murphy AA, Zacur HA, Charache P, et al, “The Effect of Tetracycline on Levels of Oral Contraceptives,” <i>Am J Obst Gynecol</i>, 1991, 164:28-33.</p>\n<p>8. Neely JL, Abate M, Swinker M, et al, “The Effect of Doxycycline on Serum Levels of Ethinyl Estradiol, Norethindrone, and Endogenous Progesterone,” <i>Obstet Gynecol</i>, 1991, 77:416-20.</p>\n<p>9. Sparrow MJ, “Pill Method Failures,” <i>N Z Med J</i>, 1987, 100:102-5.</p>\n<p>10. Archer JS and Archer DF, “Oral Contraceptive Efficacy and Antibiotic Interaction: A Myth Debunked,” <i>J Am Acad Dermatol</i>, 2002, 46:917-23.</p>\n<p>11. ACOG Practice Bulletin, The Use of Hormonal Contraception in Women With Coexisting Medical Conditions, July, 2000, The American College of Obstetricians and Gynecologists, Washington DC.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5235":"<p><b>Title</b> Imipenem / Ganciclovir-Valganciclovir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Imipenem. Specifically, the risk of seizures may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Labeling for both ganciclovir and valganciclovir state that coadministration with imipenem is not recommended. According to the imipenem labeling, avoid concomitant use with ganciclovir unless the prospective benefits of therapy outweigh the risks.</p>\n<div>\n <p><b>Ganciclovir-Valganciclovir Interacting Members</b> Ganciclovir (Systemic), ValGANciclovir</p>\n</div> \n<p><b>Discussion</b> Generalized seizures have been observed with concurrent use of imipenem/cilastatin and ganciclovir.<sup>1,2,3</sup> The labeling for these products recommend against their concomitant use.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Primaxin IV (imipenem and cilastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; December 2016.</p>\n<p>2. Cytovene-IV (ganciclovir) [prescribing information]. South San Francisco, CA: Genetech USA, Inc.; July 2017.</p>\n<p>3. Valcyte (valganciclovir) [prescribing information]. South San Francisco, CA: Genetech USA, Inc.; June 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5236":"<p><b>Title</b> Acyclovir-Valacyclovir / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Acyclovir-Valacyclovir. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Acyclovir-Valacyclovir Interacting Members</b> Acyclovir (Systemic)*, ValACYclovir*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Probenecid (1 g) has been shown to increase valacyclovir (a prodrug of acyclovir) AUC. Acyclovir AUC is increased 40% to 46%.<sup>1,2</sup> The clinical effect of this interaction is likely minimal. The mechanism of this interaction appears to be decreased acyclovir renal clearance by probenecid (likely via inhibition of the renal organic anion/cation transport system).<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Laskin OL, de Miranda P, King DH, et al, “Effects of Probenecid on the Pharmacokinetics and Elimination of Acyclovir in Humans,” <i>Antimicrob Agents Chemother</i>, 1982, 21:804.</p>\n<p>2. Rolan PE, Mailoot F, On NT, et al, “The Effects of Cimetidine and Probenecid on the Conversion of a Valine Ester of Acyclovir, 256U, to Acyclovir and Acyclovir Renal Clearance in Healthy Volunteers,” <i>Br J Clin Pharmacol</i>, 1993, 35:533P (abstract).</p>\n<p>3. Takeda M, Khamdang S, Narikawa S, et al, “Human Organic Anion Transporters and Human Organic Cation Transporters Mediate Renal Antiviral Transport,” <i>J Pharmacol Exp Ther</i>, 2002, 300(3):918-24. [PMID: 11861798]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5237":"<p><b>Title</b> Allopurinol / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Probenecid may decrease serum concentrations of the active metabolite(s) of Allopurinol. Allopurinol may increase the serum concentration of Probenecid. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Pharmacokinetic evaluations of combined allopurinol and probenecid therapy reveal a) increased renal excretion of allopurinol (or its active metabolite);<sup>1</sup> and b) increased half-life of probenecid.<sup>2,3</sup> The clinical significance of these effects is probably minimal.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Elion GB, Yu TF, Gutman AB, et al, “Renal Clearance of Oxipurinol, the Chief Metabolite of Allopurinol,” <i>Am J Med</i>, 1968, 45(1):69-77.</p>\n<p>2. Horwitz D, Thorgeirsson SS, and Mitchell JR, “The Influence of Allopurinol and Size of Dose on the Metabolism of Phenylbutazone in Patients With Gout,” <i>Eur J Clin Pharmacol</i>, 1977, 12(2):133-6.</p>\n<p>3. Yu TF and Gutman AB, “Effect of Allopurinol (4-Hydroxypyrazolo(3,4-d) Pyrimidine) on Serum and Urinary Uric Acid in Primary and Secondary Gout,” <i>Am J Med</i>, 1964, 37:885-98.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5238":"<p><b>Title</b> Penicillins / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Penicillins. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins (especially if used in high doses) if probenecid is initiated or the dose is increased.</p>\n<div>\n <p><b>Penicillins Interacting Members</b> Amdinocillin, Amoxicillin, Ampicillin*, Bacampicillin, Cloxacillin, Dicloxacillin, Flucloxacillin, Nafcillin*, Oxacillin, Penicillin G (Parenteral/Aqueous)*, Penicillin G Benzathine*, Penicillin G Procaine*, Penicillin V Benzathine, Penicillin V Potassium, Piperacillin, Temocillin, Ticarcillin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Probenecid has been shown to more than double the half-life of penicillin G.<sup>1</sup> Nafcillin, ticarcillin, and ampicillin are similarly affected.<sup>2,3</sup> Probenecid competes for renal tubular excretion, and thus reduces the elimination of the penicillin. Product labeling for various penicillin products in the US and other countries recommends avoidance of the combination of probenecid and penicillins.<sup>4,5,6,7</sup> However, this combination has been used advantageously in select cases, is available as a combination product in other countries to increase serum antibiotic concentrations, and is endorsed for the treatment of some severe infections.<sup>3,8,9,10,11</sup> An increased risk of penicillin-associated side effects (including seizures) may occur.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kampmann J, Hansen JM, Siersboek-Nielsen K, Laursen H. Effect of some drugs on penicillin half-life in blood. <i>Clin Pharmacol Ther</i>. 1972;13(4):516-519. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5042368\">[PubMed 5042368]</a></p>\n<p>2. Waller ES, Sharanevych MA, Yakatan GJ. The effect of probenecid on nafcillin disposition. <i>J Clin Pharmacol</i>. 1982;22(10):482-489. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7174857\">[PubMed 7174857]</a></p>\n<p>3. Corvaia L, Li SC, Ioannides-Demos LL, et al. A prospective study on the effects of oral probenecid on the pharmacokinetics of intravenous ticarcillin in patients with cystic fibrosis. <i>J Antimicrob Chemother</i>. 1992;30(6):875-878. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1289366\">[PubMed 1289366]</a></p>\n<p>4. Augmentin XR (amoxicillin and clavulanate potassium) [prescribing information]. Bristol, TN: Dr. Reddy's Laboratories Tennessee LLC; April 2014.</p>\n<p>5. Amoxi-Clav (amoxicillin and clavulanic acid) [product monograph]. Laval, Quebec, Canada: Pro Doc LTEE; September 2009.</p>\n<p>6. Augmentin Intravenous (amoxicillin and potassium clavulanate) [summary of product characteristics]. Stockley Park West, Uxbridge, Middlesex: GlaxoSmithKline UK; October 2013.</p>\n<p>7. Augmentin Intravenous (amoxicillin and potassium clavulanate) [summary of product characteristics]. Worthing, United Kingdom: SmithKline Beecham PLC; November 2013.</p>\n<p>8. Krogsgaard MR, Hansen BA, Slotsbjerg T, Jensen P. Should probenecid be used to reduce the dicloxacillin dosage in orthopaedic infections? A study of the dicloxacillin-saving effect of probenecid. <i>Pharmacol Toxicol</i>. 1994;74(3):181-184. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8008725\">[PubMed 8008725]</a></p>\n<p>9. Wu H, Liu M, Wang S, et al. Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers. <i>Clin Ther</i>. 2010;32(3):597-606. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20399996\">[PubMed 20399996]</a></p>\n<p>10. Tanizaki R, Nishijima T, Aoki T, et al. High-dose oral amoxicillin plus probenecid is highly effective for syphillis in patients with HIV infection. <i>Clin Infect Dis</i>. 2015;61(2):177-183. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25829004\">[PubMed 25829004]</a></p>\n<p>11. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26042815\">[PubMed 26042815]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5239":"<p><b>Title</b> Cephalosporins / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Cephalosporins. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for toxic effects of cephalosporins (especially if used in high doses) if probenecid is initiated or the dose is increased. Dose adjustments may be necessary for some cephalosporins.</p>\n<div>\n <p><b>Cephalosporins Interacting Members</b> Cefaclor, Cefadroxil, Cefazedone, CeFAZolin, Cefcapene, Cefdinir, Cefditoren*, Cefepime, Cefixime, Cefminox, Cefoperazone, Cefotaxime*, CefoTEtan, Cefotiam, CefOXitin*, Cefpirome, Cefpodoxime, Cefprozil, Ceftaroline Fosamil, CefTAZidime, Ceftezole, Ceftibuten, Ceftizoxime, Ceftobiprole, Ceftolozane, CefTRIAXone, Cefuroxime, Cephalexin, Cephalothin*, Cephradine, Flomoxef</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Probenecid has been shown to more than double the half-life of penicillin G.<sup>1</sup> Nafcillin, ticarcillin, and ampicillin are similarly affected.<sup>2,3</sup> Cephalosporins are similarly affected by probenecid. The AUC of cefditoren was increased 122% during coadministration,<sup>4</sup> and the average steady-state concentration of cefotaxime was increased approximately 80% with concurrent probenecid.<sup>5</sup> The half-life for both cephalothin and cefoxitin were approximately 2-fold higher with concurrent probenecid (1 g IV) in a study of 12 healthy volunteers,<sup>6</sup> and labeling for cephalothin notes that probenecid almost doubles maximum serum concentrations of cephalothin and may increase the risk for cephalothin toxicity.<sup>7,8</sup><br><br>Probenecid apparently competes for cephalosporin renal tubular excretion, and thus reduces the elimination of the antibiotic. This effect is used advantageously in selected cases to increase serum antibiotic concentrations. An increased risk of cephalosporin-associated side effects may occur.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kampmann J, Hansen JM, Siersboek-Nielsen K, Laursen H. Effect of some drugs on penicillin half-life in blood. <i>Clin Pharmacol Ther</i>. 1972;13(4):516-519. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5042368\">[PubMed 5042368]</a></p>\n<p>2. Waller ES, Sharanevych MA, Yakatan GJ. The effect of probenecid on nafcillin disposition. <i>J Clin Pharmacol</i>. 1982;22:482-489. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7174857\">[PubMed 7174857]</a></p>\n<p>3. Corvaia L, Li SC, Ioannides-Demos LL, et al. A prospective study of the effects of oral probenecid on the pharmacokinetics of intravenous ticarcillin in patients with cystic fibrosis. <i>J Antimicrob Chemother</i>. 1992;30:875-878. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1289366\">[PubMed 1289366]</a></p>\n<p>4. Spectracef (cefditoren pivoxil) [prescribing information]. Cary, NC: Cornerstone Therapeutics Inc; September 2009.</p>\n<p>5. Claforan (cefotaxime) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; September 2011.</p>\n<p>6. Goodwin CS, Raftery EB, Goldberg AD, Skeggs H, Till AE, Martin CM. Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin. <i>Antimicrob Agents Chemother</i>. 1974;6(3):338-346. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15830485\">[PubMed 15830485]</a></p>\n<p>7. Keflin (cefalotin) [summary of product characteristics]. St. Leonards, New South Wales, Autralia: Aspen Pharmacare Australia Pty Ltd; October 2008.</p>\n<p>8. Keflin (cephalothin) [summary of product characteristics]. Cosmopolis, Sao Paulo, Brazil: Antibiotics Brazil Ltda.; February 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5241":"<p><b>Title</b> Dapsone (Systemic) / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Dapsone (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of dapsone if a uricosuric agent is initiated/dose increased, or decreased effects if a uricosuric agent is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Serum dapsone concentrations were increased approximately 50% in 12 normal male subjects 4 hours after coadministration with probenecid.<sup>1</sup> Recovery of dapsone and its metabolites in the urine was decreased. No information regarding clinical effects of this interaction were noted. <br><br>The mechanism of this interaction is unknown. The possibility appears reasonable that probenecid inhibits the urinary excretion of dapsone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Goodwin CS and Sparell G, “Inhibition of Dapsone Excretion by Probenecid,” <i>Lancet</i>, 1969, ii:884.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5242":"<p><b>Title</b> Ganciclovir-Valganciclovir / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Ganciclovir-Valganciclovir. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for signs/symptoms of ganciclovir/valganciclovir toxicity when used with probenecid.</p>\n<div>\n <p><b>Ganciclovir-Valganciclovir Interacting Members</b> Ganciclovir (Systemic)*, ValGANciclovir</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Ganciclovir maximum serum concentration (Cmax) and AUC were increased an average of 40% and 53%, respectively, when oral ganciclovir (1000 mg every 8 hours) was combined with probenecid in a study of HIV-infected adults.<sup>1</sup> <br><br>The mechanism of this interaction appears to be decreased ganciclovir renal clearance by probenecid (likely via inhibition of the renal organic anion/cation transport system).<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cimoch PJ, Lavelle J, Pollard R, et al, “Pharmacokinetics of Oral Ganciclovir Alone and in Combination with Zidovudine, Didanosine, and Probenecid in HIV-Infected Subjects,” <i>J Acquir Immune Defic Syndr Hum Retrovirol</i>, 1998, 17(3):227-34. [PMID: 9495222]</p>\n<p>2. Takeda M, Khamdang S, Narikawa S, et al, “Human Organic Anion Transporters and Human Organic Cation Transporters Mediate Renal Antiviral Transport,” <i>J Pharmacol Exp Ther</i>, 2002, 300(3):918-24. [PMID: 11861798]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5243":"<p><b>Title</b> Methotrexate / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Methotrexate. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> If possible, the concomitant use of methotrexate and uricosuric agents should be avoided. If used concomitantly, the methotrexate dosage will likely need reduced. Monitor for evidence of methotrexate toxicity. Lower therapeutic doses (e.g. antirheumatic doses) of methotrexate would pose a lower risk of toxicity than antineoplastic doses.</p> \n<p><b>Discussion</b> Three separate studies (totaling 28 patients) have documented 2- to 4-fold increases in serum methotrexate concentrations when concomitantly administered with probenecid.<sup>1,2,3</sup> <br><br>The likely mechanism of this interaction is probenecid inhibition of renal tubular secretion of methotrexate, causing methotrexate to accumulate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Aherne GW, Piall E, Marks V, et al, “Prolongation and Enhancement of Serum Methotrexate Concentrations by Probenecid,” <i>Br Med J</i>, 1978, 1:1097-9.</p>\n<p>2. Howell SB, Olshen RA, and Rice JA, “Effect of Probenecid on Cerebrospinal Fluid Methotrexate Kinetics,” <i>Clin Pharmacol Ther</i>, 1979, 26:641-6.</p>\n<p>3. Lilly MB and Omura GA, “Clinical Pharmacology of Oral Intermediate-Dose Methotrexate With or Without Probenecid,” <i>Cancer Chemother Pharmacol</i>, 1985, 15:220-2.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5244":"<p><b>Title</b> Nitrofurantoin / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Nitrofurantoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for increased nitrofurantoin serum concentrations and adverse effects, as well as for decreased nitrofurantoin urinary concentrations and signs/symptoms of a diminished therapeutic response to nitrofurantoin therapy when used concomitantly with probenecid.</p> \n<p><b>Discussion</b> According to nitrofurantoin prescribing information, renal tubular secretion of nitrofurantoin may be inhibited by uricosuric agents (e.g., probenecid, sulfinpyrazone).<sup>1</sup> Failure to achieve adequate nitrofurantoin levels in the urine may lead to a diminished therapeutic response and potential therapeutic failure. Two animal studies (both in rats) examining this potential interaction have yielded conflicting results, with one study finding that probenecid significantly decreased the renal tubular secretion of nitrofurantoin,<sup>2</sup> and the other finding that probenecid did not have an important effect on the urinary excretion of nitrofurantoin.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Macrodantin (nitrofurantoin). Cincinnati, OH: Proctor &amp; Gamble Pharmaceuticals, Inc., October 2007.</p>\n<p>2. Braunlich H, Bonow A, Schroter S, “Age-Dependence of Renal Tubular Reabsorption of Nitrofurantoin,” <i>Arch Int Pharmacodyn Ther</i>, 1978, 232(1):92-101. [PMID: 27154]</p>\n<p>3. Veronese M, Salvaterra M, Barzaghi D, et al, “Effects of Different Drugs on the Urinary Excretion of Nifurpipone (NP) and of Nitrofurantoin (NTF) in the Rat,” <i>Arzneimittelforschung</i>, 1975, 25(9):1417-20. [PMID: 1242665]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5245":"<p><b>Title</b> PRALAtrexate / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of PRALAtrexate. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Closely monitor for increased pralatrexate serum concentrations and/or possible toxicity with concomitant use of probenecid. Monitor for decreased pralatrexate concentrations/effects with discontinuation of probenecid.</p> \n<p><b>Discussion</b> According to pralatrexate prescribing information, concomitant use with probenecid resulted in a reduced clearance and increased exposure to pralatrexate.<sup>1</sup> In a phase I study of 17 patients with solid tumors, concurrent use of probenecid increased pralatrexate AUC and elimination half-life.<sup>2</sup> Similarly, a study in mice found that coadministration of probenecid was associated with increased intracellular accumulation and persistance of pralatrexate, as well as improved clinical/tumor response to treatment.<sup>3</sup><br><br>Studies with the related compound methotrexate further support the existence and significance of this interaction. Three separate studies (total of 28 patients) have documented 2- to 4-fold increases in serum methotrexate concentrations when concomitantly administered with probenecid.<sup>4,5,6</sup><br><br>Probenecid apparently inhibits the activity of various efflux transporters that are responsible for both the efflux of pralatrexate/methotrexate out of tumor cells as well as the renal tubular secretion of these agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Folotyn (pralatrexate). Westminster, CO: Allos Therapeutics, Inc., 2009.</p>\n<p>2. Fury MG, Krug LM, Azzoli CG, et al, “A Phase I Clinical Pharmacologic Study of Pralatrexate in Combination with Probenecid in Adults with Advanced Solid Tumors,” <i>Cancer Chemother Pharmacol</i>, 2006, 57(5):671-7. [PMID: 16136310]</p>\n<p>3. Sirotnak FM, Wendel HG, Bornmann WG, et al, “Co-administration of Probenecid, an Inhibitor of a cMOAT/MRP-like Plasma Membrane ATPase, Greatly Enhanced the Efficacy of a New 10-deazaaminopterin Against Human Solid Tumors In Vivo,” <i>Clin Cancer Res</i>, 2000, 6(9):3705-12. [PMID: 10999764]</p>\n<p>4. Aherne GW, Piall E, Marks V, et al, “Prolongation and Enhancement of Serum Methotrexate Concentrations by Probenecid,” <i>Br Med J</i>, 1978, 1:1097-9.</p>\n<p>5. Howell SB, Olshen RA, and Rice JA, “Effect of Probenecid on Cerebrospinal Fluid Methotrexate Kinetics,” <i>Clin Pharmacol Ther</i>, 1979, 26:641-6.</p>\n<p>6. Lilly MB and Omura GA, “Clinical Pharmacology of Oral Intermediate-Dose Methotrexate With or Without Probenecid,” <i>Cancer Chemother Pharmacol</i>, 1985, 15:220-2.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5246":"<p><b>Title</b> Probenecid / Salicylates</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Salicylates may diminish the therapeutic effect of Probenecid. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of probenecid if a salicylate is initiated/dose increased, or increased effects if a salicylate is discontinued/dose decreased.</p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid*, Aspirin*, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The daily urinary uric acid excretion with concomitant aminosalicylate sodium (6 g/day) and probenecid (3 g/day) or sulfinpyrazone (600 mg/day) was not more than one-sixth of the excretion caused by either agent alone.<sup>1</sup> Available evidence suggests that large, chronic doses of salicylates (those that result in serum concentrations of at least 5 mg/dL) are more likely to cause clinical effects.<sup>2,3,4,5</sup> <br><br>The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Seegmiller JE and Grayzel AI, “Use of the Newer Uricosuric Agents in the Management of Gout,”<i>JAMA</i>, 1960, 173:1076-80.</p>\n<p>2. Pascale LR, Dubin A, Bronsky D, et al, “Inhibition of the Uricosuric Action of Benemid by Salicylate,” <i>J Lab Clin Med</i>, 1955, 45(5):771-7.</p>\n<p>3. Yu TF, Dayton PG, and Gutman AB, “Mutual Suppression of the Uricosuric Effects of Sulphinpyrazone and Salicylate: A Study in Interaction Between Drugs,” <i>J Clin Invest</i>, 1963, 4:1330.</p>\n<p>4. Kersley GD, Cook ER, and Tovey DC, “Value of Uricosuric Agents and in Particular of G28315 in Gout,” <i>Ann Rheum Dis</i>, 1958, 17(3):326-33.</p>\n<p>5. Regal RE, “Aspirin and Uricosurics: Interaction Revisited,” <i>Drug Intell Clin Pharm</i>, 1987, 21(2):219-20.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5247":"<p><b>Title</b> Theophylline Derivatives / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of dyphylline if a uricosuric agent is initiated/dose increased, or decreased effects if a uricosuric agent is discontinued/dose decreased.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Dyphylline*<br><b>Exceptions</b> Aminophylline, Theophylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The clearance of dyphylline (20 mg/kg) was decreased 45% (and half-life increased 88%) in 12 normal subjects when preceded by a single dose of probenecid (1 g).<sup>1</sup> Dyphylline is significantly eliminated via renal excretion, and such is inhibited by probenecid. The extent of the effect under chronic dosing conditions is unknown. Aminophylline and theophylline, being eliminated primarily by hepatic metabolism, would not likely be appreciably affected by the uricosuric.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. May DC and Jarboe CH, “Inhibition of Clearance of Dyphylline by Probenecid,” <i>N Engl J Med</i>, 1981, 304:791. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7464894\">[PubMed 7464894]</a></p>\n<p>2. Chen TW and Patton TF, “Effect of Probenecid on the Pharmacokinetics of Aminophylline,” <i>Drug Intell Clin Pharm</i>, 1983, 17:465-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6861638\">[PubMed 6861638]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5248":"<p><b>Title</b> Digoxin / Liraglutide</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Liraglutide may decrease the serum concentration of Digoxin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Liraglutide prescribing information describes a pharmacokinetic study carried out to assess the effects of steady-state liraglutide on the single-dose oral pharmacokinetics of digoxin (1 mg).<sup>1</sup> When administered 7 hours after liraglutide, digoxin maximum concentration was decreased by 31% and total digoxin exposure was decreased by 16%. Maximum concentration was achieved at 1.5 hours with liraglutide, compared to 1 hour without liraglutide.<br><br>Liraglutide delays gastric emptying, which could explain the delay in achieving maximum concentration in this study. The mechanism by which liraglutide may decrease digoxin absorption is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victoza (liraglutide). Princeton, NJ: Novo Nordisk Inc, January 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5249":"<p><b>Title</b> Lisinopril / Liraglutide</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Liraglutide may decrease the serum concentration of Lisinopril. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Liraglutide prescribing information describes a pharmacokinetic study carried out to assess the effects of steady-state liraglutide on the single-dose oral pharmacokinetics of lisinopril (20 mg).<sup>1</sup> When administered 5 minutes after liraglutide, lisinopril maximum concentration was decreased by 27% and total lisinopril exposure was decreased by 15%. Maximum concentration was achieved at 8 hours with liraglutide, compared to 6 hours without liraglutide.<br><br>Liraglutide delays gastric emptying, which could explain the delay in achieving maximum concentration in this study. The mechanism by which liraglutide may decrease lisinopril absorption is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victoza (liraglutide). Princeton, NJ: Novo Nordisk Inc, January 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5250":"<p><b>Title</b> AtorvaSTATin / Liraglutide</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Liraglutide may decrease the serum concentration of AtorvaSTATin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Liraglutide prescribing information describes a pharmacokinetic study carried out to assess the effects of steady-state liraglutide on the single-dose oral pharmacokinetics of atorvastatin (40 mg). When administered 5 hours after liraglutide, atorvastatin maximum concentration was decreased by 38% but total atorvastatin exposure was unchanged. Maximum concentration was achieved at 3 hours with liraglutide, compared to 1 hour without liraglutide.<br><br>Liraglutide delays gastric emptying, which could explain the delay in achieving maximum concentration in this study.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victoza (liraglutide). Princeton, NJ: Novo Nordisk Inc, January 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5251":"<p><b>Title</b> Progestins (Contraceptive) / Bile Acid Sequestrants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the serum concentration of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Administer oral progestin-containing contraceptives at least 1 to 4 hours prior to or 4 to 6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin, Colesevelam, Colestipol</p>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> Though specific published data for progestin contraceptives are not available, one report describes a patient in whom one phase of the elimination of ethinylestradiol was shortened from 8.2 hours to 4.8 hours with concurrent cholestyramine.<sup>1</sup> Prescribing information for individual bile acid sequestrants acknowledge a known or potential interaction between these agents and both estrogen and progestin contraceptives.<sup>2,3</sup><br><br>The exact mechanism of any interaction is unclear, as both decreased oral contraceptive absorption and decreased enterohepatic reabsorption are possible mechanisms. Bile acid sequestrant prescribing information suggests that the interaction is at least primarily related to impaired absorption, recommending separation of bile acid sequestrant and oral contraceptive administration in order to avoid or minimize the interaction.<sup>2,3</sup> However, other authors have reported that enterohepatic reabsorption is an important determinant of ethinylestradiol concentrations/exposure and that cholestyramine could hasten ethinylestradiol elimination by interfering with this process.<sup>1,4</sup> Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of these interacting drugs may also be warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bolt HM, “Interactions Between Clinically Used Drugs and Oral Contraceptives,” <i>Environ Health Perspect</i>, 1994, 102 Suppl 9:35-8. [PMID: 7698081]</p>\n<p>2. Prescribing information. Cholestyramine. Spring Valley, NY: Par Pharmaceutical Companies, Inc., 05/06.</p>\n<p>3. Prescribing information. WelChol (colesevelam). Parsippany, NJ: Daiichi Sankyo, Inc., 1/2008.</p>\n<p>4. Bolt HM, Bolt M, Kappus H, “Interaction of Rifampicin Treatment with Pharmacokinetics and Metabolism of Ethinyloestradiol in Man,” <i>Acta Endocrinol (Copenh)</i>, 1977, 85(1):189-197. [PMID: 577076]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5252":"<p><b>Title</b> Progestins (Contraceptive) / AtorvaSTATin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> AtorvaSTATin may increase the serum concentration of Progestins (Contraceptive). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> The AUC of norethindrone (as part of an estrogen-progestin combination oral contraceptive) was increased 28% in 12 female subjects when coadministered with atorvastatin.<sup>1</sup> The AUC of ethinyl estradiol was increased 19%. The clinical implications of these pharmacokinetic changes appear negligible. Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration. The mechanism of the observed changes is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yang BB, Siedlik PH, Smithers JA, et al, “Atorvastatin Pharmacokinetic Interactions With Other CYP3A4 Substrates: Erythromycin and Ethinyl Estradiol,” [Abstract], <i>Pharm Res</i>, 1996, 13(Sup 9):S437.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5253":"<p><b>Title</b> Benzodiazepines (metabolized by glucuronidation) / Progestins (Contraceptive)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Progestins (Contraceptive) may decrease the serum concentration of Benzodiazepines (metabolized by glucuronidation). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of benzodiazepines that undergo glucuronidation (e.g., lorazepam, oxazepam, temazepam) if an progestin contraceptive is initiated or the dose is increased. NOTE: Toxic effects of benzodiazepines metabolized by oxidation (e.g., diazepam, triazolam) may manifest when combined with a progestin derivative.</p>\n<div>\n <p><b>Benzodiazepines (metabolized by glucuronidation) Interacting Members</b> LORazepam, Oxazepam, Temazepam</p>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> Hormonal contraceptives have been reported to increase the clearance of benzodiazepines that undergo glucuronidation.<sup>1</sup> A second report failed to identify any significant effects.<sup>2</sup> Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stoehr GP, Kroboth PD, Juhl RP, et al, “Effect of Oral Contraceptives on Triazolam, Temazepam, Alprazolam, and Lorazepam Kinetics,” <i>Clin Pharmacol Ther</i>, 1984, 36:683-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6149030\">[PubMed 6149030]</a></p>\n<p>2. Abernethy DR, Greenblatt DJ, Ochs HR, et al, “Lorazepam and Oxazepam Kinetics in Women on Low-Dose Oral Contraceptives,” <i>Clin Pharmacol Ther</i>, 1983, 33:628-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6132698\">[PubMed 6132698]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5255":"<p><b>Title</b> Progestins (Contraceptive) / Felbamate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Felbamate may decrease the serum concentration of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Contraceptive failure is possible. Patients must be instructed to use alternative, nonhormonal forms of contraception during felbamate therapy. It may be possible to use higher doses of the hormonal contraceptive to ensure adequate concentrations of circulating hormones. Careful monitoring of serum hormone concentrations may be the only way to ensure adequate dosing. If agents are used concomitantly, monitor for signs of reduced hormone concentrations (e.g., breakthrough bleeding) noting that the absence of such signs do not indicate therapeutic success.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> The AUC of gestodene (received via an oral contraceptive containing 75 mcg + ethinyl estradiol 30 mcg) was decreased an average of 42% in 31 normal women following the addition of felbamate (2400 mg/day from day 15 of month 1 to day 14 of month 2 of ovulation cycle) to their regimens.<sup>1,2</sup> No subjects showed any evidence of ovulation during the placebo-controlled study, however breakthrough bleeding was noted in one subject. Ethinyl estradiol concentrations were decreased by 13%. The mechanism of these interactions is unknown, but may be related to the ability of felbamate to increase the metabolism of some chemical entities. The effect of this interaction on the reliability of oral contraceptives is unknown. Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Banfield C, Saano V, Glue P, et al, “Effects of Felbamate on Oral Contraceptive Pharmacokinetics,” <i>Clin Pharmacol Ther</i>, 1995, 57:207.</p>\n<p>2. Saano V, Glue P, Banfield CR, et al, “Effects of Felbamate on the Pharmacokinetics of a Low-Dose Combination Oral Contraceptive,” <i>Clin Pharmacol Ther</i>, 1995, 58(5):523-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7586946\">[PubMed 7586946]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5256":"<p><b>Title</b> Progestins (Contraceptive) / Mycophenolate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Mycophenolate may decrease the serum concentration of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Women of childbearing potential who are receiving mycophenolate mofetil should consider using an alternative and/or additional form of contraception.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> Average AUC values for levonorgestrel (0.05 mg to 0.2 mg) were significantly decreased (average 15% decrease) with the addition of mycophenolate mofetil (1 g twice daily x 3 menstrual cycles); there was also evidence of considerable interpatient variability in response to the combination.<sup>1</sup> These findings were sufficient to cause the mycophenolate mofetil product labeling to include a statment cautioning women that mycophenolate could impair the effectiveness of oral contraptives.<sup>1</sup> Labeling also recommends that women consider using additional means of contraception while receiving mycophenolate. This recommendation appears particularly prudent given the risk of pregnancy loss and congenital malformations associated with the use of mycophenolate mofetil during pregnancy.<sup>1</sup> Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing Information. CellCept (mycophenolate mofetil). Nutley, NJ: Roche Laboratories Inc., September 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5257":"<p><b>Title</b> Progestins (Contraceptive) / OXcarbazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> OXcarbazepine may decrease the serum concentration of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> If oxcarbazepine must be used in a patient desiring effective birth control, hormonal contraceptives may not provide adequate protection against conception. Contraceptive failure is possible. Patients must be instructed to use alternative, nonhormonal contraceptives. It is important to note that breakthrough bleeding, though an important sign regarding the diminished effect of hormonal contraceptives, might not be present in spite of the occurrence of an interaction. When using levonorgestrel as an emergency contraceptive, recommendations outside of the United States suggest doubling the dose of levonorgestrel to 3 mg in women who have used enzyme inducing drugs in the previous 4 weeks.<sup>1</sup></p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> The AUC of levonorgestrel (as an oral contraceptive combined with ethinyl estradiol) was decreased approximately 47% in 16 normal women when oxcarbazepine was added to their regimens.<sup>2</sup> The estrogen was decreased to a similar extent. Breakthrough bleeding was noted in some subjects. Earlier studies yielded similar results.<sup>3,4</sup> In spite of the menstrual changes, no cases of failed contraception have been identified. <br><br>The prescribing information for oxcarbazepine states that concurrent use of oxcarbazepine with hormonal contraceptives may render these contraceptives less effective.<sup>5</sup><br><br>The mechanism of these interactions may be related to the ability of oxcarbazepine to increase hepatic metabolism of the hormones (ie, increase first pass effect). Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. The Medicines and Healthcare products Regulatory Agency (MHRA). Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy. <i>Drug Safety Update</i>. 2016;10(2):1-8. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/553274/Sept_2016_DSU.pdf. Accessed September 28, 2016.</p>\n<p>2. Fattore C, Cipolla G, Gatti G, et al, “Induction of Ethinylestradiol and Levonorgestrel Metabolism by Oxycarbazepine in Healthy Women,” <i>Epilepsia</i>, 1999, 40(6):783-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10368079\">[PubMed 10368079]</a></p>\n<p>3. Klosterskov-Jensen P, Saano V, Haring P, et al, “Possible Interaction Between Oxcarbazepine and an Oral Contraceptive,” <i>Epilepsia</i>, 1992, 33:1149-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1464278\">[PubMed 1464278]</a></p>\n<p>4. Sonnen AE, “Oxcarbazepine and Oral Contraceptives,” <i>Acta Neurol Scand</i>, 1990, 82(Suppl 133):37.</p>\n<p>5. Trileptal (oxcarbazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5259":"<p><b>Title</b> Progestins (Contraceptive) / Retinoic Acid Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Retinoic Acid Derivatives may diminish the therapeutic effect of Progestins (Contraceptive). Retinoic Acid Derivatives may decrease the serum concentration of Progestins (Contraceptive). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Two forms of effective contraception should be used in patients receiving retinoic acid derivatives. The manufacturer of Accutane does not identify oral hormonal contraceptives as ineffective; however they do warn that “microdosed progesterone preparations (minipills) may be an inadequate method of contraception during Accutane therapy.”<sup>1</sup></p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n <p><b>Retinoic Acid Derivatives Interacting Members</b> Acitretin, Alitretinoin (Systemic), Alitretinoin (Topical), Bexarotene (Systemic), ISOtretinoin (Systemic), Tretinoin (Systemic)<br><b>Exceptions</b> Adapalene, Bexarotene (Topical), Tretinoin (Topical)</p>\n</div> \n<p><b>Discussion</b> The maximum serum concentration (Cmax) of norethindrone (as part of a combination oral contraceptive regimen) was decreased 11% in 26 subjects during concomitant isotretinoin therapy as measured on day 20 of an oral contraceptive cycle.<sup>2</sup> The AUC of ethinyl estradiol in the same study was decreased 9%. The clinical relevance of these pharmacokinetic changes appears negligible. The manufacturer does not identify hormonal contraceptives as ineffective means of contraception; however, they note that an interaction that decreases the effectiveness of the hormonal contraception “cannot be ruled out.”<sup>1</sup> The mechanism of these changes is unknown. A patient taking levonorgestrel (0.03 mg) as an oral contraceptive experienced a 6-fold increase in levonorgestrel serum concentrations after 3 cycles of acitretin therapy.<sup>3</sup> Whether or not this effect, even if proved to be related to acitretin therapy, is evidence of potential contraceptive failure is unknown. The manufacturer of Accutane makes the following statement in its product package insert: “Microdosed progesterone preparations (minipills) may be an inadequate method of contraception during Accutane therapy.”<sup>1</sup> Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Accutane [package insert]. Nutley, NJ: Roche Laboratories, Inc, 2004.</p>\n<p>2. Hendrix CW, Jackson KA, Whitmore E, et al, “The Effect of Isotretinoin on the Pharmacokinetics and Pharmacodynamics of Ethinyl Estradiol and Norethindrone,” <i>Clin Pharmacol Ther</i>, 2004, 75(5):464-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15116059\">[PubMed 15116059]</a></p>\n<p>3. Berbis P, Bun H, Geiger JM, et al, “Acitretin (RO10-1670) and Oral Contraceptives: Interaction Study,” <i>Arch Dermatol Res</i>, 1988, 280(6):388-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2973286\">[PubMed 2973286]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5260":"<p><b>Title</b> Progestins (Contraceptive) / Rosuvastatin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Rosuvastatin may increase the serum concentration of Progestins (Contraceptive). <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> The AUC of ethinyl estradiol and norgestrel (administered as a combination oral combination) were increased 26% and 34%, respectively, in 18 normal female subjects when co-administered with rosuvastatin for the entire 21-day cycle.<sup>1</sup> No alterations in the efficacy of the oral contraceptive would be expected. No changes in the efficacy of rosuvastatin occurred. Rosuvastatin does not affect CYP-mediated hormone metabolism, and therefore is not proposed to have altered the clearance of the hormones. Rosuvastatin may have contributed to changes in oral bioavailability, but a mechanism is unclear. Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Simonson SG, Martin PD, Warwick MJ, et al, “The Effect of Rosuvastatin on Oestrogen and Progestin Pharmacokinetics in Healthy Women Taking an Oral Contraceptive,” <i>Br J Clin Pharmacol</i>, 2004, 57(3):279-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14998424\">[PubMed 14998424]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5261":"<p><b>Title</b> Selegiline / Progestins (Contraceptive)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Progestins (Contraceptive) may increase the serum concentration of Selegiline. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of selegiline if a hormonal contraceptive is initiated or the dose is increased. The increased selegiline serum concentrations may result in a loss of MAOI-A selectivity, and potentially cause a host of additional problems related to nonselective MAOI activity.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> The serum concentrations of oral selegiline were increased in 4 women by approximately 20-fold while concomitantly receiving oral, hormonal contraceptives.<sup>1</sup> The potential for increased incidence of side effects, and drug interactions due to loss of monoamine oxidase-B selectivity, is enhanced. The mechanism of this interaction is unknown. It has been postulated that hormonal contraceptives may diminish N-demethylation metabolism of selegiline. Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Laine K, Antilla M, Helminen A, et al, “Dose Linerity Study of Selegiline Pharmacokinetics After Oral Administration: Evidence for Strong Drug Interaction With Female Sex Steroids,” <i>Br J Clin Pharmacol</i>, 1999, 47:249-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10215747\">[PubMed 10215747]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5262":"<p><b>Title</b> Progestins (Contraceptive) / Voriconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Voriconazole may increase the serum concentration of Progestins (Contraceptive). Progestins (Contraceptive) may increase the serum concentration of Voriconazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased side effects of progestins and voriconzole during concomitant therapy.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> The AUC of norethindrone (1 mg daily as part of a combination oral contraceptive) was increased 53% in normal subjects when coadministered with voriconazole (400 mg every 12 hours on day 1, then 200 mg every 12 hours for 3 days).<sup>1</sup> The AUC of voriconazole was increased 46%. Voriconazole likely inhibited the CYP3A4-mediated metabolism of norethindrone. The mechanism of the observed increase in voriconazole is unclear. Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vfend [package insert]. New York, NY: Pfizer Roerig, 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5264":"<p><b>Title</b> Vitamin K Antagonists / Exenatide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Exenatide may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Increase the frequency of INR monitoring when starting/stopping/altering exenatide treatment. Resume routine INR monitoring once a stable therapeutic INR is established.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Prescribing information for exenatide describes postmarketing reports of elevated INR (with and without associated bleeding) in patients receiving warfarin and exenatide concomitantly.<sup>1</sup> In a study of 16 healthy volunteers, the impact of steady-state exenatide 10 mcg twice daily on the single-dose pharmacokinetics and pharmacodynamics (INR increase) of warfarin 25 mg was minimal.<sup>2</sup> Time to achieve maximum systemic warfarin concentrations were delayed by an average of 1 hour and 2 hours for the R and S enantiomers, respectively.<br><br>The mechanism of any interaction between these drugs is unknown. A delay in achieving maximum concentrations following an oral dose may be related to delayed gastric emptying caused by exenatide.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Byetta (exenatide). San Diego, CA: Amylin Pharmaceuticals, Inc, October 2009.</p>\n<p>2. Soon D, Kothare PA, Linnebjerg H, et al, “Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men,” <i>J Clin Pharmacol,</i> 2006, 46(10):1179-87. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16988207\">[PubMed 16988207]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5265":"<p><b>Title</b> Acetaminophen / Tapentadol</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Tapentadol does not appear to affect serum concentration of Acetaminophen. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> A clinical study of 24 healthy volunteers showed similar single-dose pharmacokinetics of tapentadol and its primary inactive metabolite tapentadol-<i>O</i>-glucuronide in subjects receiving tapentadol 80 mg with and without acetaminophen coadministration (1 g every 6 hours for 7 doses).<sup>1</sup> This study was prompted by <i>in vitro</i> evidence suggesting that acetaminophen may increase the rate of tapentadol glucuronidation, a process mediated by uridine diphosphate-glucuronosyltransferase (UGT) enzymes UGT1A9 and UGT2B7.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Smit JW, Oh C, Rengelshausen J, et al, “Effects of Acetaminophen, Naproxen, and Acetylsalicylic Acid on Tapentadol Pharmacokinetics: Results of Two Randomized, Open-Label, Crossover, Drug-Drug Interaction Studies,” <i>Pharmacotherapy,</i> 2010, 30(1):25-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20030470\">[PubMed 20030470]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5266":"<p><b>Title</b> Aspirin / Tapentadol</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Tapentadol does not appear to affect serum concentration of Aspirin. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> A clinical study of 38 healthy volunteers showed similar single-dose pharmacokinetics of tapentadol and its primary inactive metabolite tapentadol-<i>O</i>-glucuronide in subjects receiving tapentadol 80 mg with and without acetylsalicylic acid coadministration (325 mg every 24 hours for 2 doses).<sup>1</sup> This study was prompted by <i>in vitro</i> evidence that suggested that acetylsalicylic acid may decrease the rate of tapentadol glucuronidation, a process mediated by uridine diphosphate-glucuronosyltransferase (UGT) enzymes UGT1A9 and UGT2B7.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Smit JW, Oh C, Rengelshausen J, et al, “Effects of Acetaminophen, Naproxen, and Acetylsalicylic Acid on Tapentadol Pharmacokinetics: Results of Two Randomized, Open-Label, Crossover, Drug-Drug Interaction Studies,” <i>Pharmacotherapy,</i> 2010, 30(1):25-34.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5267":"<p><b>Title</b> Tapentadol / Naproxen</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Naproxen may increase the serum concentration of Tapentadol. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> A clinical study of 38 healthy volunteers showed roughly 17% increases in exposure to tapentadol and its primary inactive metabolite tapentadol-<i>O</i>-glucuronide in subjects receiving tapentadol 80 mg with naproxen coadministration (500 mg every 12 hours for 4 doses).<sup>1</sup> These increases in exposure were accompanied by an increase in adverse event rates from 60% without acetylsalicylic acid to 83% with acetylsalicylic acid (most commonly dizziness, nausea, vomiting, and headache), although rates as high as 96% were seen in other arms of this study when tapentadol 80 mg was given alone. The clinical impact of a 17% increase in exposure to tapentadol is likely minimal.<br><br>This study was prompted by <i>in vitro</i> evidence that suggested that naproxen may decrease the rate of tapentadol glucuronidation, a process mediated by uridine diphosphate-glucuronosyltransferase (UGT) enzymes UGT1A9 and UGT2B7.<sup>1</sup> Inhibition of these enzymes by naproxen may in part explain the interaction seen.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Smit JW, Oh C, Rengelshausen J, et al, “Effects of Acetaminophen, Naproxen, and Acetylsalicylic Acid on Tapentadol Pharmacokinetics: Results of Two Randomized, Open-Label, Crossover, Drug-Drug Interaction Studies,” <i>Pharmacotherapy,</i> 2010, 30(1):25-34.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5268":"<p><b>Title</b> Meropenem / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Meropenem. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of meropenem and probenecid.</p> \n<p><b>Discussion</b> Meropenem prescribing information describes a 56% increase in meropenem systemic exposure with probenecid coadministration and recommends against the use of these agents concomitantly.<sup>1</sup> Probenecid competes with the antibiotic for active tubular secretion and thus decreases meropenem renal elimination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Merrem (meropenem). Wilmington, DE: AstraZeneca Pharmaceuticals LP, July 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5269":"<p><b>Title</b> Ertapenem / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Ertapenem. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for toxic effects of ertapenem (especially if used in high doses) if probenecid is initiated or the dose is increased.</p> \n<p><b>Discussion</b> The renal clearance of ertapenem was reduced by 35% when coadministered with probenecid (500 mg every 6 hours).<sup>1</sup> Probenecid competes with ertapenem for active tubular secretion; however, the effect does not appear large enough to consider using probenecid to extend the half-life of the antibiotic.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Invanz (ertapenem). Whitehouse Station, NJ: Merck &amp; Co, Inc, May 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5270":"<p><b>Title</b> Imipenem / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Imipenem. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for toxic effects of imipenem (especially if used in high doses) if probenecid is initiated or the dose is increased.</p> \n<p><b>Discussion</b> The renal clearance of ertapenem was reduced by 35% when coadministered with probenecid (500 mg every 6 hours).<sup>1</sup> Probenecid similarly affects the excretion of imipenem.<sup>2</sup> Probenecid competes with carbapenem antibiotics (such as imipenem, ertapenem) for active tubular secretion; however, the effect does not appear large enough to consider using probenecid to extend the half-life of the antibiotic.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Invanz (ertapenem). Whitehouse Station, NJ: Merck &amp; Co, Inc, May 2009.</p>\n<p>2. Norrby SR, Bjornegard B, Ferber F, et al, “Pharmacokinetics of Imipenem in Healthy Volunteers,” <i>J Antimicrob Chemother</i>, 1983, Suppl D:109-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6583194\">[PubMed 6583194]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5271":"<p><b>Title</b> Antipsychotic Agents / Metoclopramide</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Metoclopramide may enhance the adverse/toxic effect of Antipsychotic Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of metoclopramide in combination with other agents associated with development of extrapyramidal reactions (e.g. tardive dyskinesia) or neuroleptic malignant syndrome.</p>\n<div>\n <p><b>Antipsychotic Agents Interacting Members</b> Amisulpride, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Benperidol, Blonanserin, Brexpiprazole, Bromperidol, Cariprazine, ChlorproMAZINE, Clothiapine, CloZAPine, Droperidol, Flupentixol, FluPHENAZine, Haloperidol, Iloperidone, Loxapine, Lurasidone, Methotrimeprazine, Molindone, OLANZapine, Paliperidone, Periciazine, Perphenazine, Pimozide, Pipamperone [INT], Pipotiazine, Prochlorperazine, Promazine, QUEtiapine, RisperiDONE, Sulpiride, Thioridazine, Thiothixene, Trifluoperazine, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The use of metoclopramide in combination with other agents associated with development of neuroleptic malignant syndrome or extrapyramidal reactions such as tardive dyskinesia should be avoided per metoclopramide prescribing information.<sup>1</sup><br><br>Dopaminergic activity within the nigrostriatal pathway (at dopamine D1 receptors) and striatopallidal pathway (at dopamine D2 receptors) regulates output from the basal ganglia which controls movement.<sup>2</sup> Metoclopramide inhibits central D2 receptors, which may cause an imbalance in dopaminergic activity between the nigrostriatal and striatopallidal pathways leading to movement-related side effects.<sup>3</sup> Other medications that inhibit central dopaminergic activity either directly (e.g. antipsychotics) or indirectly (e.g. serotonergic antidepressants) may increase the likelihood of serious movement-related side effects in patients receiving metoclopramide. The pathophysiology of neuroleptic malignant syndrome is poorly understood, but the syndrome is associated with many of the same drugs (e.g. antipsychotics, serotonergic antidepressants) as extrapyramidal side effects and similar precautions regarding the use of multiple associated agents should be taken.<sup>1,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Metozolv (metoclopramide HCl). Morrisville, North Carolina: Salix Pharmaceuticals, September 2009.</p>\n<p>2. Gerfen CR, “Molecular Effects of Dopamine on Striatal-Projection Pathways,” <i>Trends Neurosci</i>, 2000, 23(Suppl):S64-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p>3. Rao AS and Camilleri M, “Review Article: Metoclopramide and Tardive Dyskinesia,” <i>Aliment Pharmacol Ther</i>, 2010, 31(1):11-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19886950\">[PubMed 19886950]</a></p>\n<p>4. Stevens DL, “Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,” <i>Ann Pharmacother</i>, 2008, 42(9):1290-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18628446\">[PubMed 18628446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5272":"<p><b>Title</b> Selective Serotonin Reuptake Inhibitors / Metoclopramide</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Metoclopramide may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine, FluvoxaMINE, PARoxetine, Sertraline, Vilazodone, Vortioxetine</p>\n</div> \n<p><b>Discussion</b> The use of metoclopramide in combination with other agents associated with development of neuroleptic malignant syndrome or extrapyramidal reactions such as tardive dyskinesia should be avoided per metoclopramide prescribing information.<sup>1</sup> Additionally, there may be some increased risk of serotonin syndrome with combined therapy with selective serotonin reuptake inhibitors (SSRIs) based on one case report.<sup>2</sup> In this case, a 72 year old patient who had been taking sertraline for more than 1 year experienced signs and symptoms of serotonin syndrome within hours of a single metoclopramide dose. A second case report of serotonin syndrome with this combination has been published but is only available in French.<sup>3</sup><br><br>Dopaminergic activity within the nigrostriatal pathway (at dopamine D1 receptors) and striatopallidal pathway (at dopamine D2 receptors) regulates output from the basal ganglia which controls movement.<sup>4</sup> Metoclopramide inhibits central D2 receptors, which may cause an imbalance in dopaminergic activity between the nigrostriatal and striatopallidal pathways leading to movement-related side effects.<sup>5</sup> Other medications that inhibit central dopaminergic activity either directly (e.g. antipsychotics) or indirectly (e.g. serotonergic antidepressants) may increase the likelihood of serious movement-related side effects in patients receiving metoclopramide. The pathophysiology of neuroleptic malignant syndrome is poorly understood, but the syndrome is associated with many of the same drugs (e.g. antipsychotics, serotonergic antidepressants) as extrapyramidal side effects and similar precautions regarding the use of multiple associated agents should be taken.<sup>1,6</sup> An increase in serotonin syndrome with the combination of SSRIs and metoclopramide may be the result of dopaminergic and/or serotonergic actions of metoclopramide in combination with serotonergic effects of SSRIs.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Metozolv ODT (metoclopramide HCl) [prescribing information]. Morrisville, NC: Salix Pharmaceuticals, Inc.; September 2011.</p>\n<p>2. Fisher AA, Davis MW. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. <i>Ann Pharmacother</i>. 2002;36(1):67-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11816261\">[PubMed 11816261]</a></p>\n<p>3. Vandemergel X, Beukinga I, Neve P. Serotonin syndrome secondary to the use of sertraline and metoclopramide. <i>Rev Med Brux</i>. 2000;21(3):161-163. [French]. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10925598\">[PubMed 10925598]</a></p>\n<p>4. Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. <i>Trends Neurosci</i>. 2000;23(Suppl):S64-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p>5. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. <i>Aliment Pharmacol Ther</i>. 2010;31(1):11-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19886950\">[PubMed 19886950]</a></p>\n<p>6. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18628446\">[PubMed 18628446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5273":"<p><b>Title</b> Tricyclic Antidepressants / Metoclopramide</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Metoclopramide may enhance the adverse/toxic effect of Tricyclic Antidepressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms and neuroleptic malignant syndrome.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> The use of metoclopramide in combination with other agents associated with development of neuroleptic malignant syndrome or extrapyramidal reactions such as tardive dyskinesia should be avoided per metoclopramide prescribing information.<sup>1</sup> <br><br>Dopaminergic activity within the nigrostriatal pathway (at dopamine D1 receptors) and striatopallidal pathway (at dopamine D2 receptors) regulates output from the basal ganglia which controls movement.<sup>2</sup> Metoclopramide inhibits central D2 receptors, which may cause an imbalance in dopaminergic activity between the nigrostriatal and striatopallidal pathways leading to movement-related side effects.<sup>3</sup> Other medications that inhibit central dopaminergic activity either directly (e.g. antipsychotics) or indirectly (e.g. serotonergic antidepressants) may increase the likelihood of serious movement-related side effects in patients receiving metoclopramide. The pathophysiology of neuroleptic malignant syndrome is poorly understood, but the syndrome is associated with many of the same drugs (e.g. antipsychotics, serotonergic antidepressants) as extrapyramidal side effects and similar precautions regarding the use of multiple associated agents should be taken.<sup>1,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Metozolv ODT (metoclopramide HCl) [prescribing information]. Morrisville, NC: Salix Pharmaceuticals, Inc.; September 2011.</p>\n<p>2. Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. <i>Trends Neurosci</i>. 2000;23(Suppl):S64-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p>3. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. <i>Aliment Pharmacol Ther</i>. 2010;31(1):11-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19886950\">[PubMed 19886950]</a></p>\n<p>4. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18628446\">[PubMed 18628446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5274":"<p><b>Title</b> Metoclopramide / Droperidol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Droperidol may enhance the adverse/toxic effect of Metoclopramide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of metoclopramide in combination with other agents associated with development of extrapyramidal reactions (e.g. tardive dyskinesia) or neuroleptic malignant syndrome.</p> \n<p><b>Discussion</b> The use of metoclopramide in combination with other agents associated with development of neuroleptic malignant syndrome or extrapyramidal reactions such as tardive dyskinesia should be avoided per metoclopramide prescribing information.<sup>1</sup><br><br>Dopaminergic activity within the nigrostriatal pathway (at dopamine D1 receptors) and striatopallidal pathway (at dopamine D2 receptors) regulates output from the basal ganglia which controls movement.<sup>2</sup> Metoclopramide inhibits central D2 receptors, which may cause an imbalance in dopaminergic activity between the nigrostriatal and striatopallidal pathways leading to movement-related side effects.<sup>3</sup> Other medications that inhibit central dopaminergic activity either directly (e.g. antipsychotics) or indirectly (e.g. serotonergic antidepressants) may increase the likelihood of serious movement-related side effects in patients receiving metoclopramide. The pathophysiology of neuroleptic malignant syndrome is poorly understood, but the syndrome is associated with many of the same drugs (e.g. antipsychotics, serotonergic antidepressants) as extrapyramidal side effects and similar precautions regarding the use of multiple associated agents should be taken.<sup>1,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Metozolv (metoclopramide HCl). Morrisville, North Carolina: Salix Pharmaceuticals, September 2009.</p>\n<p>2. Gerfen CR, “Molecular Effects of Dopamine on Striatal-Projection Pathways,” <i>Trends Neurosci</i>, 2000, 23(Suppl):S64-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p>3. Rao AS, Camilleri M, “Review Article: Metoclopramide and Tardive Dyskinesia,” <i>Aliment Pharmacol Ther</i>, 2010, 31(1):11-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19886950\">[PubMed 19886950]</a></p>\n<p>4. Stevens DL, “Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,” <i>Ann Pharmacother</i>, 2008, 42(9):1290-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18628446\">[PubMed 18628446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5275":"<p><b>Title</b> Promethazine / Metoclopramide</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Metoclopramide may enhance the adverse/toxic effect of Promethazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of metoclopramide in combination with other agents associated with development of extrapyramidal reactions (e.g. tardive dyskinesia) or neuroleptic malignant syndrome.</p> \n<p><b>Discussion</b> The use of metoclopramide in combination with other agents associated with development of neuroleptic malignant syndrome or extrapyramidal reactions such as tardive dyskinesia should be avoided per metoclopramide prescribing information.<sup>1</sup><br><br>Dopaminergic activity within the nigrostriatal pathway (at dopamine D1 receptors) and striatopallidal pathway (at dopamine D2 receptors) regulates output from the basal ganglia which controls movement.<sup>2</sup> Metoclopramide inhibits central D2 receptors, which may cause an imbalance in dopaminergic activity between the nigrostriatal and striatopallidal pathways leading to movement-related side effects.<sup>3</sup> Other medications that inhibit central dopaminergic activity either directly (e.g. antipsychotics) or indirectly (e.g. serotonergic antidepressants) may increase the likelihood of serious movement-related side effects in patients receiving metoclopramide. The pathophysiology of neuroleptic malignant syndrome is poorly understood, but the syndrome is associated with many of the same drugs (e.g. antipsychotics, serotonergic antidepressants) as extrapyramidal side effects and similar precautions regarding the use of multiple associated agents should be taken.<sup>1,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Metozolv (metoclopramide HCl). Morrisville, North Carolina: Salix Pharmaceuticals, September 2009.</p>\n<p>2. Gerfen CR, “Molecular Effects of Dopamine on Striatal-Projection Pathways,” <i>Trends Neurosci</i>, 2000, 23(Suppl):S64-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p>3. Rao AS and Camilleri M, “Review Article: Metoclopramide and Tardive Dyskinesia,” <i>Aliment Pharmacol Ther</i>, 2010, 31(1):11-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19886950\">[PubMed 19886950]</a></p>\n<p>4. Stevens DL, “Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,” <i>Ann Pharmacother</i>, 2008, 42(9):1290-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18628446\">[PubMed 18628446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5276":"<p><b>Title</b> Sulfonylureas / Glucagon-Like Peptide-1 Agonists</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: Use of lixisenatide should be avoided in patients receiving both basal insulin and a sulfonylurea.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Sulfonylureas. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider sulfonylurea dose reductions when used in combination with glucagon-like peptide-1 agonists. Avoid the use of lixisenatide in patients receiving both basal insulin and a sulfonylurea.</p>\n<div>\n <p><b>Glucagon-Like Peptide-1 Agonists Interacting Members</b> Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide</p>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, TOLAZamide, TOLBUTamide</p>\n</div> \n<p><b>Discussion</b> Manufacturers of all glucagon-like peptide-1 agonists warn that hypoglycemia has occurred when these agents were used in combination with sulfonylureas and that dose reductions of sulfonylureas should be considered in patients receiving both agents.<sup>1,2,3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Byetta</i> (exenatide) [prescribing information]. San Diego, CA: Amylin Pharmaceuticals Inc; October 2009.</p>\n<p>2. <i>Victoza</i> (liraglutide) [prescribing information]. Princeton, NJ: Novo Nordisk Inc; January 2010.</p>\n<p>3. <i>Tanzeum</i> (albiglutide) [prescribing information]. Wilmington, DE: GlaxoSmithKline LLC; April 2014.</p>\n<p>4. <i>Trulicity</i> (dulaglutide) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; September 2014.</p>\n<p>5. <i>Lyxumia</i> (lixisenatide) [summary of product characteristics]. Singapore: Sanofi-Aventis Singapore; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5277":"<p><b>Title</b> MethylPREDNISolone / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider methylprednisolone dose reduction in patients receiving strong CYP3A4 inhibitors and monitor for increased steroid related adverse effects.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The AUC of both oral and intravenous methylprednisolone (48 mg or 16 mg single dose) increased 2.5- to 3.9-fold in 3 pharmacokinetic studies when administered following a 4-day course of itraconazole.<sup>1,2,3</sup> The AUC of intravenous methylprednisolone (20 mg) increased 2.5-fold after a 6 day course of ketoconazole (200 mg daily),<sup>4</sup> and the dose of intravenous methylprednisolone had to be reduced approximately 60% when administered with ketoconazole (200 mg daily for 7 days) in order to maintain a similar AUC with methylprednisolone alone.<sup>5</sup> In all 5 studies, suppression of endogenous cortisol was significantly greater with the combination of a CYP3A4 inhibitor and methylprednisolone than with methylprednisolone alone. However, with ketoconazole as the CYP3A4 inhibitor, it is unclear what role the known inhibitory effects on cortisol production ketoconazole itself played.<sup>4,5</sup> Increases in methylprednisolone exposure have also been observed in studies with nefazodone,<sup>6</sup> clarithromycin,<sup>7</sup> and the moderate CYP3A4 inhibitors diltiazem<sup>8,9</sup> and erythromycin.<sup>10</sup> A case report describes the development of steroid-related toxicity (myopathy and insulin resistance) after itraconazole initiation in a lung transplant patient taking methylprednisolone 12 mg daily that resolved after itraconazole discontinuation.<sup>11</sup> <br><br>The likely mechanism of this interaction is CYP3A4 inhibition resulting in reduced methylprednisolone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. <i>Br J Clin Pharmacol</i>. 2001;51(5):443-450. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11422002\">[PubMed 11422002]</a></p>\n<p>2. Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. <i>Clin Pharmacol Ther</i>. 1998;64(4):363-368. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9797792\">[PubMed 9797792]</a></p>\n<p>3. Varis T, Kivisto KT, Backman JT, Neuvonen PJ. Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. <i>Pharmacol Toxicol</i>. 1999;85(1):29-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10426160\">[PubMed 10426160]</a></p>\n<p>4. Glynn AM, Slaughter RL, Brass C, D’Ambrosio R, Jusko WJ. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. <i>Clin Pharmacol Ther</i>. 1986;39(6):654-659. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3709030\">[PubMed 3709030]</a></p>\n<p>5. Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ. Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. <i>Clin Pharmacol Ther</i>. 1987;42(4):465-470. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3311551\">[PubMed 3311551]</a></p>\n<p>6. Kotlyar M, Brewer ER, Golding M, Carson SW. Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. <i>J Clin Psychopharmacol</i>. 2003;23(6):652-656. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14624194\">[PubMed 14624194]</a></p>\n<p>7. Fost DA, Leung DY, Martin RJ, Brown EE, Szefler SJ, Spahn JD. Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. <i>J Allergy Clin Immunol</i>. 1999;103(6):1031-1035. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10359882\">[PubMed 10359882]</a></p>\n<p>8. Varis T, Backman JT, Kivisto KT, Neuvonen PJ. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. <i>Clin Pharmacol Ther</i>. 2000;67(3):215-221. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10741623\">[PubMed 10741623]</a></p>\n<p>9. Booker BM, Magee MH, Blum RA, Lates CD, Jusko WJ. Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. <i>Clin Pharmacol Ther</i>. 2002;72(4):370-382. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12386639\">[PubMed 12386639]</a></p>\n<p>10. LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M. Inhibition of methylprednisolone elimination in the presence of erythromycin therapy. <i>J Allergy Clin Immunol</i>. 1983;72(1):34-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6602160\">[PubMed 6602160]</a></p>\n<p>11. Linthoudt H, Van Raemdonck D, Lerut T, Demedts M, Verleden G. The association of itraconazole and methylprednisolone may give rise to important steroid-related side effects. <i>J Heart Lung Transplant</i>. 1996;15(11):1165. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8956126\">[PubMed 8956126]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5279":"<p><b>Title</b> Bortezomib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Closely monitor patients for signs of increased bortezomib toxicity and consider a dose reduction if co-administering bortezomib with strong inhibitors of CYP3A4.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Bortezomib AUC increased an average of 35% when the strong CYP3A4 inhibitor ketoconazole (400 mg daily on days 6-9) was given with bortezomib (1 mg/m<sup>2</sup> IV x 21 days) in a randomized control trial of patients with solid tumors (n=12).<sup>1</sup> Bortezomib-mediated proteosome inhibition (a measure of bortezomib activity) was increased by 24-46% with concomitant ketoconazole, but there was no reported difference in the occurance of adverse events between bortezomib plus ketoconazole and the bortezomib alone group. A case series describes increased neutropenia and thrombocytopenia in 3 patients who received both bortezomib and the strong CYP3A inhibitor itraconazole; this was in contrast to 3 other patients who received bortezomib but without itraconazole.<sup>2</sup><br><br>The mechanism for this apparent interaction is primarily ketoconazole-mediated inhibition of bortezomib metabolism via CYP3A. Several enzymes appear to participate in the metabolism of bortezomib, but CYP3A4 has been described as the primary enzyme responsible.<sup>3,4</sup> A similar interaction would be expected with other strong inhibitors of CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Venkatakrishnan K, Rader M, Ramanathan RK, et al, “Effect of the CYP3A Inhibitor Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients with Advanced Solid Tumors: A Prospective, Multicenter, Open-Label, Randomized, Two-Way Crossover Drug-Drug Interaction Study,” <i>Clin Ther</i>, 2009, 31 Pt2:2444-58. [PubMed 20110052]</p>\n<p>2. Iwamoto T, Ishibashi M, Fujieda A, et al, “Drug Interaction Between Itraconazole and Bortezomib: Exacerbation of Peripheral Neuropathy and Thrombocytopenia Induced by Bortezomib,” <i>Pharmacotherapy</i>, 2010, 30(7):661-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20575631\">[PubMed 20575631]</a></p>\n<p>3. Uttamsingh V, Lu C, Miwa G, et al, “Relative Contributions of the Five Major Human Cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the Hepatic Metabolism of the Proteasome Inhibitor Bortezomib,” <i>Drug Metab Dispos</i>, 2005, 33(11):1723-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16103134\">[PubMed 16103134]</a></p>\n<p>4. Pekol T, Daniels JS, Labutti J, et al, “Human Metabolism of the Proteasome Inhibitor Bortezomib: Identification of Circulating Metabolites,” <i>Drug Metab Dispos</i>, 2005, 33(6):771-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15764713\">[PubMed 15764713]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5280":"<p><b>Title</b> OxyCODONE / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of OxyCODONE. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Closely monitor the analgesic response to oxycodone in patients taking St John's wort, particularly when starting or stopping St John's wort and/or when attempting to convert from an opioid that is not significantly metabolized by CYP3A to oxycodone.</p> \n<p><b>Discussion</b> Oxycodone AUC and maximum serum concentration (Cmax) decreased an average of 50% and 29%, respectively, when oxycodone (15 mg x 1 on day 14 of 15) was administered with St John’s wort (Jarsin brand; 300 mg three times daily x 15 days) in a randomized control trial of 12 healthy participants.<sup>1</sup> Though the study also attempted to measure the analgesic consequences of this potential interaction (via the cold pressor test), the authors concluded there was insufficient power to adequately detect any such pharmacodynamic differences (no significant differences were observed).<br><br>The mechanism of this apparent interaction is likely induction of the CYP3A-mediated metabolism of oxycodone by St John's wort, a known CYP3A inducer.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nieminen TH, Hagelberg NM, Saari TI, et al, “ St John's Wort Greatly Reduces the Concentrations of Oral Oxycodone,” <i>Eur J Pain</i>, 2010, Jan 25 [Epub ahead of print]. [PubMed 20106684]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5281":"<p><b>Title</b> Temsirolimus / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fluconazole may increase serum concentrations of the active metabolite(s) of Temsirolimus. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Temsirolimus dosage adjustments may be necessary when starting, stopping, or changing therapy with fluconazole or any other azole antifungal. Monitor the serum concentrations and clinical effects of sirolimus closely in all patients receiving fluconazole or any systemic azole antifungal.</p> \n<p><b>Discussion</b> Two published case reports describe increased sirolimus concentrations (3.5- to 4.7-fold) following the initiation of fluconazole therapy.<sup>1,2</sup> In one case, sirolimus concentrations increased from 10ng/mL to 35ng/mL despite an initial 25% reduction in sirolimus dose at the time fluconazole was started and a further reduction in sirolimus dose 5 days prior to the maximum observed elevation in sirolimus concentration.<sup>1</sup> These observed sirolimus concentration elevations are consistent with an in vitro model using human hepatocytes suspended in human plasma that predicted an approximate 3-fold increase in sirolimus AUC with clinically achieved concentrations of fluconazole.<sup>3</sup><br><br>The likely mechanism of this interaction is fluconazole inhibition of the CYP3A4-mediated metabolism and/or p-glycoprotein (P-gp) transport of sirolimus. Of note, a study in rats finding that ketoconazole increased the sirolimus AUC by 3-5-fold questioned the role of P-gp inhibition in this interaction, and suggesting the involvement of an unknown mechanism, including the possible involvement of another sirolimus transporter.<sup>4</sup> Interestingly, other data support the possible involvement of a novel transporter (i.e., besides P-gp) in sirolimus disposition.<sup>5</sup><br><br>CYP3A4 is the major enzyme responsible for metabolism of temsirolimus.<sup>6</sup> Sirolimus is the principal metabolite and is a substrate of both CYP3A4 and P-gp.<sup>6,7</sup> Elimination of sirolimus is slower than elimination of temsirolimus, leading to 2.4-2.7 times greater exposure to sirolimus than temsirolimus following a 25 mg intravenous (IV) temsirolimus dose.<sup>6,8</sup> Sirolimus exposure following 25 mg IV temsirolimus averaged around 3,810 ng*h/mL in the first week post-dose in one study,<sup>8</sup> which compares to approximately 400-600 ng*h/mL daily (2,800-4,200 ng*h/mL weekly) when sirolimus is dosed orally twice daily to therapeutic trough concentrations in renal transplant recipients.<sup>7,9</sup> Based on published pharmacokinetic (PK) data for sirolimus in patients receiving temsirolimus 25 mg IV weekly,<sup>8</sup> assuming a maximum blood concentration of 65.9 ng/mL, a half-life of 48.8 hours, and linear elimination predicted trough sirolimus concentrations would be around 6 ng/mL and accumulation with repeated doses would be low. <br><br>Known drug interactions involving sirolimus are presumed to apply whether patients are administered temsirolimus or sirolimus. Interactions have been demonstrated with the CYP3A4/P-gp inhibitor ketoconazole<sup>10,11</sup> and CYP3A4/P-gp inducer rifampin<sup>7,12</sup> with sirolimus given alone or originating as a metabolite of temsirolimus. The magnitude of these interactions is lower with temsirolimus, which may be attributable to IV dosing of temsirolimus which bypasses first-pass transporter and metabolic effects. Metabolism of temsirolimus itself appears to be much less sensitive to CYP3A4 and P-gp inhibition and induction than sirolimus.<sup>10,12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cervelli MJ, “Fluconazole-Sirolimus Drug Interaction,” <i>Transplantation</i>, 2002, 74:1477-8.</p>\n<p>2. Sadaba B, Campanero MA, Quetglas EG, et al, “Clinical Relevance of Sirolimus Drug Interactions in Transplant Patients,” <i>Transplant Proc</i>, 2004, 36:3226-8.</p>\n<p>3. Lu C, Berg C, Prakash SR, et al, “Prediction of Pharmacokinetic Drug-Drug Interactions Using Human Hepatocyte Suspension in Plasma and Cytochrome P450 Phenotypic Data. III. In Vitro-in Vivo Correlation with Fluconazole,” <i>Drug Metab Dispos</i>, 2008, 36:1261-6.</p>\n<p>4. Wacher VJ, Silverman JA, Wong S, et al, “Sirolimus Oral Absorption in Rats Is Increased by Ketoconazole but Is Not Affected by D-Alpha-Tocopheryl Poly(Ethylene Glycol 1000) Succinate,” <i>J Pharmacol Exp Ther</i>, 2002, 303:308-13.</p>\n<p>5. Paine MF, Leung LY, Lim HK, et al, “Identification of a Novel Route of Extraction of Sirolimus in Human Small Intestine: Roles of Metabolism and Secretion,” <i>J Pharmacol Exp Ther</i>, 2002, 301:174-86.</p>\n<p>6. Prescribing information. Torisel (temsirolimus). Philadelphia, PA: Wyeth Inc., May 2007.</p>\n<p>7. Prescribing information. Rapamune (sirolimus). Philadelphia, PA: Wyeth Pharmaceuticals Inc., November 2009.</p>\n<p>8. Atkins MB, Hidalgo M, Stadler WM, et al, “Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Refractory Renal Cell Carcinoma,” <i>J Clin Oncol</i>, 2004, 22(5):909-18. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14990647\">[PubMed 14990647]</a></p>\n<p>9. Zimmerman JJ and Kahan BD, “Pharmacokinetics of Sirolimus in Stable Renal Transplant Patients after Multiple Oral Dose Administration,” <i>J Clin Pharmacol</i>, 1997, 37(5):405-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9156373\">[PubMed 9156373]</a></p>\n<p>10. Boni JP, Leister C, Burns J, et al, “Differential Effects of Ketoconazole on Exposure to Temsirolimus following Intravenous Infusion of Temsirolimus,” <i>Br J Cancer</i>, 2008, 98(11):1797-802. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18458675\">[PubMed 18458675]</a></p>\n<p>11. Foren LC, et al, “Sirolimus Oral Bioavailability Increases Ten-Fold with Concomitant Ketoconazole,” <i>Clin Pharmacol Ther</i>, 1999, 65:159 [abstract].</p>\n<p>12. Boni J, Leister C, Burns J, et al, “Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications,” <i>J Clin Pharmacol</i>, 2007, 47(11):1430-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17913896\">[PubMed 17913896]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5282":"<p><b>Title</b> Temsirolimus / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Itraconazole may increase serum concentrations of the active metabolite(s) of Temsirolimus. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of itraconazole with temsirolimus is not recommended and should be avoided.</p> \n<p><b>Discussion</b> Sirolimus concentrations increased nearly 9-fold following the addition of itraconazole (600 mg initially, then decreased to 400 mg/day) in one patient.<sup>1</sup> Sirolimus concentrations decreased from 9.6 ng/mL on the day of itraconazole initiation to 6.8 ng/mL (which prompted an increase in sirolimus dose from 8 mg/day to 10 mg/day), but sirolimus concentrations rapidly rose (up to 82.5 ng/mL) thereafter. Despite a decrease in sirolimus dose (from 7 mg/day to 5 mg/day), sirolimus concentrations increased more than 2-fold in one patient following the initiation of itraconazole (200 mg BID).<sup>2</sup> Another report describes a patient who required a doubling of their sirolimus dose (from 0.75mg/day to 1.5mg/day) following a change from itraconazole (400 mg/day) to amphotericin B.<sup>3</sup><br><br>The likely mechanism of this interaction is itraconazole inhibition of the CYP3A4-mediated metabolism and/or p-glycoprotein (P-gp) transport of sirolimus. Of note, a study in rats finding that ketoconazole increased the sirolimus AUC by 3- to 5-fold questioned the role of P-gp inhibition in this interaction, and suggesting the involvement of an unknown mechanism, including the possible involvement of another sirolimus transporter.<sup>4</sup> Interestingly, other data support the possible involvement of a novel transporter (i.e., besides P-gp) in sirolimus disposition.<sup>5</sup><br><br>CYP3A4 is the major enzyme responsible for metabolism of temsirolimus.<sup>6</sup> Sirolimus is the principal metabolite and is a substrate of both CYP3A4 and P-gp.<sup>6,7</sup> Elimination of sirolimus is slower than elimination of temsirolimus, leading to 2.4- to 2.7-times greater exposure to sirolimus than temsirolimus following a 25 mg intravenous (IV) temsirolimus dose.<sup>6,8</sup> Sirolimus exposure following 25 mg IV temsirolimus averaged around 3,810 ng*h/mL in the first week post-dose in one study,<sup>8</sup> which compares to approximately 400-600 ng*h/mL daily (2,800-4,200 ng*h/mL weekly) when sirolimus is dosed orally twice daily to therapeutic trough concentrations in renal transplant recipients.<sup>7,9</sup> Based on published pharmacokinetic (PK) data for sirolimus in patients receiving temsirolimus 25 mg IV weekly,<sup>8</sup> assuming a maximum blood concentration of 65.9 ng/mL, a half-life of 48.8 hours, and linear elimination predicted trough sirolimus concentrations would be around 6 ng/mL and accumulation with repeated doses would be low. <br><br>Known drug interactions involving sirolimus are presumed to apply whether patients are administered temsirolimus or sirolimus. Interactions have been demonstrated with the CYP3A4/P-gp inhibitor ketoconazole<sup>10</sup> and CYP3A4/P-gp inducer rifampin<sup>7,11</sup> with sirolimus given alone or originating as a metabolite of temsirolimus. The magnitude of these interactions is lower with temsirolimus, which may be attributable to IV dosing of temsirolimus which bypasses first-pass transporter and metabolic effects. Metabolism of temsirolimus itself appears to be much less sensitive to CYP3A4 and P-gp inhibition and induction than sirolimus.<sup>10,11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kuypers DR, Claes K, Evenepoel P, et al, “Drug Interaction between Itraconazole and Sirolimus in a Primary Renal Allograft Recipient,” <i>Transplantation</i>, 2005, 79:737.</p>\n<p>2. Said A, Garnick JJ, Dieterle N, et al, “Sirolimus-Itraconazole Interaction in a Hematopoietic Stem Cell Transplant Recipient,” <i>Pharmacotherapy</i>, 2006, 26:289-95.</p>\n<p>3. Sadaba B, Campanero MA, Quetglas EG, et al, “Clinical Relevance of Sirolimus Drug Interactions in Transplant Patients,” <i>Transplant Proc</i>, 2004, 36:3226-8.</p>\n<p>4. Wacher VJ, Silverman JA, Wong S, et al, “Sirolimus Oral Absorption in Rats Is Increased by Ketoconazole but Is Not Affected by D-Alpha-Tocopheryl Poly(Ethylene Glycol 1000) Succinate,” <i>J Pharmacol Exp Ther</i>, 2002, 303:308-13.</p>\n<p>5. Paine MF, Leung LY, Lim HK, et al, “Identification of a Novel Route of Extraction of Sirolimus in Human Small Intestine: Roles of Metabolism and Secretion,” <i>J Pharmacol Exp Ther</i>, 2002, 301:174-86.</p>\n<p>6. Prescribing information. Torisel (temsirolimus). Philadelphia, PA: Wyeth Inc., May 2007.</p>\n<p>7. Prescribing information. Rapamune (sirolimus). Philadelphia, PA: Wyeth Pharmaceuticals Inc., November 2009.</p>\n<p>8. Atkins MB, Hidalgo M, Stadler WM, et al, “Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Refractory Renal Cell Carcinoma,” <i>J Clin Oncol</i>, 2004, 22(5):909-18. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14990647\">[PubMed 14990647]</a></p>\n<p>9. Zimmerman JJ and Kahan BD, “Pharmacokinetics of Sirolimus in Stable Renal Transplant Patients after Multiple Oral Dose Administration,” <i>J Clin Pharmacol</i>, 1997, 37(5):405-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9156373\">[PubMed 9156373]</a></p>\n<p>10. Boni JP, Leister C, Burns J, et al, “Differential Effects of Ketoconazole on Exposure to Temsirolimus following Intravenous Infusion of Temsirolimus,” <i>Br J Cancer</i>, 2008, 98(11):1797-802. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18458675\">[PubMed 18458675]</a></p>\n<p>11. Boni J, Leister C, Burns J, et al, “Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications,” <i>J Clin Pharmacol</i>, 2007, 47(11):1430-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17913896\">[PubMed 17913896]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5284":"<p><b>Title</b> Temsirolimus / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase serum concentrations of the active metabolite(s) of Temsirolimus. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Temsirolimus dosage adjustments will likely be necessary when starting, stopping, or changing therapy with ketoconazole. A clinical study suggests an approximately 50% temsirolimus dose reduction should be considered. Monitor the serum concentrations and clinical effects of sirolimus closely in all patients receiving ketoconazole or any systemic azole antifungal.</p> \n<p><b>Discussion</b> A study of healthy adults given temsirolimus 5 mg intravenous (IV) showed no change in temsirolimus pharmacokinetics (PK) with ketoconazole (400 mg) coadministration bud did show 2.2-fold and 3.2-fold increases in maximum concentration and total drug exposure, respectively, of its primary metabolite sirolimus.<sup>1</sup> In a study of oral sirolimus (5mg x1), total drug exposure was increased approximately 10-fold in 23 healthy subjects when administered following a 10-day course of ketoconazole (200 mg/day).<sup>2</sup> The sirolimus half-life was unchanged. This observed 10-fold increase in sirolimus AUC is consistent with an in vitro model using human hepatocytes suspended in human plasma that predicted a nearly 9-fold increase in sirolimus AUC with clinically achieved concentrations of ketoconazole.<sup>3</sup> A case series reports intentional use of this interacting combination to decrease sirolimus dose requirements in six kidney transplant recipients.<sup>4</sup> Ketoconazole (100-200mg) was safely used with sirolimus in this population, permitting use of sirolimus doses that were only 1/8 to 1/4 of the pre-ketoconazole dose. <br><br>The likely mechanism of this interaction is ketoconazole inhibition of the CYP3A4-mediated metabolism and/or p-glycoprotein (P-gp) transport of sirolimus. Of note, a study in rats finding that ketoconazole increased the sirolimus AUC by 3-5-fold questioned the role of P-gp inhibition in this interaction, and suggesting the involvement of an unknown mechanism, including the possible involvement of another sirolimus transporter.<sup>5</sup> Interestingly, other data support the possible involvement of a novel transporter (i.e., besides P-gp) in sirolimus disposition.<sup>6</sup><br><br>CYP3A4 is the major enzyme responsible for metabolism of temsirolimus.<sup>7</sup> Sirolimus is the principal metabolite and is a substrate of both CYP3A4 and P-gp.<sup>7,8</sup> Elimination of sirolimus is slower than elimination of temsirolimus, leading to 2.4-2.7 times greater exposure to sirolimus than temsirolimus following a 25 mg intravenous (IV) temsirolimus dose.<sup>7,9</sup> Sirolimus exposure following 25 mg IV temsirolimus averaged around 3,810 ng*h/mL in the first week post-dose in one study,<sup>9</sup> which compares to approximately 400-600 ng*h/mL daily (2,800-4,200 ng*h/mL weekly) when sirolimus is dosed orally twice daily to therapeutic trough concentrations in renal transplant recipients.<sup>8,10</sup> Based on published pharmacokinetic (PK) data for sirolimus in patients receiving temsirolimus 25 mg IV weekly,<sup>9</sup> assuming a maximum blood concentration of 65.9 ng/mL, a half-life of 48.8 hours, and linear elimination predicted trough sirolimus concentrations would be around 6 ng/mL and accumulation with repeated doses would be low. <br> <br>Known drug interactions involving sirolimus are presumed to apply whether patients are administered temsirolimus or sirolimus. Interactions have been demonstrated with the CYP3A4/P-gp inhibitor ketoconazole<sup>1,2</sup> and CYP3A4/P-gp inducer rifampin<sup>8,11</sup> with sirolimus given alone or originating as a metabolite of temsirolimus. The magnitude of these interactions is lower with temsirolimus, which may be attributable to IV dosing of temsirolimus which bypasses first-pass transporter and metabolic effects. Metabolism of temsirolimus itself appears to be much less sensitive to CYP3A4 and P-gp inhibition and induction than sirolimus.<sup>1,11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Boni JP, Leister C, Burns J, et al, “Differential Effects of Ketoconazole on Exposure to Temsirolimus following Intravenous Infusion of Temsirolimus,” <i>Br J Cancer</i>, 2008, 98(11):1797-802. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18458675\">[PubMed 18458675]</a></p>\n<p>2. Foren LC, et al, “Sirolimus Oral Bioavailability Increases Ten-Fold With Concomitant Ketoconazole,” <i>Clin Pharmacol Ther</i>, 1999, 65:159 [abstract].</p>\n<p>3. Lu C, Hatsis P, Berg C, et al, “Prediction of Pharmacokinetic Drug-Drug Interactions Using Human Hepatocyte Suspension in Plasma and Cytochrome P450 Phenotypic Data. Ii. In Vitro-in Vivo Correlation with Ketoconazole,” <i>Drug Metab Dispos</i>, 2008, 36:1255-60.</p>\n<p>4. Thomas PP, Manivannan J, John GT, et al, “Sirolimus and Ketoconazole Co-Prescription in Renal Transplant Recipients,” <i>Transplantation</i>, 2004, 77:474-5.</p>\n<p>5. Wacher VJ, Silverman JA, Wong S, et al, “Sirolimus Oral Absorption in Rats Is Increased by Ketoconazole but Is Not Affected by D-Alpha-Tocopheryl Poly(Ethylene Glycol 1000) Succinate,” <i>J Pharmacol Exp Ther</i>, 2002, 303:308-13.</p>\n<p>6. Paine MF, Leung LY, Lim HK, et al, “Identification of a Novel Route of Extraction of Sirolimus in Human Small Intestine: Roles of Metabolism and Secretion,” <i>J Pharmacol Exp Ther</i>, 2002, 301:174-86.</p>\n<p>7. Prescribing information. Torisel (temsirolimus). Philadelphia, PA: Wyeth Inc., May 2007.</p>\n<p>8. Prescribing information. Rapamune (sirolimus). Philadelphia, PA: Wyeth Pharmaceuticals Inc., November 2009.</p>\n<p>9. Atkins MB, Hidalgo M, Stadler WM, et al, “Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Refractory Renal Cell Carcinoma,” <i>J Clin Oncol</i>, 2004, 22(5):909-18. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14990647\">[PubMed 14990647]</a></p>\n<p>10. Zimmerman JJ and Kahan BD, “Pharmacokinetics of Sirolimus in Stable Renal Transplant Patients after Multiple Oral Dose Administration,” <i>J Clin Pharmacol</i>, 1997, 37(5):405-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9156373\">[PubMed 9156373]</a></p>\n<p>11. Boni J, Leister C, Burns J, et al, “Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications,” <i>J Clin Pharmacol</i>, 2007, 47(11):1430-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17913896\">[PubMed 17913896]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5285":"<p><b>Title</b> Temsirolimus / Posaconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Posaconazole may increase serum concentrations of the active metabolite(s) of Temsirolimus. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Temsirolimus dosage adjustments may be necessary when starting, stopping, or changing therapy with posaconazole or any other azole antifungal. Monitor the serum concentrations and clinical effects of sirolimus closely in all patients receiving posaconazole or any systemic azole antifungal.</p> \n<p><b>Discussion</b> The AUC of sirolimus (2mg x1) was increased an average of 8.9-fold in healthy subjects when administered on day 7 of a 16-day regimen of posaconazole (400mg every 12 hours).<sup>1</sup> Several studies and case reports also describe adverse effects, increased sirolimus concentrations, and/or decreased dose requirements with concurrent use of other azole antifungals, including voriconazole,<sup>2,3,4,5,6</sup> ketoconazole,<sup>7,8,9</sup> fluconazole,<sup>5,10,11</sup> and itraconazole.<sup>5,12,13</sup> The combination of posaconazole with sirolimus is listed as contraindicated in posaconazole prescribing information.<sup>14</sup><br><br>The likely mechanism of this interaction is posaconazole inhibition of the CYP3A4-mediated metabolism and/or p-glycoprotein (P-gp) transport of sirolimus.<br><br>CYP3A4 is the major enzyme responsible for metabolism of temsirolimus.<sup>15</sup> Sirolimus is the principal metabolite and is a substrate of both CYP3A4 and P-gp.<sup>15,16</sup> Elimination of sirolimus is slower than elimination of temsirolimus, leading to 2.4-2.7 times greater exposure to sirolimus than temsirolimus following a 25 mg intravenous (IV) temsirolimus dose.<sup>15,17</sup> Sirolimus exposure following 25 mg IV temsirolimus averaged around 3,810 ng*h/mL in the first week post-dose in one study,<sup>17</sup> which compares to approximately 400-600 ng*h/mL daily (2,800-4,200 ng*h/mL weekly) when sirolimus is dosed orally twice daily to therapeutic trough concentrations in renal transplant recipients.<sup>16,18</sup> Based on published pharmacokinetic (PK) data for sirolimus in patients receiving temsirolimus 25 mg IV weekly,<sup>17</sup> assuming a maximum blood concentration of 65.9 ng/mL, a half-life of 48.8 hours, and linear elimination predicted trough sirolimus concentrations would be around 6 ng/mL and accumulation with repeated doses would be low. <br><br>Known drug interactions involving sirolimus are presumed to apply whether patients are administered temsirolimus or sirolimus. Interactions have been demonstrated with the CYP3A4/P-gp inhibitor ketoconazole<sup>19,20</sup> and CYP3A4/P-gp inducer rifampin<sup>16,21</sup> with sirolimus given alone or originating as a metabolite of temsirolimus. The magnitude of these interactions is lower with temsirolimus, which may be attributable to IV dosing of temsirolimus which bypasses first-pass transporter and metabolic effects. Metabolism of temsirolimus itself appears to be much less sensitive to CYP3A4 and P-gp inhibition and induction than sirolimus.<sup>19,21</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Moton A, Ma L, Krishna G, et al, “Effects of Oral Posaconazole on the Pharmacokinetics of Sirolimus,” <i>Curr Med Res Opin</i>, 2009, Feb 2 (ePub ahead of print).</p>\n<p>2. Prescribing information. Vfend (voriconazole). New York, NY: Pfizer Inc, March 2008.</p>\n<p>3. Surowiec D, DePestel DD, Carver PL, “Concurrent Administration of Sirolimus and Voriconazole: A Pilot Study Assessing Safety and Approaches to Appropriate Management,” <i>Pharmacotherapy</i>, 2008, 28:719-29.</p>\n<p>4. Marty FM, Lowry CM, Cutler CS, et al, “Voriconazole and Sirolimus Coadministration after Allogeneic Hematopoietic Stem Cell Transplantation,” <i>Biol Blood Marrow Transplant</i>, 2006, 12:552-9.</p>\n<p>5. Sadaba B, Campanero MA, Quetglas EG, et al, “Clinical Relevance of Sirolimus Drug Interactions in Transplant Patients,” <i>Transplant Proc</i>, 2004, 36:3226-8.</p>\n<p>6. Mathis AS, Shah NK, Friedman GS, “Combined Use of Sirolimus and Voriconazole in Renal Transplantation: A Report of Two Cases,” <i>Transplant Proc</i>, 2004, 36:2708-9.</p>\n<p>7. Lu C, Hatsis P, Berg C, et al, “Prediction of Pharmacokinetic Drug-Drug Interactions Using Human Hepatocyte Suspension in Plasma and Cytochrome P450 Phenotypic Data. Ii. In Vitro-in Vivo Correlation with Ketoconazole,” <i>Drug Metab Dispos</i>, 2008, 36:1255-60.</p>\n<p>8. Thomas PP, Manivannan J, John GT, et al, “Sirolimus and Ketoconazole Co-Prescription in Renal Transplant Recipients,” <i>Transplantation</i>, 2004, 77:474-5.</p>\n<p>9. Wacher VJ, Silverman JA, Wong S, et al, “Sirolimus Oral Absorption in Rats Is Increased by Ketoconazole but Is Not Affected by D-Alpha-Tocopheryl Poly(Ethylene Glycol 1000) Succinate,” <i>J Pharmacol Exp Ther</i>, 2002, 303:308-13.</p>\n<p>10. Lu C, Berg C, Prakash SR, et al, “Prediction of Pharmacokinetic Drug-Drug Interactions Using Human Hepatocyte Suspension in Plasma and Cytochrome P450 Phenotypic Data. Iii. In Vitro-in Vivo Correlation with Fluconazole,” <i>Drug Metab Dispos</i>, 2008, 36:1261-6.</p>\n<p>11. Cervelli MJ, “Fluconazole-Sirolimus Drug Interaction,” <i>Transplantation</i>, 2002, 74:1477-8.</p>\n<p>12. Said A, Garnick JJ, Dieterle N, et al, “Sirolimus-Itraconazole Interaction in a Hematopoietic Stem Cell Transplant Recipient,” <i>Pharmacotherapy</i>, 2006, 26:289-95.</p>\n<p>13. Kuypers DR, Claes K, Evenepoel P, et al, “Drug Interaction between Itraconazole and Sirolimus in a Primary Renal Allograft Recipient,” <i>Transplantation</i>, 2005, 79:737.</p>\n<p>14. Prescribing information. Noxafil (posaconazole). Kenilworth, NJ: Schering Corporation, 12/08.</p>\n<p>15. Prescribing information. Torisel (temsirolimus). Philadelphia, PA: Wyeth Inc., May 2007.</p>\n<p>16. Prescribing information. Rapamune (sirolimus). Philadelphia, PA: Wyeth Pharmaceuticals Inc., November 2009.</p>\n<p>17. Atkins MB, Hidalgo M, Stadler WM, et al, “Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Refractory Renal Cell Carcinoma,” <i>J Clin Oncol,</i> 2004, 22(5):909-18. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14990647\">[PubMed 14990647]</a></p>\n<p>18. Zimmerman JJ and Kahan BD, “Pharmacokinetics of Sirolimus in Stable Renal Transplant Patients after Multiple Oral Dose Administration,” <i>J Clin Pharmacol,</i> 1997, 37(5):405-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9156373\">[PubMed 9156373]</a></p>\n<p>19. Boni JP, Leister C, Burns J, et al, “Differential Effects of Ketoconazole on Exposure to Temsirolimus following Intravenous Infusion of Temsirolimus,” <i>Br J Cancer,</i> 2008, 98(11):1797-802. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18458675\">[PubMed 18458675]</a></p>\n<p>20. Foren LC, et al, “Sirolimus Oral Bioavailability Increases Ten-Fold with Concomitant Ketoconazole,” <i>Clin Pharmacol Ther</i>, 1999, 65:159 [abstract].</p>\n<p>21. Boni J, Leister C, Burns J, et al, “Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications,” <i>J Clin Pharmacol,</i> 2007, 47(11):1430-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17913896\">[PubMed 17913896]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5286":"<p><b>Title</b> TiaGABine / Gemfibrozil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Gemfibrozil may increase the serum concentration of TiaGABine. Both total and unbound concentrations may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor clinical response to tiagabine closely when used with gemfibrozil, monitoring patients closely for signs and symptoms of tiagabine toxicity.</p> \n<p><b>Discussion</b> A case report describes a patient who had been taking tiagabine (16 mg TID) and carbamazepine (500 mg BID) and experienced weakness, confusion, and possible loss of consciousness within approximately an hour of taking one dose of gemfibrozil (600 mg).<sup>1</sup> The patient was later admitted to a clinical care center for controlled rechallenge. Following a single, low gemfibrozil (300 mg) dose, the patient reported lightheadedness lasting several hours. Of note, tiagabine serum concentrations were 59% and 75% higher at 2 hours and 5 hours, respectively, following gemfibrozil administration (vs. concentrations measured on both the days prior to and after concurrent gemfibrozil). Measurement of unbound tiagabine concentrations also appeared to increase following gemfibrozil. Carbamazepine concentrations were not significantly different following gemfibrozil rechallenge.<br><br>The specific mechanism for this interaction is unclear. The authors of this case report hypothesized that gemfibrozil may have displaced tiagabine from both tissue and plasma protein binding sources, explaining both the increase in unbound and total tiagabine concentrations.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Burstein AH, Boudreau EA, Theodore WH, “Increase in Tiagabine Serum Concentration with Coadministration of Gemfibrozil,” <i>Ann Pharmacother</i>, 2009, 43(2):379-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19193595\">[PubMed 19193595]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5287":"<p><b>Title</b> Reverse Transcriptase Inhibitors (Non-Nucleoside) / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Specifically, St. Johns Wort may increase the metabolism of Reverse Transcriptase Inhibitors (Non-Nucleoside). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of St. John's Wort with non-nucleoside reverse transcriptase inhibitors (NNRTIs).</p>\n<div>\n <p><b>Reverse Transcriptase Inhibitors (Non-Nucleoside) Interacting Members</b> Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine</p>\n</div> \n<p><b>Discussion</b> In five HIV positive subjects, concomitant administration of nevirapine and St. John's Wort was associated with an average 35% increase in nevirapine clearance.<sup>1</sup> The U.S. prescribing information for the non-nucleoside reverse transcriptase inhibitors (NNRTIs) delavirdine, nevirapine, etravirine, efavirenz, and rilpivirine recommend against concomitant use with St. John's Wort.<sup>2,3,4,5,6</sup> Nevirapine Canadian product monograph specifically contraindicates concomitant use with products that contain St. John's Wort.<sup>7</sup> St John's wort likely induces CYP3A4 metabolism of NNRTIs. Decreased exposure to NNRTI therapy may lead to loss of virologic response and resistance to therapy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. de Maat M, Hoetelmans RM, Mathot RA, et al, “Drug Interaction Between St. John's Wort and Nevirapine,” <i>AIDS</i>, 2001, 15(3):420-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11273226\">[PubMed 11273226]</a></p>\n<p>2. Prescribing information. Rescriptor (delavirdine). New York, NY:Pfizer, Inc., May 2008.</p>\n<p>3. Prescribing information. Viramune (nevirapine). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., January 2010.</p>\n<p>4. Prescribing information. Intelence (etravirine). Raritan, NJ:Tibotec Inc., September 2009.</p>\n<p>5. Prescribing information. Sustiva (efavirenz). Princeton, NJ:Bristol-Myers Squibb Co., September 2009.</p>\n<p>6. Prescribing information. Edurant (rilpivirine). Raritan NJ: Tibotec Therapeutics, May 2011.</p>\n<p>7. Product monograph. Viramune (nevirapine). Burlington, Ontario: Boehringer Ingelheim (Canada) Ltd., May 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5288":"<p><b>Title</b> Norepinephrine / Inhalational Anesthetics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Inhalational Anesthetics may enhance the arrhythmogenic effect of Norepinephrine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid use of norepinephrine in patients receiving inhalational anesthetics such as halothane.</p>\n<div>\n <p><b>Inhalational Anesthetics Interacting Members</b> Desflurane, Halothane, Isoflurane, Sevoflurane</p>\n</div> \n<p><b>Discussion</b> Prescribing information for norepinephrine warns that halothane may sensitize the heart to arrhythmic actions of sympathomimetic drugs such as norepinephrine, and that this combination is generally considered contraindicated because of the risk of ventricular tacchycardia or fibrillation.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Levophed (norepinephrine bitartrate). Lake Forest, IL: Hospira, Inc, June 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5289":"<p><b>Title</b> Isoproterenol / Inhalational Anesthetics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Inhalational Anesthetics may enhance the arrhythmogenic effect of Isoproterenol. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid use of isoproterenol in patients receiving inhalational anesthetics such as halothane.</p>\n<div>\n <p><b>Inhalational Anesthetics Interacting Members</b> Desflurane, Halothane, Isoflurane, Sevoflurane</p>\n</div> \n<p><b>Discussion</b> Prescribing information for isoproterenol advises cautious use (if any use at all) with inhalational anesthetics such as halothane, as inhalational anesthetics may sensitize the heart to arrhythmic actions of sympathomimetic drugs.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Isuprel (isoproterenol hydrochloride). Lake Forest, IL: Hospira, Inc, 2004.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5290":"<p><b>Title</b> DOPamine / Inhalational Anesthetics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Inhalational Anesthetics may enhance the arrhythmogenic effect of DOPamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid use of dopamine in patients receiving halogenated hydrocarbon anesthetics. If these agents must be used concurrently, monitor for arrhythmia. Dopamine induced ventricular arrhythmia may be reversible with propranolol based on animal data.</p>\n<div>\n <p><b>Inhalational Anesthetics Interacting Members</b> Desflurane, Halothane, Isoflurane, Sevoflurane</p>\n</div> \n<p><b>Discussion</b> Prescribing information for dopamine advises extreme caution with concomitant use of dopamine and halogenated hydrocarbon anesthetics because these agents may increase cardiac autonomic irritability and sensitivity to arrhythmogenic actions of catecholamines.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Dopamine hydrochloride. Shirley, NY: American Regent Laboratories, April 2001.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5292":"<p><b>Title</b> Lovastatin / SITagliptin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> SITagliptin may enhance the myopathic (rhabdomyolysis) effect of Lovastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor closely for evidence of rhabdomyolysis or other toxicities with use of this combination. Advise patients to promptly report any signs or symptoms of muscle-related toxicity.</p> \n<p><b>Discussion</b> Several case reports describe patients who developed rhabdomyolysis days to months after the addition of sitagliptin to ongoing treatment with an HMG-CoA reductase inhibitor (aka “statin”). All four published case reports involve patients who were 60 to 76 years-of-age, with the sitagliptin added between approximately one week and six months prior to patient presentation.<sup>1,2,3,4</sup> Two cases involve atorvastatin,<sup>1,2</sup> with one each involving simvastatin and lovastatin.<sup>3,4</sup> Although each report implicates a sitagliptin-statin interaction as the likely, or at least a plausible, culprit behind the rhabdomyolysis development, each case featured other possible contributing factors, such as concurrent use of CYP3A4 inhibitors, older patient age, and/or use of moderate to high statin doses. The presence of these factors, combined with the lack of a clear, biologically plausible mechanism by which sitagliptin would increase the risk of statin-related rhabdomyolysis, raise questions regarding the precise role of sitagliptin as a contributing factor in these cases.<br><br>Authors of these case reports have suggested possible inhibition of CYP3A4 and/or p-glycoprotein, or sitagliptin-mediated impairments in renal function as explanations for the potential interactions.<sup>1,2,3,4</sup> Sitagliptin had no significant impact on simvastatin pharmacokinetics in one controlled study, increasing the AUC of the active simvastatin acid by only 12%.<sup>5</sup> While selected, higher-risk individuals may experience a greater-than-average interaction between these agents, possibly explaining these few observed cases, it seems at least equally plausible that other factors, besides a sitagliptin-statin interaction, account for the toxicity observed in these cases.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Khan MW, Kurian S, Bishnoi R. Acute-onset rhabdomyolysis secondary to sitagliptin and atorvastatin interaction. <i>Int J Gen Med</i>. 2016;9:103-106. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27199569\">[PubMed 27199569]</a></p>\n<p>2. Bhome R, Penn H. Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction. <i>Diabet Med</i>. 2012;29(5):693-694. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22023482\">[PubMed 22023482]</a></p>\n<p>3. DiGregorio RV, Pasikhova Y. Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction. <i>Pharmacotherapy</i>. 2009;29(3):352-356. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19249953\">[PubMed 19249953]</a></p>\n<p>4. Kao DP, Kohrt HE, Kugler J. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. <i>Diabet Med</i>. 2008;25(10):1229-1230. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19046202\">[PubMed 19046202]</a></p>\n<p>5. Bergman AJ, Cote J, Maes A, et al. Effect of sitagliptin on the pharmacokinetics of simvastatin. <i>J Clin Pharmacol</i>. 2009;49(4):483-488. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19204138\">[PubMed 19204138]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5293":"<p><b>Title</b> Simvastatin / SITagliptin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> SITagliptin may enhance the myopathic (rhabdomyolysis) effect of Simvastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor closely for evidence of rhabdomyolysis or other toxicities with use of this combination. Advise patients to promptly report any signs or symptoms of muscle-related toxicity.</p> \n<p><b>Discussion</b> Several case reports describe patients who developed rhabdomyolysis days to months after the addition of sitagliptin to ongoing treatment with an HMG-CoA reductase inhibitor (aka “statin”). All four published case reports involve patients who were 60 to 76 years-of-age, with the sitagliptin added between approximately one week and six months prior to patient presentation.<sup>1,2,3,4</sup> Two cases involve atorvastatin,<sup>1,2</sup> with one each involving simvastatin and lovastatin.<sup>3,4</sup> Although each report implicates a sitagliptin-statin interaction as the likely, or at least a plausible, culprit behind the rhabdomyolysis development, each case featured other possible contributing factors, such as concurrent use of CYP3A4 inhibitors, older patient age, and/or use of moderate to high statin doses. The presence of these factors, combined with the lack of a clear, biologically plausible mechanism by which sitagliptin would increase the risk of statin-related rhabdomyolysis, raise questions regarding the precise role of sitagliptin as a contributing factor in these cases.<br><br>Authors of these case reports have suggested possible inhibition of CYP3A4 and/or p-glycoprotein, or sitagliptin-mediated impairments in renal function as explanations for the potential interactions.<sup>1,2,3,4</sup> Sitagliptin had no significant impact on simvastatin pharmacokinetics in one controlled study, increasing the AUC of the active simvastatin acid by only 12%.<sup>5</sup> While selected, higher-risk individuals may experience a greater-than-average interaction between these agents, possibly explaining these few observed cases, it seems at least equally plausible that other factors, besides a sitagliptin-statin interaction, account for the toxicity observed in these cases.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Khan MW, Kurian S, Bishnoi R. Acute-onset rhabdomyolysis secondary to sitagliptin and atorvastatin interaction. <i>Int J Gen Med</i>. 2016;9:103-106. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27199569\">[PubMed 27199569]</a></p>\n<p>2. Bhome R, Penn H. Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction. <i>Diabet Med</i>. 2012;29(5):693-694. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22023482\">[PubMed 22023482]</a></p>\n<p>3. DiGregorio RV, Pasikhova Y. Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction. <i>Pharmacotherapy</i>. 2009;29(3):352-356. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19249953\">[PubMed 19249953]</a></p>\n<p>4. Kao DP, Kohrt HE, Kugler J. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. <i>Diabet Med</i>. 2008;25(10):1229-1230. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19046202\">[PubMed 19046202]</a></p>\n<p>5. Bergman AJ, Cote J, Maes A, et al. Effect of sitagliptin on the pharmacokinetics of simvastatin. <i>J Clin Pharmacol</i>. 2009;49(4):483-488. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19204138\">[PubMed 19204138]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5294":"<p><b>Title</b> OxyCODONE / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of OxyCODONE. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Closely monitor the analgesic response to oxycodone in patients taking rifampin, particularly when starting or stopping rifampin and/or when attempting to convert from an opioid that is not significantly metabolized by CYP3A to oxycodone.</p> \n<p><b>Discussion</b> Oxycodone AUC was decreased by an average of 86% when oxycodone (15 mg orally x1) was administered on day 7 of rifampin administration (600 mg/day) in a study of 12 volunteers.<sup>1</sup> In a separate phase of the same study, oxycodone AUC was an average of 53% lower when intravenous oxycodone (0.1 mg/kg x1) was given on day 7 of rifampin administration. Assessments of the oxycodone's pharmacodynamics (using various visual analog scales to test response to heat and cold stimuli) revealed a decreased clinical effect of oxycodone when given with rifampin.<br><br>A case report similarly describes decreased clinical effectiveness of oxycodone when used with rifampin in a 60 year-old male patient.<sup>2</sup> Also of note in this report is that the patient had 3 consecutive negative urinary oxycodone screens over a 2-month period while receiving concurrent rifampin. Subsequent analysis of oxycodone parent and metabolite serum concentrations led the patient's caregiver to determine that the patient had been adherent to therapy but had experienced decreased analgesia due to the rifampin drug interaction.<br><br>The likely mechanism of this probable interaction is increased oxycodone metabolism via CYP3A caused by rifampin-mediated induction of CYP3A.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nieminen TH, Hagelberg NM, Saari TI, et al, “Rifampin Greatly Reduces the Plasma Concentrations of Intravenous and Oral Oxycodone,” <i>Anesthesiology</i>, 2009, 110(6):1371-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19417618\">[PubMed 19417618]</a></p>\n<p>2. Lee HK, Lewis LD, Tsongalis GJ, et al, “Negative Urine Opioid Screening Caused by Rifampin-Mediated Induction of Oxycodone Hepatic Metabolism,” <i>Clin Chim Acta</i>, 2006, 367(1-2):196-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16414038\">[PubMed 16414038]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5295":"<p><b>Title</b> Collagenase (Systemic) / Anticoagulants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer systemic collagenase with caution to any patient who has received an anticoagulant within the past 7 days. If used together, monitor patients closely for sign/symptoms of excessive bruising and/or bleeding.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n</div> \n<p><b>Discussion</b> Collagenase prescribing information notes that 38-70% of patients in the two main clinical trials experiences bruising and/or bleeding at the injection site, and the prescribing information urges caution when using collagenase in patients who have used an anticoagulant within 7 days prior to injection.<sup>1</sup> This warning does not extend to those patients using only low dose aspirin (i.e., 150 mg or less per day).<br><br>The degree to which this possible interaction is related to a direct effect of collagenase (vs. the route of administration, or primarily “an injection interaction”) is unclear, but given the relatively high rate of bruising/bleeding reported in non-anticoagulated patients, caution with this combination appears warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xiafelx (collagenase clostridium histolyticum). Malvern, PA: Auxilium Pharmaceuticals, Inc., 02/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5296":"<p><b>Title</b> Collagenase (Systemic) / Agents with Antiplatelet Properties</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer systemic collagenase with caution to any patient who has received an antiplatelet agent within the past 7 days. If used together, monitor patients closely for sign/symptoms of excessive bruising and/or bleeding. This warning does not apply to the concurrent use of low-dose (150 mg/day or less) aspirin.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Collagenase prescribing information notes that 38-70% of patients in the two main clinical trials experiences bruising and/or bleeding at the injection site, and the prescribing information urges caution when using collagenase in patients who have used an anticoagulant within 7 days prior to injection.<sup>1</sup> This warning does not extend to those patients using only low dose aspirin (i.e., 150 mg or less per day).<br><br>The degree to which this possible interaction is related to a direct effect of collagenase (vs. the route of administration, or primarily “an injection interaction”) is unclear, but given the relatively high rate of bruising/bleeding reported in non-anticoagulated patients, caution with this combination appears warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xiafelx (collagenase clostridium histolyticum). Malvern, PA: Auxilium Pharmaceuticals, Inc., 02/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5297":"<p><b>Title</b> Amphotericin B / Antineoplastic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antineoplastic Agents may enhance the adverse/toxic effect of Amphotericin B. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for possible increases in renal toxicity, bronchospasm, and hypotension if amphotericin is given concomitantly with antineoplastic agents.</p>\n<div>\n <p><b>Amphotericin B Interacting Members</b> Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex</p>\n <p><b>Antineoplastic Agents Interacting Members</b> Altretamine, Amsacrine, AzaCITIDine, Belotecan, Bendamustine, Bleomycin, Busulfan, Cabazitaxel, Capecitabine, CARBOplatin, Carmustine, Chlorambucil, CISplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine (Conventional), Dacarbazine, DACTINomycin, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Decitabine, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), EpiRUBicin, EriBULin, Estramustine, Etoposide, Etoposide Phosphate, Floxuridine, Fludarabine, Fluorouracil (Systemic), Fotemustine, Gemcitabine, Hydroxyurea, IDArubicin, Ifosfamide, Irinotecan (Conventional), Irinotecan (Liposomal), Ixabepilone, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, Methotrexate, MitoMYcin (Systemic), MitoXANTRONE, Nelarabine, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), PEMEtrexed, Pentostatin, Pixantrone, PRALAtrexate, Procarbazine, Raltitrexed, Streptozocin, Tegafur, Temozolomide, Teniposide, Thioguanine, Thiotepa, Topotecan, Trabectedin, Treosulfan, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine</p>\n</div> \n<p><b>Discussion</b> Prescribing information for amphotericin B recommends cautious use in combination with antineoplastic agents due to a possible increased risk for renal toxicity, bronchospasm, and hypotension.<sup>1,2,3</sup> Bronchospasm and hypotension have been seen in cases where amphotericin B was added to a chemotherapy regimen in an attempt to overcome tumor resistance,<sup>4,5</sup> and the risk of renal toxicity may be increased when amphotericin B is used in combination with other nephrotoxic agents.<sup>1,2,3</sup><br><br>The mechanism of this proposed drug interaction is unknown. Numerous in vitro and animal studies have shown a potential for enhanced tumor uptake of antineoplastic agents and synergistic cytotoxicity in combination with amphotericin.<sup>6,7,8,9</sup> However, studies in humans using amphotericin B as part of a chemotherapy regimen to take advantage of this effect have not always shown increased toxicity and have rarely shown any of the renal, bronchial, or blood pressure effects outlined in amphotericin B prescribing information.<sup>10,11,12,13,14,15,16,17</sup> An increased risk of renal toxicity would be expected with addition of amphotericin B to nephrotoxic antineoplastic agents<sup>1,2,3</sup> and has been shown with chemotherapy regimens.<sup>18</sup> However, the extent to which this recommendation may apply to all antineoplastic agents is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Fungizone (amphotericin B). Princeton, NJ: Bristol-Myers Squibb Co., June 2009. </p>\n<p>2. Prescribing information. Ambisome (amphotericin B). Deerfield, IL: Astellas Pharma US, Inc, October 2008.</p>\n<p>3. Prescribing information. Abelcet (amphotericin B lipid complex). Bridgewater, NJ: Enzon Pharmaceuticals, Inc, November 1995.</p>\n<p>4. Presant CA, Klahr C, Santala R, “Amphotericin B Induction of Sensitivity to Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) plus Cyclophosphamide in Human Neoplasia,” <i>Ann Intern Med</i>, 1977, 86(1):47-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=264783\">[PubMed 264783]</a></p>\n<p>5. Presant CA, Hillinger S, Klahr C, “Phase II Study of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC No. 409962) with Amphotericin B in Bronchogenic Carcinoma,” <i>Cancer</i>, 1980, 45(1):6-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6243243\">[PubMed 6243243]</a></p>\n<p>6. Stewart DJ and Evans WK, “Non-Chemotherapeutic Agents that Potentiate Chemotherapy Efficacy,” <i>Cancer Treat Rev</i>, 1989, 16(1):1-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2659168\">[PubMed 2659168]</a></p>\n<p>7. Crnalic S, Bergstrom P, Lofvenberg R, et al, “Antagonistic Effect of Amphotericin B on Carboplatin Antitumor Activity in Human Osteosarcoma Xenografts,” <i>Anticancer Drugs</i>, 1996, 7(4):489-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8826618\">[PubMed 8826618]</a></p>\n<p>8. Beketic-Oreskovic L and Osmak M, “Modulation of Resistance to Cisplatin by Amphotericin B and Aphidicolin in Human Larynx Carcinoma Cells,” <i>Cancer Chemother Pharmacol</i>, 35(4):327-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7828276\">[PubMed 7828276]</a></p>\n<p>9. Morikage T, Ohmori T, Nishio K, et al, “Modulation of Cisplatin Sensitivity and Accumulation by Amphotericin B in Cisplatin-Resistant Human Lung Cancer Cell Lines,” <i>Cancer Res</i>, 1993, 53(14):3302-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8391922\">[PubMed 8391922]</a></p>\n<p>10. Presant CA, Klahr C, Olander J, et al, “Amphotericin B plus 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC no. 409962) in Advanced Cancer. Phase I and Preliminary Phase II Results,” <i>Cancer</i>, 1976, 38(5):1917-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=991105\">[PubMed 991105]</a></p>\n<p>11. Presant CA, Metter GE, Multhauf P, et al, “Effects of Amphotericin B with Combination Chemotherapy on Response Rates and on Survival in Non-Small Cell Carcinoma of the Lung,” <i>Cancer Treat Rep</i>, 1984, 68(4)651-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6201270\">[PubMed 6201270]</a></p>\n<p>12. Presant CA, Bartolucci AA, Lowenbraun S, et al, “Effects of Amphotericin B on Combination Chemotherapy of Metastatic Sarcomas,” <i>Cancer</i>, 1984, 53(2):214-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6360332\">[PubMed 6360332]</a></p>\n<p>13. Gonzalez-Manzano R, Vleitez JM, Tangco E, et al, “Phase II Evaluation of Doxorubicin, Ifosfamide, and Dacarbazine plus Amphotericin B in the Treatment of Metastatic Soft Tissue Sarcomas. A Pilot Study,” <i>Am J Clin Oncol</i>, 1993, 16(4):332-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8328412\">[PubMed 8328412]</a></p>\n<p>14. Krutchik AN, Buzdar AU, Blumenschein GR, et al, “Amphotericin B and Combination Chemotherapy in the Treatment of Refractory Metastatic Breast Carcinoma and Sarcoma,” <i>Cancer Treat Rep</i>, 1978, 62(10):1565-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=709557\">[PubMed 709557]</a></p>\n<p>15. Presant CA, Multhauf P, Metter G, “Reversal of Cancer Chemotherapeutic Resistance by Amphotericin B - A Broad Phase I-II Pilot Study,” <i>Eur J Cancer Clin Oncol</i>, 1987, 23(6):683-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3653189\">[PubMed 3653189]</a></p>\n<p>16. Sarna G, Lowitz BB, Ganz PA, et al, “Amphotericin B plus Combination Chemotherapy for Extensive Non-Small Cell Bronchogenic Carcinoma,” <i>Cancer Chemother Pharmacol</i>, 1980, 5(2):89-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7471319\">[PubMed 7471319]</a></p>\n<p>17. Presant CA, Kennedy P, Wiseman C, et al, “Pilot Phase II Trial of Amphotericin and CCNU in Renal and Colorectal Carcinomas,” <i>Eur J Cancer Clin Oncol</i>, 1986, 22(3):329-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3709601\">[PubMed 3709601]</a></p>\n<p>18. Chabot GG, Pazdur R, Valeriote FA, et al, “Pharmacokinetics and Toxicity of Continuous Infusion Amphotericin B in Cancer Patients,” <i>J Pharm Sci</i>, 1989, 78(4):307-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2724094\">[PubMed 2724094]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5298":"<p><b>Title</b> Fluvastatin / Cholestyramine Resin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cholestyramine Resin may decrease the serum concentration of Fluvastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Administer fluvastatin at least 1 hour or greater (particularly with extended-release form) before, or at least 4 hours after cholestyramine to minimize the risk for any significant interaction.</p> \n<p><b>Discussion</b> Fluvastatin prescribing information describes reductions in the AUC (50%) and Cmax (50% to 80%) of immediate-release fluvastatin when administered concomitantly or within 4 hours after cholestyramine.<sup>1</sup> Significant and enhanced clinical effects were noted with administration of immediate-release fluvastatin at least 4 hours after cholestyramine. <br><br>Similar findings have also been reported with other statins. Pravastatin prescribing information describes a 40% to 50% decrease in AUC when coadministered with cholestyramine.<sup>2</sup> <br>Addition of cholestyramine (24 g/day x 4 weeks) to 33 males previously randomized to pravastatin monotherapy (5, 10, or 20 mg BID x 4 weeks), decreased pravastatin AUC 18% to 49%. The authors suggest that pravastatin absorption was decreased by cholestyramine.<sup>3</sup><br><br>When administering fluvastatin prior cholestyramine, it would seem prudent to allow at least 1 hour or greater (particularly with extended-release form) to lessen the risk for interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Lescol (fluvastatin). East Hanover, NJ: Novartis Pharmaceuticals Corp., October 2006.</p>\n<p>2. Prescribing information. Pravachol (pravastatin). Princeton, NJ: Bristol-Myers Squibb Company, March 2007.</p>\n<p>3. Pan HY, DeVault AR, Swites BJ, et al, “Pharmacokinetics and Pharmacodynamics of Pravastatin Alone and With Cholestyramine in Hypercholesterolemia,” <i>Clin Pharmacol Ther</i>, 1990, 48(2):201-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2116260\">[PubMed 2116260]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5299":"<p><b>Title</b> Pravastatin / Bile Acid Sequestrants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the serum concentration of Pravastatin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin, Colesevelam, Colestipol</p>\n</div> \n<p><b>Discussion</b> Pravastatin prescribing information describes a 40% to 50% decrease in AUC when coadministered with the bile-acid binding resins cholestyramine and colestipol.<sup>1</sup> Addition of cholestyramine (24 g/day x 4 weeks) to 33 males previously randomized to pravastatin monotherapy (5, 10, or 20 mg BID x 4 weeks), decreased pravastatin AUC 18% to 49%.<sup>2</sup> The authors suggest that pravastatin absorption was decreased by cholestyramine. Despite the reduction in pravastatin exposure, significant reductions (compared to baseline) in total and LDL cholesterol and a significant increase in HDL cholesterol were noted following concomitant therapy. Pravastatin prescribing information recommends separating administration (at least 1 hour before or 4 hours after) from these resins.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Pravachol (pravastatin). Princeton, NJ: Bristol-Myers Squibb Company, March 2007.</p>\n<p>2. Pan HY, DeVault AR, Swites BJ, et al, “Pharmacokinetics and Pharmacodynamics of Pravastatin Alone and With Cholestyramine in Hypercholesterolemia,” <i>Clin Pharmacol Ther</i>, 1990, 48(2):201-7.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}